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ABSTRACT 
 
Prostate cancer (Choudhury et al., 2014) is the leading cause of non-
cutaneous malignancy and is the second most commonly diagnosed 
cancer among men after lung cancer. QRFP is a secreted protein that is 
extensively expressed in the brain with highest expression levels in the 
medulla, pituitary gland, cerebellum, retina, and vestibular nucleus; in the 
periphery it is expressed in the adipose tissue prostate gland, bladder, 
colon, testis and in the parathyroid and thyroid gland. QRFP is a member 
of the RF amide neuropeptide family. This family might be implicated in 
extensive array of biological activities for instance, food intake, 
cardiovascular functioning, blood pressure, analgesia, aldosterone 
secretion and locomotor activity, resulting in orexinergic activities. It is 
suggested that obesity is one of the contributing factors for aggressive form 
of prostate cancer. There is a strong association between adipokines and 
aggressive form of various cancers. QRFP has been recently described as 
an adipokine that exerts its functions via activation of the G protein coupled 
receptor GPR103. At present the role of the QRFP and GPR103 in prostate 
cancer has not been explored in detail. I studied the potential role of the 
adipokine QRFP in prostate cancer. The three prostate cancer cell lines: 
PC3, DU145 (Orbetzova, 2012) and LNCaP (androgen-sensitive) were 
used as models for my studies. Nevertheless, no studies to date have 
investigated the effects of QRFP and GPR103 in prostate cancer. This 
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prompted me to examine the expression and function of QRFP and 
GPR103 in the human prostate cells. Also I sought to identify the role of 
QRFP and GPR103 in prostate cancer. The novel data presented in this 
study demonstrates that QRFP & GPR103 genes and protein are 
expressed in both human prostate tissue and prostate cancer cell lines. 
Expression of both QRFP and GPR103 were higher in PCa tissues 
compared to controls. Moreover, an ELISA detected circulate QRFP serum 
levels were lower in human cancer patients compared to benign and 
healthy group. Stimulation with QRFP induced MAPK signalling cascades, 
AKT, AGR-2 expression, MMP 2, Caspase-3 and AMPK in PC3 & DU145 
cells. QRFP also increased PC3 & DU145 cells migration and invasion, 
nonetheless QRFP showed induced suppression cell proliferation in PC3, 
DU145 and LNCaP cells.  
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GENERAL INTRODUCTION 
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1  BACKGROUND 
 
1.1 THE NORMAL PROSTATE GLAND  
The prostate gland is a part of the male reproductive system involved in 
production of seminal fluid, an alkaline liquid which is rich in spermine, 
cholesterol, fibrinogens, fibrinolysin, zinc and acid phosphatase, 
phospholipids, citric acid and some proteins, however the exact function of 
the prostate gland still remains unclear. This gland is important in 
protecting the lower urinary tract from infection and inflammation, and for 
men fertility. The growth and activity of prostate is dependent on male 
hormones; androgens (Crawford, 2005).                                                        
Anatomically prostate gland is situated deep in the pelvis surrounding the 
proximal urethra, beneath the urinary bladder and facade the rectum. The 
size of prostate gland differs by age. Normal adult human prostate is 
typically slightly larger than a walnut and weighs around 20-25 grams. The 
prostate is comprises of four essential zones based on the glandular 
components, embryonic origins, and form a patho-physiological basis of 
benign prostatic hyperplasia (BPH) and prostate cancer (Alshaker et al.). 
 The peripheral zone (PZ): Extends along the posterior and lateral 
surfaces of the gland, consists of 70 % of prostatic volume and is 
more prone to develop cancer. 
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 The central zone (Leongamornlert et al.):  The area surrounding the 
utricle and contains the ejaculatory ducts. This constitutes up to 
25% of the normal prostate volume, CZ has more smooth muscle 
than the PZ, which makes this zone comparatively resistant to 
inflammation and hyperplasia. 
 The transition zone (Venkateswaran and Klotz): This covered only 
5% of the total prostatic volume. It surrounds the proximal urethra 
and is the state of the prostate, contains sub- mucosal and mucosal 
glands that grows throughout life and is responsible for the benign 
prostatic hypertrophy (BPH). 
 The anterior fibro-muscular zone: situated anteriorly and contains 
no glandular tissue and is made up of only muscle and fibrous 
tissue. Therefore it does not become hyperplastic (Lee et al., 2011). 
  PZ and CZ are referred to as external prostate while TZ and 
anterior fibro-muscular zone are termed as interior prostate. These 
zones contain essentially no glandular tissue (Iremashvili et al., 
2012b).  
Histologically the prostate is divided into two parts glandular tissues and 
duct, glandular tissue is involved in secretion of fluid and ducts, which 
consist of 7 % of the gland and the remaining 30 % non-glandular tissue, 
which is fibromuscularstroma. The fibromuscularstroma covers prostate 
gland, which is also referred as capsule and is shaped by tubuloacinar 
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glands and connective tissue comprising smooth muscle. The gland 
padded essentially with two main forms of epithelial cells:  Basal cells and 
secretory cells within various cells types mediated among basal cells and 
secretory cells. Basal cells are located at the exterior of the gland under 
the secretory cells. Secretory cells are cuboid formed with pale to clear 
cytoplasm. This deep coat is a main feature, as it is missing in malignancy 
(Iremashvili et al., 2012a) & (Reese, 2016). 
 
 
 
 
Figure 1.1 Diagram view of the cell types in the interior a human prostatic 
duct from (Abate-Shen and Shen, 2000). 
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1.1.1   ANDROGENS: 
Testosterone is the main androgen steroid hormone secreted by the 
testicular leydig cells which is controlled by a complex chain of signals 
referred to as the hypothalamic-pituitary-gonadal axis. This accounts for 
the majority of circulating androgen response to luteinizing hormone 
(Hoogland et al.) about 94 %- 97 %; the remaining androgen production 
arises essentially from the adrenals and peripheral conversion of estrogen 
by aromatase (Hiort et al., 1998). Testosterone that circulates in the 
plasma is essentially bound to one of two kinds of plasma protein sex-
hormone binding globulin (SHBGs) or with albumin and only testosterone 
set free can enters into prostate cells through diffusion. However, the 
mechanism for testosterone carrying from the leydig cell to the blood 
stream or lymph is not completely identified (Rove et al., 2012). 
Testosterone is irreversibly converted into an active metabolic 5 α- 
dihydrotestosterone (DHT), via enzyme 5- α. After being formed, DHT has 
a higher binding affinity to the androgen receptor (AR) to control prostatic 
cellular proliferation and survival, or might be additional metabolized along 
a number of alternative pathways. The transformation of testosterone to 
DHT is depending on organs, for instance in prostrate, since DHT is the 
major biological active androgen. Hydroxysteroid dehydrogenases control 
ligand the binding of AR in the human prostate (Godoy et al., 2011) & 
(Amaral et al., 2013). 
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Figure 1.2 Hormonal regulation of the male reproductive system  
At the hypothalamic pituitary gonadal axis, GnRH stimulates the release of 
follicle-stimulating hormone (FSH) which act on the testes to begin 
spermatogenesis and luteinizing hormone (LH) that secrete testosterone. 
In turn, the testes production of testosterone and the hormone inhibin 
prevent the release of GnRH, FSH, and LH in a negative feedback.  
 
Furthermore, testosterone aromatization into estrogen act as a main role 
in prostate growth by actin interaction with oestrogen receptor B and 
androgen are essential to regulate the proliferative and apoptosis change 
that happen throughout normal prostate growth and differentiation. 
Concentrations of estrogen in prostate stromal tissue are evidently 
increased in cases of benign prostate hyperplasia (BPH) (Green et al., 
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2012). The main role of androgen in normal prostate is to stimulate 
differentiation of luminal epithelial cells and to control the transcription of 
genes encoding proteins required for prostate function, for instance 
prostate specific antigen (PSA). Measuring PSA levels commonly 
employed for detection and diagnosis of neoplastic malignancies of 
prostate tissues and response to therapeutic intervention (Green et al., 
2012) & (Crawford, 2005). Conversely, PSA is not specific for PCa. Several 
other conditions can be associated with an elevated PSA level, including 
benign prostatic hyperplasia (BPH) and prostatitis. Though a PSA level 
higher than 4.0 ng/mL is generally used as an indication for prostate 
biopsy, the sensitivity and specificity of the PSA test limits its use as a 
prostate cancer screening method (Ochiai et al., 2005). In prostate cancer 
the main function of AR is less obvious, though possibly AR activity 
modulates the expression of genes related with cell cycle regulation, 
growth and survival. Irrespective of the mechanism, it is strongly observed 
that AR signalling plays a critical role in the growth and progression of PCa 
(Balk and Knudsen, 2008) & (Green et al., 2012). AR ablation therapy has 
been recently used as an approach to treatment advanced prostate cancer 
(PCa) and is initially effective in reducing the development of the disease. 
Nevertheless, it has been observed frequently, PCa appears again as an 
androgen- tumour with a related life expectancy of only15-20 months 
(Parimi et al., 2014). 
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1.2  PROSTATE CANCER (PCa) 
1.2.1 EPIDEMIOLOGY  
PCa is the leading cause of non-cutaneous malignancy and the second 
most common diagnosed cancer among men after lung cancer, and is the 
fifth most frequent cancer globally (rsted et al., 2011). Worldwide around 
1,111,689 new cases of PCa were diagnosed in 2012 (Van Rij et al., 
2016).The high rates of prostate cancer are recorded in developed 
countries approximately 3/4 of the cases appear in Australia, New Zealand, 
Western and Northern Europe and Canada.  In 2009 has documented that 
approximately 192,280 new cases of PCa diagnosed and 
approximately  27,360 recorded died in Northern America which becomes 
the highest incidence and significant death (Rosenthal and Sandler, 2010). 
There are evident differences between the incidences of clinically 
significant disease universally, nevertheless incident non-clinically 
pertinent disease is still equal. There are significant variance among 
northern and southern countries in Europe, with PCa incidence and death 
being higher in England and Wales and lower in Mediterranean countries 
(Van Rij et al., 2016). The occurrence rates are comparatively high in 
certain developing regions such as the Caribbean, South America and sub-
Saharan Africa countries. Conversely the lowest incidence is expected in 
south Asian countries (Sankaranarayanan et al., 2010). The rise in 
incidence between the developed countries is attributable to numerous 
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factors. Since the routine examination of transurethral prostatectomy 
(TURP) histology specimens and practice of serum analysis for prostate 
specific antigen (PSA) as a sign for PCa has more role to play in the 
increased incidence mainly in the more developed (Djavan et al., 2011) & 
(Giles, 2014). However, around 258,000 deaths in 2008, and the sixth 
leading cause of cancer death. The figure of deaths from prostate cancer 
is nearly similar in developed and developing regions. Death rates are 
mostly higher in mostly black populated regions such as Caribbean and 
sub-Saharan Africa, in contrast it is very lower in Asia. The PCa globally is 
expected to grow at 1.7 million new cases and 499 000 new deaths in 2030 
(Center et al., 2012).  Nevertheless, lots of men have prostate cancer with 
no symptoms therefore does not undergo any specific treatment and finally 
die of further causes. PCa shares a figure of lineaments with benign 
prostatic hyperplasia (BPH) and the putative signs of cancer, prostatic 
intraepithelial neoplasia (Martin et al.). All rise with in spread by men age, 
all need androgens for proliferate and development, and all react to 
androgen prevention treatment (Bostwick et al., 2004). The high-grade PIN 
and early stage cancer is categorized by, aberrations in markers of 
secretory differentiation, rising nuclear, progressive basal cell layer 
disorder and nuclear variations, increasing cell proliferation, variation in 
DNA sequent, and increasing genetic instability. A number of biomarkers 
demonstrate up-regulation or increase in the development from benign 
prostatic epithelium to high-grade PIN and cancer, while others are down-
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regulated or missing. Present data show that more biomarkers are up 
regulated; however, the comparative importance of each is unknown. 
There is a considerable increase in micro-vessel intensity in PIN and 
carcinoma comparison with normal prostate tissue (Jemal et al., 2003).  
1.2.2  ETIOLOGY 
The main causes of PCa are still unidentified, however there are several 
risk factors related with the development of cancers and PCa is no 
exclusion to this and risk factors are divided into two sections: Endogenous 
risk factors including (family history, hormones and race) and exogenous 
risk factors including (diet, environmental agents and other factors) are all 
involved (Venkateswaran and Klotz, 2010) & (Bostwick et al., 2004). 
1.2.3  AGE 
Age is one of the significant risk factors; there is a strong association 
between incidences and mortality of PCa with old age. Appearance of PCa 
in men under 50 years old is very unusual, with about 60% of cases 
diagnosed in men over 70 years of age (Macefield et al., 2009). Recent 
studies confirmed that PCa has a long induction period, and that many men 
carry the diseases in their 20s and 30s (Gann, 2002). 
1.2.4  ETHNICITY 
The highest incidence rates of PCa in the USA are in black American men. 
African American men presented highest incidence rates for PCa than 
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white American men. Asia is the continent with the lowest incidence 
universally; Countries for instance China and Japan have comparatively 
low rates of PCa in native people (Bostwick et al., 2004). The causes for 
this rates 60% higher risk within African Americans and 38% lower risk 
within Asian Americans in compare to white Caucasians are still unclear 
(Ferris-i-Tortajada et al., 2011). 
1.2.5  GENETIC FACTORS 
Prostate cancer like other cancers is a genetic disorder that begin by the 
accumulation of chromosomal alterations produced by the clone selection 
of aggressive cells; about 5-10% of PCa are hereditary. Recent studies, 
have identified around 100 genetic variants which linked with prostate 
cancer disease (Stegeman et al., 2015). Some of these genes such as 
BRCA1, BRCA2, or HOXB13 genes provide proteins that suppression 
tumor. Inherited alterations in these specific genes, have been linked with 
increased possibilities of many types of cancers including hereditary 
prostate cancer (Leongamornlert et al., 2014). Prostate cancer family 
history increase risk 2 to 3 times for men with first-degree relative by PCa, 
families with 3 consecutive affected generations, or families with two 
relations below the 55 ages would be considered for recommendation 
surgery. It is evident that genetics play a significant role in prostate cancer 
aetiology (Guy, 2009). On Caucasian families, found that seven 
prospective genes are recognized implicated hereditary PCa for instance 
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HPC1, PCAP, CAPB on (chromosome1), HPC2 on (chromosome17), and 
HPCX on (chromosome 8 and X chromosome) and HPC20 on 
(chromosome20) (Gronberg, 2003), (Lange, 2010) & (Goh et al., 2012).  
1.2.6  ENDOGENOUS HORMONE PROFILE 
Androgens have long been involved in prostate carcinogenesis, elevated 
levels of circulating androgen were found in African-American men 
compared to white American men. This would make a compelling 
hypothesis, conversely, the relationship between circulating and 
intraprostatic levels of androgens and PCa is still under debate (Wirén and 
Stattin, 2008). Insulin-like growth factor (IGF-1) which was found to have 
mutagenic and anti-apoptotic effects, are strongly associated with PCa risk  
(Crowe et al., 2008). Hormone levels might be affected both by exogenous 
factors; exposure to environmental chemicals and endogenous factors 
such as genetics can affect hormone activity (Bostwick et al., 2004). 
1.2.7  DIET 
Diverse dietary factors have been associated in the development of PCa 
according to epidemiologic literature of migrant populations and 
geographic variations (Wolk, 2005). However, some prospective studies 
found no clear association between dietary fat consumption and risk PCa 
(Crowe et al., 2008) & (Bosire et al., 2013).  Many dietary factors and some 
dietary patterns hold potential in prevent or/ enhance progression risk of 
PCa which are corresponding with recent dietary guidelines for Americans 
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(Lin et al., 2015). Several mechanisms have been proposed to explain 
which dietary fat intake may be possibly linked with PCa: Pro-inflammatory 
fatty acid metabolites, IGF-1 levels in the serum, free radicals, variation of 
serum androgens. The high concentration of zinc in normal prostate 
reduced >90% risk of PCa, but the relation of dietary intake of zinc on PCa 
is uncertain. An antioxidant found in tomatoes, broccoli, and asparagus, 
vitamin E, selenium, and green tea regular intake might decrease risk of 
PCa (Sonn et al., 2005). 
1.2.8  PATHOLOGIC MARKERS  
95% of the prostate tumors are adenocarcinomas, only around 4% of 
cases have transitional cell morphology and are thought to arise from the 
epithelial lining of the prostatic urethra. Few cases have neuroendocrine 
morphology. These cells are believed to arise from the neuroendocrine 
stem cells normally present in the prostate  (Dan Theodorescu et al., 2009). 
PCa is different in clinical staging, histopathological tumor growth forms, 
and survival. Thus, individual assessment of a tumor’s aggressive potential 
is critical for clinical decision-making in men with prostate cancer. Sufficient 
therapy of PCa fundamentally depends on their single histological kind, 
stage and grade of malignancy. High grades are related with early and 
rapid tumor development and consequent metastasis (Hoogland et al., 
2014).  Low grade and low stage cancers can be treated locally by curative 
intention such by external or internal radiation, radical prostatectomy, or 
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subjected to an Active Surveillance (AS) strategy (Böcking et al., 2014). 
However, the relationship between biopsy and radical prostatectomy 
specimens still remains a difficult, particularly and notably the under-
grading of the biopsy specimen. Grading the malignant prospective of 
different cancers of the prostate presently is conducted according to the 
modified Gleason-score according to the International Society for Urologic 
Pathology (ISUP), on histological sections of biopsies or resected tissue 
(Fine et al., 2012).  
Staging of PCa:  Staging of prostate cancer divided into two parts 
pathological and clinical staging. The tumor, node, metastasis staging 
(TNM) is widely used staging system for prostate cancer to clinically 
describe the anatomical range of cancer spread. It divided on 3 main 
sections of information: T- assesses the tumour, N- spread the malignancy 
to region and lymph nodes and secondary and M-cancer metastases 
outside of prostate gland (Cheng et al., 2012).    
Gleason Score: The Gleason system is the most prevalent applied 
pathological grading for PCa as an essential prognostic factor in predicting 
detections in biochemical failure, radical prostatectomy, lymph node local 
recurrences, or distant metastasis in patients without treatment, radiation 
therapy and other therapies, including high-intensity focal ultrasound 
therapy and cryo-therapy. Moreover, using hematoxylin-eosin (H&E) 
staining to describe the histological pattern of carcinoma cells (Martin et 
al., 2011) & (Montironi et al., 2010). 
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The Gleason score is calculated based on the dominant histologic grades, 
from grade 1 to grade 5. Adding the two most prevalent pattern grades, 
yielding a score ranging from 2 to 10, derives the typical score (Veltri et al., 
2012).  Since there is some indication that the least-differentiated element 
of the specimen may provide independent prognostic information, the 
score is normally provided by its separate components such Gleason 
scores 3 + 4 = 7; or 4 + 3 = 7. Needle Biopsy, first pattern with the highest 
grade must be recorded and ignoring secondary pattern. Radical 
Prostatectomy, Gleason score must be depending the primary and 
secondary patterns with a statement on the tertiary pattern (Blume-Jensen 
et al., 2015). 
1.2.9 TUMOURIGENESIS; CELL PROLIFERATION, THE CELL CYCLE 
The complicated balance conserved between cell growth and proliferation 
factors and apoptosis promoting factors are essential to the regulation of 
prostate growth. Disturbances in this homeostasis commonly cause the 
absence of apoptosis and the over activation of factors promoting cell 
survival and proliferation (Hanahan and Weinberg, 2011). The unavoidable 
consequence is a dysfunctional signaling pathway leading to 
tumorigenesis and cancer. Furthermore, cancer cells increase the 
capability to migration and invasion heterotopic tissues, through bone 
being the common site of human PCa metastasis (Bononi et al., 2011). 
Growth and proliferate of normal and cancer prostate cells are controlled 
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by many growth factor pathways which classified into three distinct groups; 
insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF) both are 
mostly stimulators of cell proliferation, survival, differentiation, migration 
and invasiveness and transforming growth factor-β (TGF-β) responsible 
apoptosis which is inhibitor prostate growth (Dasgupta et al., 2012). The 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/ mTOR signaling pathways 
have been shown to play significant roles in the transmission of 
proliferative signals from membrane bound receptors (McCubrey et al., 
2008).  Mutations may appear in the genes encoding pathway components 
including (RAF, RAS, PTEN, PIK3CA, TSC2, AKT, TSC1) or in upstream 
receptors that activate these pathways. These pathways spread this 
information by interactions with many other proteins to the nucleus to 
regulator gene expression (Steelman et al., 2011). Cell proliferation is 
induced and initiated by the act of growth factors. Cell division comprises 
of two consequent processes essentially characterized by DNA replication 
and isolation of replicated chromosomes into two separate cells called cell 
cycle (Williams and Stoeber, 2012). The cell cycle consists of four distinct 
phases: G1 phase in which the cell grows and prepares to synthesize DNA, 
S phase (DNA synthesis), G2 phase (premyotic) proteins are synthesized 
in preparation for mitosis, and M phase (mitosis) in which cell division 
occurs. Quiescent phase or G0 is a resting phase where the cell has left 
the cycle and has stopped dividing (Słonina et al.). Replication of the 
genomic DNA must be completed before the start of mitosis and is 
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achieved once in each cell cycle. Genetic disorders in the control of the 
cell cycle are occurrence in almost human cancers. Main molecules that 
are implicated cell cycle regulation and apoptosis in PCa cells such as 
cyclin-depenent kinases (CDKs), p53, p21 and p27 (Koljonen et al., 2006). 
Through proliferation a cell needs to grow and replicate its genome prior to 
dividing to generate two daughter cells. Though in cancer cells is 
essentially a disease in which cells have absent their normal checks on 
cell proliferation. Cancer cells in order to satisfy the increased supplies of 
proliferation, often display essential changes in pathways of energy 
metabolism and nutrient uptake. Many distinct oncogenes such as (AKT 
src, c-Myc, and H-ras) promot anabolic metabolism in transformed cells 
(Jones and Thompson, 2009). Prostate cancer initiates when the semen-
secreting prostate organ cells transform into cancer cells, proliferating at 
higher mitotic stages. Originally, the prostate cells begin to proliferate 
leading to tumor development in the peripheral zone of the prostate gland 
(da Silva et al., 2013). By the time these cancer cells finally proliferate to 
further invade neighboring organs, such as the, bladder, seminal vesicles, 
rectum, and urethra. Through the early metastatic stages, malignant cells 
from the initial tumor separate from their original location and migrate 
through blood and lymphatic vessels. In the advanced stages, PCa cells 
eventually spread to more terminal organs, including bones, liver, and lung. 
Metastasis is one of the main causes of death in cancer. Metastasis of PCa 
is consistence of multiple steps, including migration, invasion, 
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intravasation, circulation and extravasation of tumor cells and then 
angiogenesis (Jin et al., 2011). Furthermore, metastasis to bone is the 
most common prostate cancer metastatic (Altieri et al., 2009). Cell 
migration is crucial steps in several biological processes, including tissue 
repair and regeneration, inflammation, immune surveillance and 
embryonic morphogenesis (Condeelis et al., 2005). Abnormal regulation of 
cell migration leads to progression of several diseases, such as cancer 
invasion and metastasis (Yamaguchi and Condeelis, 2007). Invasive 
carcinoma cells gain a migratory phenotype related with increased 
activation of several genes implicated in cell motility (Bozzuto et al., 2010). 
Thus, understanding the essential mechanisms of cell migration and 
invasion are critical for comprehension of both essential biology and the 
pathology of disease (Yamaguchi et al., 2005). Cancer cells invade 
throughout the basement membrane and extracellular matrix is the feature 
of the metastatic process. Each stage in the metastatic process requires 
distinct molecular interactions between the tumor cells, the cells of the 
stroma and the extracellular matrix (ECM) (Bozzuto et al., 2010). The 
interface between normal prostate epithelial cells and the ECM is critical 
for migration cell proliferation and survival (Jin et al., 2011). Cell migration 
and invasion are stimulated via a number of chemo attractants, which 
stimulate intracellular signaling pathways that control reorganization of the 
actin cytoskeleton. Fundamental to this process is the structural and 
signaling association complexes between the cytoskeleton and ECM that 
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are identified as focal adhesions (Chen et al., 2013c). Matrix 
metalloproteinases (MMPs) have been known act to degrade the ECM. 
The level of ratios of MMP-2/-9 to tissue inhibitor of metalloproteinases-1 
(TIMP-1) In primary tumor prostrate tissues is increased relative to normal 
prostate tissues (Brehmer et al., 2003) & (Clarke et al., 2009). However, 
loss of TIMP-1 was associated with up-regulation of MMPs in malignant 
prostate cancer tissues. Additional, has been found that high 
concentrations of MMP-2/9 have been detected in plasma patients with 
metastatic disease (Morgia et al., 2005). Binding of FN to integrin results 
in MMP-2/9 over-activation through the FAK/ILK/ERK/PI3K/NF-κB 
pathways, and thus driving to ECM degradation and cancer invasion. 
Moreover, there are several intracellular molecules including Notch, Sonic 
Hedgehog, Wnt, NF-κB, Ras/Raf/MEK/MAPK, in addition the ERK/AKT 
pathways that regulator each side of each of the stages of cancer invasion 
(Stivarou and Patsavoudi, 2015). Several chemotactic such as EGF 
influences have been shown to stimulate intracellular signaling pathways 
that drive to thorny end formation through these mechanisms. Focal 
adhesion kinase (FAK) is a crucial mechanism of focal adhesion turnover, 
and is lead to increasing cell migration. A high expresser of FAK and EGFR 
in prostate cancer PC3 cell lines also associates with increased metastatic 
possible (Chen et al., 2007) & (Tremblay et al., 1996). PI3K, Rho and Ras 
activated by Src/ FAK-mediated lead to increased cell proliferation, 
angiogenesis and migration (Jin, 2011). Activation of Src stmulates cell 
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migration by different molecules including interleukin 8 (IL-8). Inhibition of 
Src blocked IL-8 prompted migration in prostate cancer LNCaP cells (Lee 
et al., 2004). There is an accumulation data describing the function of 
hepatocyte growth factor (HGF) and its receptor c-Met in PCa 
development. Interaction of HGF with its receptor and other factors 
including TGF and TG-b have been demonstrated to modulate tumor cell 
interaction, cell proliferation, cell migration, cell matrix adhesion, cell 
invasion, and angiogenesis in PCa cells (Nagle and Cress, 2011). In the 
regulation of cancer invasion, it has been stated that neuropeptides such 
as bombesin and vasoactive intestinal polypeptide (VIP) increased the 
invasive capability of prostate cancer cells PC 3 and LNCaP (Hoosein et 
al., 1993). However, the mechanism of the influence of these 
neuropeptides on tumor invasion remains ambiguous. Though, several 
neuropeptides other than VIP and bombesin are existent in the prostate 
gland, their influence on cancer invasion has yet to be specified  
(Nagakawa et al., 1998). 
1.2.10  APOPTOSIS AND ITS REGULATION 
One of the highly significant advances has been the detection that 
resistance to cell death, specifically apoptosis cell death, is critical aspect 
of both tumorgenesis and progress of resistance anti-cancer drug 
(Johnstone et al., 2008). Although, different apparatuses such as 
oncogene overexpression, genetic instability, epigenetic modifications, 
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tumor suppressor down-regulation, loss of cell cycle control and influence 
of tumor microenvironment result in progress of tumor resistance to cell 
death (apoptosis) (Hanahan and Weinberg, 2011).  Kerr, Wyllie, and Currie 
in 1972 were first used the term of apoptosis to define a morphologically 
distinct form of cell death, however some components of the apoptosis 
notion had been clearly described many years before (Elmore, 2007).  
Apoptosis known as a programmed cell death, which occurs through the 
activation of cell-intrinsic or extrinsic dependent mechanism, e.g. exposure 
to irradiation or treatment with cytotoxic drugs, by DNA damage, or by 
development death signals (Hassan et al., 2014). Apoptosis happens 
routinely during growth and aged and as a homeostatic mechanism to 
preserve cell an inhabitants in tissues (Ouyang et al., 2012). Many 
morphological changes happens during apoptosis and are characterized 
by membrane cell shrinking, membrane blebbing, nuclear fragmentation, 
chromatin aggregation, and degradation of DNA fragmentation  (Elmore, 
2007). The mechanisms of apoptosis and the associated signalling 
pathways are extremely complicated which can be initiated in a cell through 
activation of intrinsic pathway or the extrinsic pathway. The extrinsic 
pathway is initiated via the activation of the transmembrane death 
receptors on the objective cell to stimulate apoptosis, for example the 
ligands of CD95/TNF family induce apoptosis through multi-protein 
complexes and involves activation of the multiple cascade pathways and 
are quite well comprehend in molecular terms (Marsters et al., 1998).  
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In contrast, the intrinsic pathway mediated apoptosis involves mitochondria 
which is an essential player in the integration of variety of apoptotic signals, 
containing loss of hypoxia, growth factors, DNA damage, and oxidative 
stress (Spencer and Sorger, 2011). Caspases are the main initiators and 
executioners of the apoptosis pathway. So far 14 members of caspases 
have been discovered and classified into two groups, based on the lengths 
of the pro-domains. The initiator caspases (caspase-1, -2, -4, -5, -8, -9 and 
-10) have long pro-domains and function are involved in targeting and 
regulation activation (Jager and Zwacka, 2010). While executioner 
caspases (including caspase-3, 6 and 7) have short domains and are 
responsible to role more downstream in targeting and regulating apoptosis 
pathway cleaving critical substrates (Parrish et al., 2013). 
 
  
43 
 
 
Figure 1.3 The extrinsic and intrinsic pathways of apoptosis: Death 
receptor pathway (left) is initiated by the ligation of the ligands to their 
respective surface receptors (Indran et al., 2011). 
 
The two main families of proteins that regulate apoptosis are P53 and BCL-
2 family members and are found to have abnormal function and expression 
in PCa. The main member of apoptotic regulators is transforming growth 
factor beta (TGF-β) family members that also include BCL2. TGF-β 
signalling is critical for normal prostate epithelial cell proliferation and 
induction of apoptosis it acts as a tumour suppressor in initial 
tumorogenesis, however it promotes tumour growth in later stages of 
tumour progression (Rentsch et al., 2006). The BCL2 family is one of the 
main genes known to be associated with prostate carcinogenesis.  
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1.2.11  BCL-2 
The BCL-2 gene family have highlighted the role of proteins as essential 
regulators of the apoptotic pathway in variety of cells, which are classiﬁed 
based on structural and functional features as either pro-apoptotic group  
(BAX, BAK, BAD and BID) or anti-apoptotic group (BCL2, BCL-XL, BCL-
W, and MCL-1 proteins) (Tzifi et al., 2012). However, BAX families’ 
activation of mitochondria consequence that release of apoptogenic 
factors including cytochrome C, endonuclease G, Same/Diablo, and 
apoptosis including factor from the mitochondrial intermembrane space 
(Du et al., 2000). In prostatic tissues both in normal and hyperplastic, Bcl-
2 protein is expressed in the cytoplasm of basal epithelial cells. The 
occurrence of Bcl-2 overexpression is lesser in localized PCa compared 
with hormone refractory PCa. The Over-expression of Bcl-2 may assist the 
PCa cells to live in an androgen-deprived environment, and to accord 
resistance to antiandrogen therapy (Yoshino et al., 2006). 
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1.3  MITOGEN ACTIVATED PROTEIN KINASES (MAPK) 
To understand the complicated pathogenesis of prostate cancer, the 
interweave of signalling pathways and cell signal transmissions such as 
cell survival, proliferation, migration invasion, inflammation and apoptosis, 
might give a new understanding of the development, progression and 
inhibition of cancers (Chen et al., 2014a). An extensive different stimuli 
include growth factors, hormones, cytokines and environmental stresses 
stimuli cell, through activation of receptor tyrosine kinases (RTKs), by 
activation of subsequent signalling cascades which play essential roles in 
cellular processes, such as proliferation, differentiation, migration, 
apoptosis, cell metabolism, and cell cycle control (Osaki and Gama, 2013). 
One of main signalling pathway induced by members of RTK family, 
mediated through; mitogen- activated protein kinase (MAPK) (Pritchard 
and Hayward, 2013). Mitogen activated protein kinases (MAPKs) family 
consists of three distinguished group include; extracellular signal-regulated 
kinase (ERK1/2), p38 isoforms (α/ β/γ/ /δ) and c-jun N-terminal or stress-
activated protein kinases (JNK/SAPK) (Correa and Eales, 2012).   
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Figure 1.4 Schematic representation of the MAPK cascade activation 
and potential cross talk signals. MAPK signaling pathways mediate 
intracellular signalinginitiated by extracellular or intracellular stimuli. 
Activated MAPKs phosphorylate many substrate proteins including 
transcription factors, resulting in regulation of a diversity of cellular 
activities including cell proliferation, differentiation, migration, inflammatory 
responses, and apoptosis (Osaki and Gama, 2013).  
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1.3.1 EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASES 
(ERK1/2) 
The extracellular regulated kinases (ERK1/2) MAPKs are 44/42 kDa 
serine/threonine kinases, has been strongly related to cell growth, survival, 
proliferation, cell cycle, invasion, migration, and differentiation in both 
normal and cancer cells (Saini et al., 2013). Significantly, activation of 
factors of this pathway is assumed to contribute to tumorigenesis, tumor 
progression and metastatic disease in a diversity of solid tumors (Manzo-
Merino et al., 2014). Nevertheless, ERK can also promote apoptotic 
regulatory molecules counting bcl-2 family members and caspase-9 
(Thakur et al., 2009). The ERK pathway consists of (A-Raf, B-Raf, Raf-1, 
MEK1/2 and ERK1/2) are strongly activated mostly in response to growth 
factors, serum, mitogens, ligands for G protein-coupled receptors (GPCRs) 
and in solid tumors e.g. breast and prostate cancer  (Pearson et al., 2001). 
However, the ERK signaling pathway plays a role in several steps of tumor 
development. Majority of the signals activating the ERK pathway are 
initiated by receptor-mediated activation of the small G-protein, Ras -Raf 
family (Junttila et al., 2008). 
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1.3.2   p38 MAPKs 
The p38 MAPKs contains four members, p38α, p38β, p38γ, and p38δ 
(Roux and Blenis, 2004). These kinases play roles in cell differentiation, 
growth inhibition, cell survival, proliferation, and apoptosis (Risco and 
Cuenda, 2012). Mainly, all p38MAPKs are strongly activated in cells in 
response to verity of environmental and stress signals, or by pro-
inflammatory (TNFα, IL-6 or IL-1) or anti-inflammatory (EGF, TGF-β) 
cytokines and are weakly activated by growth factors or serum. Activated 
p38 phosphorylates and controls various transcription factors such as 
(p53, Elk-1, ATF-2, NF-κB, MEF-2, Max, Mac, or Stat1) and apoptotic 
mediators as Cdc25A and Bcl-2  (Thornton and Rincon, 2009). p38 has 
been revealed to promote cell survival in response to stress stimuli, such 
as in response to DNA damage. Nevertheless, p38α may also have 
oncogenic functions that are mediated by its involvement in key processes 
of cancer progression, such as invasion, inflammation and angiogenesis. 
Several propose that p38 play significant role in several cancers such as 
prostate, lung leukemia and lymphomas (Whyte et al., 2009).    
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1.3.3 c-Jun N-TERMINAL KINASE OR STRESS-ACTIVATED PROTEIN 
KINASES (JNK/SAPK) 
The first three mammalian JNK genes were discovered from rat livers 
injected with cycloheximide JNK1, JNK2, and JNK3 also known as (SAPK-
γ, SAPK-α, and SAPK-β) respectively within implicate in growth, 
morphogenesis, and cell differentiation (Bogoyevitch et al., 2010). JNK 
proteins, share a threonine-proline-tyrosine (TPY) motif, are activated in 
response to a diversity of extracellular stimuli, counting, growth factor 
deprivation, inflammation cytokines (IL-6, IL-1, and TNF), UV irradiation, 
DNA-damaging agents and mitogens (Pritchard and Hayward, 2013). 
Depending on the cellular stimulus, JNKs phosphorylate varied substrates, 
counting transcription factors (p53, AP-1, ATF-2, c-Myc, Elk-1, MLK2) and 
certain members of the Bcl-2 family (Bode and Dong, 2007). Several 
studies propose that JNK activity is chronically altered in many cancer 
types include breast, prostate, lymphoma pancreas and lung cancer 
(Zhang and Selim, 2012). Nevertheless, studies into the role of JNK in 
human prostate tissues are rare (Takahashi et al., 2010). Depending on 
cellular stimulus and types or even JNK isoform, JNKs have opposite 
function. So, JNKs can induce apoptosis by reduced tumor formation and 
malignant progression, however also may promote cell survival and 
proliferation, also involved in regulation of the cell cycle (Rodriguez-
Berriguete et al., 2012) &  (Lee et al., 2010a). 
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1.3.4   AKT/PKB KINASE 
The serine/threonine kinase Akt also named protein kinase B (PKB) has 
three isoforms revealed in mammals (Akt1/2/3 -2) encoded by genes 
(Werden and McFadden, 2010). Akt is a main regulator of multiple cellular 
processes; include glucose metabolism, proliferation, cell survival, and 
protein synthesis (Zheng et al., 2012). Therefore many studies proposed 
that AKT might associate with tumorigenesis by activated 
phosphatidylinositol 3-kinase (PI3K), which transmits signals from 
cytokines, growth factors and oncoproteins (da Silva et al., 2013). 
Furthermore, Akt pathway activated in PCa cells acts as contributing to 
cancer progression by both stimulation of cellular proliferation, migration, 
invasion and inhibit apoptosis pathway by inactivate pro-apoptotic factors 
as Bad and caspase-9 (She, 2013).  
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1.4  OBESITY RELATED TO PROSTATE CANCER 
Obesity is currently a major worldwide concern.  It is estimated that above 
of 2.1 billion people around 30% of world population with overweight or 
obese and 3.4 million deaths each year worldwide. If its incidence stays on 
its current curve, approximately 1/2 of adult population global will be 
overweight or obese by 2030. In Western Europe UK comes behind only 
Iceland of the highest levels of obesity or overweight 74% of men and 61% 
of female are either overweight or obese. There are several countries 
worldwide, including Arabic countries (Libya, Kuwait, Qatar and Egypt) 
where more than half the female population is obese (Musaiger et al., 
2011) & (Musaiger, 2011). Body mass index (BMI) is predictably used 
measurement in clinical medicine like obesity and population health. 
However, the issues related to weight gain beyond the accurate capacity 
of other markers to determine the incidence of obesity have been 
suggested with body fat percentage being one of the most practical due to 
its superior capability to stratify patients according to their cardiovascular 
risks and metabolic (Campbell, 2014). Obesity leads to increases the risk 
of developing various diseases. Type 2-diabetes, certain types of cancers 
and cardiovascular disease risk increases due to overweight elevating 
hypertension and dyslipidemia. 90 % of people with type-2 diabetes are 
overweight and patients with diabetes are leads to cause of early death, 
stroke, kidney disease, and blindness (Deshpande et al., 2008). Obesity is 
 
  
52 
 
considered one of the main significant features in the progress of insulin 
resistance, and insulin resistance might lead to type 2-diabetes. Though 
several studies have reported associations between BMI and risk of 
individual cancers including that of the prostate, pancreatic, ovarian, breast 
and colon cancer. There is strong evidence the obesity is an important 
cause of unnecessary suffering and mortality from many forms of cancer.  
Also obesity is related with worse prognostic and malignant transformation 
of epithelial cells (Campbell, 2014) & (Spangler et al., 2007). There are 
some of biological processes common that could lead to the relation BMI 
and aggressive PCa. Several hormones,  adipokines signaling and 
androgens implicated in obesity moreover play a role in the initiation and 
promotion of cancer both at systemic level and a cellular paracrine 
(Freedland and Aronson, 2004).                                                                       
Although, other studies have found no association between BMI and PCa 
(Schuurman et al., 2000). To understand the link between obesity and PCa 
are complicated since obesity is associated not only with excess BMI, 
however also with altered serum levels of many hormones, as estrogen, 
testosterone, insulin and insulin-like growth factor (IGF)-1, all of which have 
to some degree been related to PCa. Furthermore, obesity is highly 
associated with dietary intake in terms of the quantity of calories in addition 
to the amount of dietary fat, both of which have been linked to prostate 
cancer. Obesity might effect on sex hormone binding globulin, testosterone 
and estrogen, as are hormone levels and growth insulin (Wooding and 
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Rehman, 2014). High levels of metabolic factors, individually or combined, 
are not associated to the development of PCa, however are associated to 
an increased risk of disease progression, although with no proof of synergy 
between the metabolic factors (Haggstrom et al., 2012). Several studies 
suggested obese men have lower PSA values. Some men with obese 
produce less PSA than normal weight men and thus could have late 
diagnosis of PCa (Kim et al., 2013). However, some studies concluded that 
BMI is not affected the capability of the PSA level for predict adverse 
pathologic features, such as seminal vesicle invasion, extracapsular 
extension, and positive surgical margins across increasing BMI (Banez et 
al., 2009). Otherwise, obesity has a significant positive associated with 
prostate volume (PV) in several study populations. Furthermore, obesity is 
essentially produced by an excess accumulation of adipocyte tissue, and 
adipocytes are specified for the storage and synthesis of fatty acids (Kwan 
et al., 2015). Two main types of adipose tissue are known, white and 
brown, with different origins and functions. White adipose tissue (WAT) 
plays a role that related to maintaining energy homeostasis through storing 
triglycerides and releasing fatty acids for energy synthesis, also controls a 
wide range of functions including glucose and lipid homeostasis, food 
intake control, immune and inflammatory regulation, or metabolism by 
secreting a great number of adipokines (Falcao-Pires et al., 2012). The 
main role of brown adipose tissue BAT is particularly in thermogenesis, the 
produce of heat essentially mediated by the uncoupling protein-1 (UCP-1), 
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which produces heat via uncoupling mitochondrial respiration for ATP 
synthesis (Nieman et al., 2011). Actually, a growing body of evidence has 
showed the pathogenic roles of adipocytes in the cancer 
microenvironment, meaning that tumorigenesis implicates constant 
communication between tumor cells and neighboring normal cells e.g. 
adipocytes (Nieman et al., 2013). Anew study presented that cancer cells 
such as breast cancer cell did not yield fatty acids that were unlike from 
those derived from exogenous basis and both exogenous supplied fatty 
acids an endogenous synthesized were esterified to the same lipid and 
phospholipid classes in the same proportions. Might be that fatty acids 
arising from lipolysis in the peripheral adipose tissue are transferred to the 
cancer cells for growing (Bing and Trayhurn, 2008). Several studies 
proposed that cancer cells might use lipids directly from adipocytes as 
energy source, promoting tumor to grow. It has found that, patients with 
malignant melanoma, the melanoma cells are found in subcutaneous 
adipose tissues. PCa cells are exposed to adipose tissue when they invade 
the retro-pubic fat layer or metastasis to lymph nodes or bone marrow. The 
extra capsular extension of PCa cells has been stated to metastasis into 
the per-prostatic adipose tissue. Even other cancers e.g. breast, colon, 
renal, ovarian, pancreatic and gastric cancer, as well grow in the vicinity of 
adipose tissues (Nieman et al., 2013). Different mechanisms might obesity 
promotes cancer development and progressions have been suggested, 
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including the obesity related low-grade inflammation, insulin resistance, 
endocrine alterations, and hypoxia–angiogenesis processes. 
1.4.1  ROLE OF DYSFUNCTIONAL ADIPOSE TISSUE 
Adipose tissue dysfunction result of the interaction between 
adipocytes and immune cells are linked diseases including insulin 
resistance, inflammation and cancer (van Kruijsdijk et al., 2009). The 
role of these factors, including insulin resistance, chronic 
inflammation, increased levels of plasminogen activator inhibitor-1 
(PAI-1), endogenous sex steroids, leptin, and visfatin decreased 
levels of adiponectin, have been indicated to effect tumor promotion 
and cancer progression (Prieto-Hontoria et al., 2011). 
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1.5  ADIPOKINES AND PTOSTATE CANCER  
Obesity might increase, many paracrine factors and hormones, which 
motivate the steroid hormones products in cancer tissue by interact 
between epithelial compartments and stromal in tissues.  Over than 
50 hormones and cytokines, known as adipokines and 
adipocytokines are controlled and secreted by adipose tissue 
(Dalamaga et al., 2012). One of the paracrine factors is cytokines 
secreted through both fat cells and white blood cells (WBC). 
Predominantly there is association between obesity and increased 
circulating levels of cytokines, and these levels are reduced by weight 
loss. Several cytokines involved in the progression of tumors to 
malignancy including growth factors, and transcription factors. 
Adipose tissue acts as a significant endocrine organ through the 
synthesis of several adipokines, which regulate insulin sensitivity, 
control of energy intake, lipolysis and inflammatory processes 
(Catalan et al., 2013). Adipokines are associated to tumor 
development and progression due to their many activities on different 
cell types, essentially by exerting their effects throughout 
inflammatory pathways. Adiponectin and leptin, visfatin and chemerin 
are of the most important adipocyte-specific adipokines (Catalan et 
al., 2012). 
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1.5.1   LEPTIN: 
Leptin, a 16 kDa, 167-amino acid peptide, is produced mainly by 
adipocytes, which participated to the hypothesis of adipocyte and adipose 
tissue as an endocrine cell and an endocrine organ. Leptin is one of 
adipokines that controls metabolism (Pittas et al., 2004). Mainly high 
levels of endogenous hormones related with obesity, include insulin, 
insulin-like growth factor I, sex steroids, leptin and have been known as 
possible mechanisms relating overweight to PCa. In specific, the fat 
hormone leptin is showed positively associated with PCa. Moreover, 
leptin levels in the circulate blood appeared to relate directly with BMI and 
can increase from levels of non-obese subjects was 1–3 ng/mL to e.g. 
high as 100 ng/mL in obese individuals (Hoda et al., 2012b). However, 
some studies have suggested that serum leptin levels are higher in obese 
patients (Tewari et al., 2013). Leptin has a role in the regulation of body 
weight and influences cellular differentiation and PCa progression. It has 
been observed that leptin levels are higher in serum obese patients and 
that leads to increase the risk of influences cellular differentiation and PCa 
progression. Many latest reports have indicated that leptin acts as a 
mitogenic factor found in several of human tissues including heart, 
placenta, kidney, lung, pancreas, prostate, testes, and ovary (Hoda et al., 
2012b). The isoforms leptin receptors (ObRa and ObRb through ObRf) 
have been shown to occur on varied cancer cells (Choi et al., 2005). In 
vitro, it has been indicated that human PCa express the leptin receptor 
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and leptin is capable to influence growth of some prostate cancer cell lines 
(Hoda and Popken, 2008). In vitro studies using PCa cell lines DU145 and 
PC-3 have proposed that leptin could be involved in PCa cell migration 
that can influence tumour growth and progression. The MAPK signaling 
pathway is identified to be significant in cancer cells survival and growing. 
Therefore, the possible involvement of MAPK pathway in mediating the 
effects of leptin in prostate cell lines was studied by evaluating the 
phosphorylation of its downstream ERK1/2. It might be showed that leptin 
induces ERK1/2 activation in synchronism with increased cell proliferation 
in prostate cell lines (Samuel-Mendelsohn et al., 2011). Some studies 
showed that leptin enhance cell proliferation particularly in androgen-
independent DU145 and PC-3 prostate cancer cells but not in androgen-
dependent LNCaP-FGC cells. However, the effect of leptin on growth of 
PCa cells is different depending to the androgen sensitivity of the 
assessed cells (Li et al., 2010a). In contrast one study published that 
leptin can evidently induce apoptosis in human PCa cell lines. Leptin-
induced apoptosis is possibly mediated through balanced activation of 
p38 MAPK, JAK2/STAT3, and PKC pathways in PCa cells. Exposure 
prostate PC3, DU145, and LNCaP cells to leptin caused weak, however 
statistically significant, increase e in the phosphorylation of part signaling 
pathways involved in cell proliferation and apoptosis including STAT3, 
JAK2, ERK1/2, and additionally PI3K-Akt (Samuel-Mendelsohn et al., 
2011). Furthermore leptin increased cell proliferation, by activation JNK, 
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and induce inhibition of apoptosis, promoting tumor cell development, 
invasion and metastasis, supporting the role of this adipokine on PCa 
(Garofalo and Surmacz, 2006).   
1.5.2   ADEPONECTIN: 
Adiponectin, was discovered independently by different labs and has four 
alternative names as Acrp30, apM1, ADIPOQ and GBP28 mainly secreted 
from adipocytes (Nagaraju et al., 2015). Several studies have suggested 
the expression of adiponectin in various tissues such as liver, cardiac 
tissue, fetal tissue, breast milk and placenta, might indicate a probable 
paracrine/autocrine complementary role for adiponectin (Dalamaga et al., 
2012). Adiponectin expression might be increased in many methods most 
importantly by exercise, calorie restriction, and bodyweight loss (Kadowaki 
et al., 2014). Compared to other polypeptide hormones, adiponectin 
circulates at extremely high concentration levels, increasing probability that 
a smaller cleaved consequence mediates its action on different tissues. 
The association between adiponectin, inflammation and carcinogenesis is 
unclear, although one study proposes that adiponectin inhibits 
transplanted fibrosarcoma growth and infusion inhibits endothelial 
proliferation (Gialamas et al., 2011). Serum levels of adiponectin and 
insulin resistance, in compare with other adipokines, are reduced in 
response to some metabolic dysfunction, such as dyslipidemia, type-2 
diabetes, hypertension and abnormal obesity. This proposes that obesity 
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related diseases might be moderately inverted by weight loss, though 
latest reports suggest that these changes are relatively small unless there 
are extreme weight changes, e.g. severe calorie constraint (Roshanaei-
Moghaddam et al., 2009). In contrast to most adipokines, hence diponectin 
is evidentially influence reduces obesity and increase with long fasting and 
losing weight. Low adiponectin levels and insulin resistance have been 
associated to several obesity-related disease entities, such as type 2 
diabetes mellitus, hypertension, and atherosclerosis. The main role of 
adipokines is to assistance maintain metabolic homeostasis, however 
extended roles for adipokines have demonstrated their capability to 
modulate inflammation, proliferation angiogenesis, and apoptosis 
(Vansaun, 2013). Two isoforms of adiponectin receptors were known as 
Adipo R1 receptors are mainly expressed in muscle and Adipo R2 
receptors are mostly expressed in the liver (Izadi et al., 2012).  
Furthermore, it has found that PCa cells express mRNA of AdipoR1 and 
AdipoR2, cell surface receptors for adiponectin. These results lead to a 
suggestion that adiponectin inhibits growth PCa growth (Miyazaki et al., 
2005). AdipoR1 and AdipoR2, are activated many intracellular signaling 
pathway such as 5’-adenosine monophosphate-activated protein kinase 
(AMPK), nuclear factor-κB, peroxisome proliferator-activated receptor-α, 
and p38 mitogen-activated protein kinase pathways (Wanninger et al., 
2009). Adiponectin at physiological concentrations inhibits growth of PCa 
cell lines androgen-independent (DU145, PC3) and androgen-sensitive 
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(LNCaP) by stimulate phosphorylation and activation of the AMPK pathway 
(Bub et al., 2006). The hormone inhibits acts as a direct endogenous 
inhibitor of inflammation and angiogenesis and reduces cancer 
invasiveness by inhibiting the activity of matured phagocytic macrophages 
that have been linked to PCa. Obesity increases insulin secretion and 
insulin resistance. Furthermore, it can decrease adiponectin levels and 
AMPK activity that increase the risk of PCa (Kim et al., 2009) & (Izadi et 
al., 2012). The obesity -related up-regulation of insulin secretion and down-
regulation of adiponectin and, as a result, down-regulation of AMPK, are 
sensible mechanisms whereby obesity directly or indirectly impacts PCa 
progression (Li et al., 2010a). Adiponectin inhibits cell proliferation and 
induces apoptosis. Significantly, adiponectin is a mighty inhibitor of 
PI3K/AKT/mTOR that is able to decrease growth cancer cells exerted 
through insulin and growth factor-induced signaling (Hebbard and 
Ranscht, 2014). Additionally, adiponectin can stimulate JNK activation in 
PCa cells (PC-3, DU145, and LNCaP). Additionally, extremely suppress 
constitutive STAT-3 activation in DU145 and HepG2 cells (Jarde et al., 
2009). 
1.5.3   VISFATIN: 
Visfatin also known as nicotinamide phosphor ribosyltranferase (NAMPT) 
or pre-B-cell colony-enhancing factor 1 (PBEF1) was identified as an 
adipokine produced by visceral and subcutaneous fat tissues, monocytes, 
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hepatocytes, and macrophages (Friebe et al., 2011) & (Laudes et al., 
2010). Thus, several studies presented increased levels of circulating 
visfatin in obesity, cardiovascular disease and diabetes mellitus. However, 
other studies presented lower levels of visfatin in these diseases (Prieto-
Hontoria et al., 2011). Regrettably only limited studies have researched the 
effect of visfatin on cancer cells in vitro and in vivo. Increased expression 
of Visfatin/Nampt/PBEF was discovered in various types of cancers 
including ovarian cancer, malignant astrocytoma, the human PCa cell 
lines, androgen-insensitive (PC3) and androgen-sensitive (LNCaP) as well 
as in human PCa, among specific relevance and emphasis in an obese 
people  (Patel et al., 2010).  
 
 
 
 
 
 
 
 
 
 
  
63 
 
1.6   QRFP:  
Of growing significance is illuminating the role of neuropeptides in the 
androgen-independent progress of prostate cancer. However, 
neuropeptides are secreted by neuroendocrine (NE) cells. The possible 
contribution of the prostate microenvironment to cancer progress becomes 
significant. Neuropeptides are mediators of neuronal signaling in nervous 
systems that have essential functions in regulation of physiological 
processes and human behavior (Nassel and Winther, 2010). A main 
challenge in neurobiology is to comprehend the evolutionary and functional 
significance of neuropeptide in human (Mirabeau and Joly, 2013). Almost 
all of the biologically active peptides that end with the sequence RFamide. 
However, neuropeptides described by a joint carboxy-terminal arginine (R) 
with an amidated phenylalanine (F) designated C-terminal Arg–Phe–NH2 
(RFamide) motif have been identified in vertebrates. Presently five types 
of RFamide peptides recognized in mammals can be subdivided into five 
groups which are derived from various precursor protein: (Sven 
Cnattingius) Gonadotropin-inhibitory (GnIH) group, (2) Neuropeptide FF 
(NPFF) group, (3) Pyroglutamated RFamide peptide (QRFP) group, (4) 
kisspeptin/metastin group and (5) Prolactin-releasing peptide (PrRP) group 
(Elphick and Mirabeau, 2014).  
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1.6.1 RFamide PEPTIDE RECEPTORS 
Several orphan receptors become clear to respond to various members of 
the RFamide family. The PrRP receptor was the first known RFamide 
receptor that was recognized and originally described as GPR10. Later, 
the putative receptors for NPFF and NPAF were recognized and termed 
NPFF1/GPR147 and NPFF2/GPR 74. The kisspeptin receptor was 
previously revealed as orphan G-protein coupled receptor GPR54 
(Fukusumi et al., 2003). Several peptides termed QRFP (26), QRFP (43), 
P518 or P550 that have similarities with the C-terminal Arg-Phe-NH2 
peptide family (RFamide), Individually, two types might expression that 
both, 26RFa and 43RFa, act like natural ligands of the orphan receptor 
GPR103 (Kampe et al., 2006). Following studies have discovered that 
26RFa and the longer form of 26RFa, named 43RFa (QRFP) family, were 
isolated from the human hypothalamus and spinal cord (Bruzzone et al., 
2006). QRFP is a secreted protein that is extensively expressed in the 
brain with highest expression levels in the, medulla, pituitary hormone 
regulation, cerebellum, retina, vestibular nucleus and, as well expressed in 
the prostate gland, bladder, colon, artery, coronary, testis, thyroid and 
parathyroid (Findeisen et al.) & (Bruzzone et al., 2006). However, QRFP 
might be implicated in extensive array of biological activities for instance 
food intake, cardiovascular functioning, blood pressure, analgesia, 
aldosterone secretion by the adrenal gland, stimulating metabolic rate, 
locomotor activity and cancer metastasis. Moreover, 26RFa is proposed to 
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stimulate bone formation (Baribault et al., 2006). The molecular weight of 
QRFP is about 15 kDa. The QRFP receptor is an orphan G-protein coupled 
receptor and has been initially cloned in human brain cDNAs (Primeaux, 
2011). 
1.6.2   QRFP PEPTIDE RECEPTOR (GPR103) 
Several receptors are main goals for regulating hypothalamic–HNS and -
HPA axis activity (Gloriam et al., 2007). The central nervous system (CNS) 
are consists four main groups (A) Ionotropic receptors as the excitatory 
glutamate  N-methyl-d-aspartate (NMDA), or inhibitory GABAA receptors 
that produce a membrane pore to permit the stream of ions, nuclear 
receptors counting sex steroid, glucocorticoid and thyroid hormone 
receptors that control transcriptional activation, (C) receptor tyrosine 
kinases as tyrosine kinase receptor type and the epidermal growth factor 
receptor (EGFR), which stimulate intracellular signaling networks as the 
mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK) pathway and (E) G-protein-coupled receptors (GPCRs) 
(Hazell et al., 2012). G-protein-coupled receptors (GPCRs) are involved in 
many diseases such as, obesity, diabetes, hypercalcemia, hypertension, 
psychotic disorders hypothyroidism, retinitis pigmentosa and cancer, and 
are therapeutic targets for about half of all for the pharmaceutical used in 
humans (Vilardaga et al., 2010). It is also one of the major and most 
functionally and structurally varied in the human genome. Many studies 
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published that around 880-1000 known GPCRs are identified in the human 
genome (Suga and Haga, 2007). Furthermore, the 7TM receptors can be 
clustered into five families: class A (rhodopsin family), class B (adhesion 
family), class C glutamate family, class D (frizzled/taste family) and class 
E (Secretin family) (Katritch et al., 2013). Predominantly of GPCRs 
includes receptors for signals and small molecules such as light, 
hormones, amino acids, neurotransmitters, odorants, and change in size 
from small molecules tpeptides to big proteins (Baribault et al., 2006). The 
common structural feature of GPCRs is seven transmembrane 7-TM 
domains joined by alternating intracellular and extracellular loops through 
interaction by heterotrimeric G-proteins (α, β and γ subunits) as single 
monomers (Kuszak et al., 2009). Two main signal transduction pathways 
are involving with G protein–coupled receptors the cyclic AMP and 
phosphatidylinositol. Additionally activated GPCRs interact by cytosolic 
arrestins (B-arrestin-1/2), which organise uncoupling G-protein receptor in 
space and time, stimulate receptor internalization and modulate different 
distal signaling responses such as the MAP kinase cascades (Kamal et al., 
2011). However, great number of GPCRs still known as “orphan receptors” 
whose cognate ligands has not yet been identified. Identification of ligands 
for orphan GPCRs provides a foundation for comprehending the 
physiological roles of those GPCRs and their ligands, which can implicate 
the central nervous, metabolic systems, cardiovascular, reproductive, 
endocrine, immune, inflammatory and digestive. Initial data indicate that 
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GPCRs play main roles in the pathogenesis of cancers. Some GPCRs are 
over- substantial activated in many cancers, and their abnormal signaling 
is complicated in various stages of tumorigenesis and metastasis (Lee et 
al., 2001a) & (Takayasu et al., 2006).                                                                    
GPR103 also named (QRFPR, AQ27, SP9155), originally recognized in 
2001, which is part of GPCRs class (A) and activated via the (QRFPs) 
(Xiao et al., 2014). GPR103 demonstrates similarities with orexin, 
neuropeptide FF, and cholecystokinin receptors. Its mRNA has been 
discovered mainly in the brain including the, thalamus, hypothalamus, 
pituitary, basal forebrain, cerebral cortex, and pons in humans. The long 
form of GPR103 was cloned from hypothalamus cDNA library and a 
genomic library (Jiang et al., 2003). GPR103 encoded a 455 amino acid 
protein and phylogenetic analysis showed that the orphan receptor shares 
characters with peptide-binding receptors. In human, 26RFa/QRFP has 
been discovered to be a high-affinity endogenous ligand for the earlier 
identified orphan GPCR, GPR103 (QRFPR) and commonly activates the 
Gq/Gi signal transduction pathway (Ukena et al., 2014). Considered a 
ligand for the G- protein coupled receptor GPR103, QRFP may possibly 
have orexigenic act, thereby acting as an appetite stimulant (Ukena et al., 
2010). Orexins originally considered, as neuropeptide appear to be 
expressed in peripheral tissues. However, newly neuropeptides Orexins 
acting at the GPCR orexin receptor 1 (OX1R) have indicated to suppress 
the progress of colon cancer cells via stimulating apoptosis throughout 
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cytochrome C release from mitochondria and Caspase activation 
(Laburthe and Voisin, 2012).  
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1.7 HYPOTH ESIS  
This interesting discovery of regulation of neuropeptides on cancer, 
suggest that play a role in cancer pathophysiology either directly or 
indirectly. In addition, with obesity playing a role in cancer pathogenesis it 
is timely that peptides that regulate energy homeostasis may also play a 
role in caner biology. This leads me to investigate the role of other 
neuropeptides, such as QRFP on prostate cancer.   
 
1.8    AIMS 
 To identify and explore the potential expression and function of 
QRFP and its receptor GPR103 in human prostate cancer tissue 
and cell lines (PC3, DU145 and LNCaP). 
 To identify the functional effects of QRFP on prostate cancer cell 
lines. 
 To study the effects of QRFP on intracellular signalling pathways in 
PCa cells. 
 To demonstrate the regulation of QRFP and GPR103 by adipokines 
and hormones on prostate cancer cells. 
 To measurement the QRFP levels in human serum blood. 
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CHAPTER 2 
 
MATERIAL AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
  
71 
 
 2.1  MATERIALS  
 
2.1.1  EQUIPMENT 
‘Mr. Frosty’ cryo-freezing unit: Fisher Scientific, Loughborough, UK. 
Fuji medical X-ray film: Fuji Photo Film Company, Tokyo, Japan. 
NanoDrop spectrophotometer: Labtech International, Ringmer, UK. 
Spectrophotometer (Beckman DU640): Beckman Instruments Inc, 
California, and USA. 
2.1.2  BIOCHEMICAL REAGENTS AND KITS: 
Bovine serum albumin (BSA): Sigma-Aldrich, Gillingham, UK. 
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) kit: 
Promega, UK. 
Ethidium Bromide: Sigma-Aldrich, Gwellingham, UK. 
Ammonium persulphate (APS): Sigma-Aldrich, Gwellingham, UK. 
10X protein running buffer: Department of Biological Sciences, University 
of Warwick – Media Preparation. 
Protein gel running buffer: Department of Biological Sciences, University 
of Warwick – Media Preparation.  
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10X protein transfer buffer: Department of Biological Sciences, University 
of Warwick – Media Preparation. 
Polyvinylidene difluoride (PVDF) membranes: Millipore, Billerica, MA, USA 
N, N, N’, N’- tetramethylethylenediamine (TEMED): Sigma-Aldrich, 
Gwellingham, UK. 
30% Acrylamide: Bis Acrylamide (37.5:1): GENE FLOW, Fradley, UK. 
PH 7.8 Tris-EDTA buffer: Sigma-Aldrich, Gwellingham, UK. 
Halt™ Protease Inhibitor Single-Use Cocktail (100X). Life Technologies, a 
Thermo Fisher Scientific brand, UK. 
PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa. Life 
Technologies, a Thermo Fisher Scientific brand, UK. 
PrimerDesign Ltd Precision Reverse Transcription kit: Primer Design Ltd, 
Southampton. 
Radio-immunoprecipitation Assay or lysis buffer (RIPA): Sigma-Aldrich, St. 
Louis, MO, USA. 
TBE agarose gel running buffer- Department of Biological Sciences, 
University of Warwick – Media Preparation. 
TE (Tris-HCL/EDTA) buffer- Department of Biological Sciences, University 
of Warwick – Media Preparation.  
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Tris Buffered Saline (TBS) containing 0.1% TIen-20: Department of 
Biological Sciences, University of Warwick – Media Preparation.  
Tris-HCL [tris (hydroxymethyl) aminomethane, pH adjusted with HCl]: 
Sigma-Aldrich, Gwellingham, UK. 
YO-PRO® (Life Technologies, Carlsbad, CA, USA). 
Hoechst® stain (Invitrogen, Eugene, OR, USA). 
β-mercaptoethanol: Sigma-Aldrich, Gillingham, UK. 
SYBR® Select Master Mix, Life Technologies, a Thermo Fisher Scientific 
brand, UK. 
Trypsin solution: Department of Biological Sciences, University of Warwick 
– Media Preparation. 
Camptothesin: BioVision, California, USA. 
GenElute™Mammalian Total RNA Miniprep kit (Sigma-Aldrich, St. Louis, 
MO, USA). 
Bis-chorionic Acid (BCA), Sigma Aldrich, Dorset, UK. 
Anti-GPR103 antibody (Acris Antibodies, Herford, Germany). 
Anti-QRFP-43 antibody (Phoenix Pharmaceuticals, Belmont, CA). 
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2.1.3   CELL CULTURE MEDIA AND CELL LINES 
HAMS-F12 and RPMI-1640 culture media was purchased from Sigma-
Aldrich (Gillingham,UK) and from Invitrogen (Paisley, UK) respectively. 
 Fetal Calf Serum (FCS) was from (Fisher Scientific, UK). 
Phosphate Buffered Solution (PBS): Department of Biological Sciences, 
University of Warwick – Media Preparation. 
Becton Dickinson (BD) Falcon™ 25, 75 and 175cm2 cell culture flasks 
were used for all cell cultures as appropriate. 
Antibiotic-Antimycotic (100X) from (Gibco, Life Technologies). 
Human prostate cancer cell lines (PC3, DU145 and LNCaP) were obtained 
from the American Type Tissue Association (ATCC, Manassas, VA, USA). 
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2.2  METHODS 
2.2.1  COLLECTION OF HUMAN SAMPLES  
Human prostate tissue was obtained from men undergoing prostate 
procedures (e.g. radical retro-pubic prostatectomy (RRP), transurethral 
resection of the prostate (TURP) and transrectal ultrasound (TRUS) and 
prostate biopsy) at University Hospital, Coventry (University hospitals 
Coventry & Warwickshire (UHCW) NHS Trust). A favourable ethical 
opinion was obtained from the NHS National Research Ethics Service 
(North West 3 Research Ethics Committee - Liverpool East) prior to tissue 
collection. Local Research & Development UHCW NHS Trust) approval 
was also obtained prior to the commencement of tissue collection at 
University Hospital, Coventry. Men undergoing prostate surgery for either 
benign or malignant conditions or undergoing a prostate biopsy for 
suspected cancer either with an elevated age-specific PSA or with an 
abnormal prostate investigation were approached for potential inclusion 
into the study. Patients were given a full explanation of the nature of the 
study including the potential benefits and risks of taking part. Potential 
participants were also given an information sheet (see Appendix A) with 
which to make an informed decision about their inclusion in the study. 
Patients who were willing to be recruited for inclusion in the study were 
asked to sign a consent form. Patients received a signed copy of the 
consent form (see Appendix B) and a further signed copy of the consent 
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form was subsequently filed in the patient records. In some cases, patients 
had catheters in situ and so this was noted at the time of recruitment. The 
patients’ medical and drug history was taken as well as any prior treatment, 
if any, for prostate cancer. During TURP procedures and TRUS & prostate 
biopsies prostate tissue was collected and immediately snap frozen in 
liquid nitrogen and stored at -80 oC until use. Radical prostatectomy 
specimens were removed en-bloc and were formalin-fixed-paraffin-
embedded as per standard hospital practice. Tissue was available for use 
after the hospital pathologist had issued a final pathology report of the 
specimen for grading/staging purposes.  
2.2.2   CELL CULTURE   
Prostate cancer cell lines (PC3, DU145 and LNCaP) cells were cultured, 
as per manufacturer’s instructions, in Hams-F12, and RPMI media 
respectively, supplemented with 10 % fatal calf serum (FCS), 5 ml of 100x 
Antibiotic-Antimycotic and cultured in 75 cm2cell culture flasks. Flasks were 
incubated in a humidified incubator at 37°C in 5 % CO2 and routinely 
passaged at approximately 70-80 % confluence (examined by microscopic 
inspection). Prior to each experiment in all tests, cells were used between 
the third and twenty-five passages only 
2.2.3  SUBCULTURE OF ADHERENT CELLS: 
Cells were washed with PBS. 2-3 ml of Trypsin EDTA solution were added 
to the flask (T75 cm2) and incubated at 37 ºC for 3-5 minutes until the cells 
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detached. 8-10 ml of fresh medium was transferred into the flask to block 
further trypsinization. After centrifugation at 1000 rpm for 5 min, the cells 
were re-suspended with fresh medium. A part of the cell solution was taken 
and transferred into a new flask containing 15 ml of growth media for 
further culturing. Every 2 –3 days the media was replaced with fresh media. 
2.2.4  RESERVATION OF CELLS: 
Cells were prepared as described previously for splitting and then 
centrifuged at 1000rpm for 5 minutes. The cells were re-suspended in cryo-
protective medium (5% dimethyl sulfoxides DMSO, 95 % FBS). 1ml of the 
cell suspension was dispensed into a cryogenic vial and then stored in a 
cryo-freezing container at -80 ºC. After 48 hours, the cells were transferred 
into liquid nitrogen.  
2.2.5  CELL COUNTS USING HEMOCYTOMETER: 
Haemocytometer was used to determine the cell density (cells/ ml) of 
medium and hence the appropriate volume of cell suspension to use when 
freezing cells or plating cells out prior to experiments. The haemocytometer 
was cleaned by using 70 % ethanol solution and the cover-slip placed in 
the correct position on the glass slide. The appearance of Newton’s rings, 
rainbow-like interference patterns, which are visible on holding the 
haemocytometer up to the light, indicated that the cover slip was in the 
right position. The cell suspension was mixed and 50 µl removed and 
mixed with an equal volume of Trypan Blue solution that penetrates the 
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membrane of nonviable cells, staining them blue. The haemocytometer 
chamber was filled by placing a Gilson’s tip containing the cell suspension 
and Trypan Blue mixture at the junction of the cover-slip and the counting 
chamber. The haemocytometer was then viewed under a microscope. The 
scored area was brought into focus and under low magnification. 
Generally, cells in the left-hand and top grid markings were included while 
those in the right hand and bottom markings were excluded. The total 
number of viable cells was then calculated as follows: 
Total number of viable cells = Total cell volume x 2 (dilution factor in Trypan 
Blue) x mean number of unstained cells (unstained count/2) x 104.                   
If the cell count was low, more than two 1mm2 areas were counted and 
averaged. 
2.3   TOTAL RNA EXTRACTION AND COMPLEMENTARY 
DEOXYRIBONUCLIC ACID (cDNA) SYNTHESIS 
Total RNA was extracted from human prostate cancer tissue and cell lines 
PC3, DU145 and LNCaP using Qiagen RNeasy plus Mini Kit. RNA 
samples were treated by RNase-free DNase to eliminate genomic DNA 
contamination and the concentration quantified. The purity and quantity of 
the extracted RNA was measured by a Nano-Drop spectrophotometer. 
Generally, 1 microgram of total RNA was reverse transcribed into cDNA, 
by using Moloney Murine Leukemia Virus (M-MuLV) Reverse 
Transcriptase and random hexamers as primers.   
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2.3.1   REAL TIME QUANTITATIVE PCR 
The sequences for the sense and antisense primers respectively are listed 
in (Table 1). SYBR Green® real-time PCR was performed on an ABI 7500 
fast real time PCR using the primers listed in table 1. PCR was performed 
using 4 μl (1:5 diluted) cDNA in 10 μl Master Mix, 4 μl water and 1 μl sense 
and antisense primers. A series of three dilutions for each cDNA was used 
to ensure linear amplification and to measure primer efficiency. For 
analysis, expression of genes of interest were normalised against the 
expression of the housekeeping gene 18s RNA or GAPDH. Negative 
controls for all the reactions included preparations lacking cDNA or RNA-
lacking reverse transcriptase in place of the cDNA. The relative mRNA 
levels were expressed as a ratio using the "2-∆ct method" for comparing 
relative expression results between treatments in real-time PCR.  All gene 
expressions were measured by real-time PCR, using 1 µg total RNA and 
oligo-dT primers as RT primers. 
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Table 2.1 Primer Sequences of the sense and anti-sense primers. 
Gene / 
product size 
Forward primer Reverse primer 
hQRFP 
(136bp) 
5’-
AGGCAGGACGAAGGCAG
TGA -3’ 
5’-
GACCGAAGCGGAAG
CTGAAG-3’ 
hGPR103 
(140bp) 
5’-
CCAGTCTACCGCTGTTGT
GA-3’ 
5’-
GCCAGACCACACCTA
GCATT-3’ 
GAPDH 
(190bp) 
5’-TGC ACC ACC AAC TGC 
TTA G-3’ 
5’-GAT GCA GGG ATG 
ATG TTC-3’ 
 
2.3.2   SEQUENCE ANALYSIS  
The PCR products samples were purified from the 1% agarose gel using 
the QIAquick Gel Extraction Kit (Qiagen, Crawley, UK). PCR products were 
then sequenced in an automated DNA sequencer, and the sequence data 
were analysed using Blast Nucleic Acid Database Searches from the 
National Centre for Biotechnology Information, confirming the identity of 
the products. 
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2.4  WESTERN BLOTTING 
2.4.1 DETERMINATION OF PROTEIN CONCENTRATION  
Protein concentrations were determined calorimetrically using the BCA 
(bicinchoninic acid) protein assay kit. 
2.4.2   MAKING: SDS-PAGE gel  
Using Bio-Rad mini Protean II Gel system 8 % or 10 % SDS-PAGE gel was 
made up, respectively, according to manufacturer’s protocol. First the 
resolving gel was prepared by adding 30 % Acrylamide: Bisacrylamide 
(37.5:1),1.5M Tris-HCL tris (hydroxymethyl) amino-methane, pH adjusted 
with HCl], pH 8.0), pH 8.8, 10% SDS, deionised water, 10% ammonium 
persulfate (APS) and N, N, N’, N’- Tetramethylethylenediamine (TEMED). 
The mixture was poured into the casting system to gain the length of gel 
required, leaving sufficient space for the stacking gel and then allowed to 
set at 20 oC for 30 minutes. Apart from 1.5 M Tris-HCl, pH 8.8 (substituted 
by 0.5 M Tris-HCl, pH 6.8), the stacking gel was prepared using all of the 
reagents as described above. The mixture was subsequently applied on 
top of the pre-set resolving gel and a comb was placed to allow Well 
formation. The gel was allowed to set at 20 oC for 20 minutes. The gel was 
located into the electrophoresis running system and adequate running 
buffer was added to the tank. 
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2.4.3   WESTERN BLOTTING OF CELL LYSATES AND   
CONDITIONED MEDIA  
 
Sample preparation 
Western blotting was used to assess protein levels in cell lysates and 
conditioned media from both treated and untreated prostate cancer cell 
lines. Protein lysates were prepared by adding equal amounts of radio-
immunoprecipitation lysis buffer 1x RIPA buffer to disrupt cells & tissues, 
centrifuged at 8,000 rpm for 5 minutes and resulting protein lysates were 
quantified using a BCA (bicinchoninic acid) protein assay kit.  5 µl of each 
cell supernatant or standard was added to 96 well plate and a 195 µl of a 
mixture of CuSO4, PBS and BCA solution, was added to each well (4 µl 
CuSO4, 5 µl PBS and 200 µl of BCA solution) each well or sample. 
Followed by incubation for 20-30 minutes at 37°C and the absorbance was 
measured using a plate reader (Multiskan Ascent 96/384 Plate Reader) at 
570 nm. Samples were adjusted to equal amounts using standard 2X 
Laemmli buffer and placed in a boiling water bath for 5 min, and then 
allowed to cool at room temperature. The proteins were separated by SDS-
PAGE and transferred to poly vinylidene difluoride (PVDF) membranes at 
100 V for one hour in a transfer buffer containing 20 mM tris, 150 mM 
glycine, and 20 % methanol. PVDF membranes were blocked in tris 
buffered saline (TBS) containing 0.1 % TIen-20 and 5 % BSA for one or 
two hours. The PVDF membranes were incubated with the relevant 
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primary antibodies overnight at 4°C. On the following day, membranes 
were washed thoroughly four times in 60min with TBS-0.1% Tween before 
incubation with the appropriate secondary antibody for one hour at room 
temperature. Antibody complexes were visualized using 
chemiluminescence ECL+. The appropriate positive and negative controls 
were utilised. The densities were measured using a scanning densitometer 
coupled to scanning software ImageQuant™. 
Table 2.2 Table demonstrating antibodies used for western blotting with 
concentrations and relevant secondary antibodies. 
Primary antibody Concentration Secondary 
antibody 
Concentra
tion 
Phospho – AKT 1: 1000 Anti – rabbit 1: 5000 
Phospho –QRFP 1: 4000 Anti – rabbit 1: 12000 
Phospho – GPR103 1 :3000 Anti – rabbit 1: 8000 
Phospho – P38 1: 1000 Anti – rabbit 1: 2000 
Phospho – JNK 1 :1000 Anti – rabbit 1: 2000 
Phospho – AGR2 1: 1000 Anti – sheep 1: 4000 
Phospho–  
Csapease-3 
1: 1000 Anti – rabbit 1: 1000 
 
B-actin 1: 15 000 Anti – rabbit 1: 10 000 
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2.4.4 MAPK- (ERK1/2, p38 and JNK1/2 MAPK) AND AKT 
ACTIVATION ANALYSIS 
Prostate cancer cell line PC3 and DU145 cells were serum starved 
overnight seeded on to 6 well plates., and then treated with or without 
QRFP 100 nM for different time pointe (0 = Basal, 5, 15, 30 and 60 minutes) 
for MAPK ERK, P38, JNK and AKT studies and incubation with QRFP for 
24 hours to detect downstream signalling pathways. Cells were then lysed 
with RIPA buffer and adjusted to equal amounts using Laemmli buffer, 
mixed, sonicated, boiled, centrifuged (5,000 rpm for 3 minutes), and stored 
at -20 ºC until use. 15-25 µg total protein per well was loaded onto 10 % 
SDS-PAGE gel. Following this, proteins were transferred onto PVDF 
membranes, blocked in tris buffered saline (TBS) containing 0.1% TIen-20 
and 5 % BSA for one hour. The PVDF membranes were incubated with 
primary antibody for phosphorylated proteins (ERK/ p38/ JNKs/ Akt) 
overnight at 4°C respectively (table 2.2). Membranes were washed 
thoroughly for 60min with TBS-0.1% Tween before incubation with the 
secondary antibody for one hour at room temperature. Antibody complexes 
were visualized using chemiluminescence ECL prime. The densities were 
measured using a scanning densitometer coupled to scanning software 
Image Quant™. 
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2.4.5  STRIPOING AND RE-PROBING MEMBRANES WITH TOTAL 
ANTIBODIES 
DENSITOMETRY ANALYSES OF WESTERN BLOTS  
The membranes were submerged in stripping buffer 10 % SDS (1M Tris-
HCl, pH 6.8, β-mercaptoethanol) and incubated at 50oC for 30 minutes 
with occasional gentle agitation followed by washing with TBS-0.1 % 
Tween at room temperature 10 minutes twice. PVDF membranes were 
blocked in tris buffered saline (TBS) containing 0.1 % TIen-20 and 5% BSA 
for one hour at room temperature. The PVDF membranes were re-probed 
with primary antibody for total ERK, p38, JNK, Akt and GAPDH 1:1000 
dilution overnight at 4°C. On the following day, membranes were washed 
thoroughly for 60min with TBS-0.1 % Tween before incubation with the 
secondary antibody for one hour at room temperature. Antibody complexes 
were visualized using chemiluminescence ECL prime. The densities were 
measured using a scanning densitometer coupled to scanning software 
Image Quant™. 
2.5  PHOSPHO-KINASE ARRAY 
The Human Phospho-Kinase Array was achieved to analyzing profiling 
protein phosphorylation at the cellular level, which is fundamental to 
understand how the intracellular signaling pathways respond to changes 
external and internal stimulations. This array allows for the simultaneous 
detect of the relative phosphorylation of 43 proteins. 
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2.5.1  SAMPLES PREOARARTION  
Twenty -four hours after culture PC3 and DU145 Cells in T75 cm2 flask, 
cells were starved for 24 hours and then stimulated with QRFP (basal, 1, 
10 and100nM) for different time point 5, 15, 30 and 60 minutes. Cells were 
washed with PBS and lysed by Lysis Buffer provided with the kit (R&D 
Systems) mixed with protease & phosphatase Inhibitor cocktail and then 
rocked gently for 30 min at 4 °C. The supernatant lysate is collected by 
microcentrifugation at 14,000 × g for 5 min and the protein concentrations 
were quantified using a BCA (bicinchoninic acid) protein assay kit.  
2.5.2   ARRAY PROCEDURE  
The Human Phospho-Kinase Array was separated into 2 parts of 
membranes (A & B) and the nitrocellulose membranes were blocked with 
the given blocking array buffer. These were later incubated with cell lysate 
overnight at 4 °C on a rocking platform shaker. Later membranes were 
washed three times with 1x wash buffer for 10 minutes on a shaker to 
remove boundless proteins. Membranes (A&B) were incubated with 
antibody A and B cocktail respectively for 2 hours then followed by further 
washing with 1x wash buffer x3. Then membranes were incubated with a 
mixture of biotinylated detection antibodies and streptavidin HRP 
secondary antibodies. Chemiluminescent ECL Prime exposure reagents 
were applied to detect spot densities. Blot array images were examined by 
using the GeneTools image analysis software (Syngene). The averaged 
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density of duplicated spots representative each phosphorylated kinase 
protein was defined and used for the relative alterations in phosphorylated 
kinase. 
2.6 PROLIFERATION, MIGRATION AND INVASION ASSAY 
Several techniques and kits are available to use to measure many aspects 
of cell proliferation, cell viability such as MTS assay. The tetrazolium 
compound MTS assay is a quantitative colorimetric assay and highly 
sensitive method for assaying cell proliferation and survival in mammalian. 
Cell migration and invasion in addition to proliferation, are significant facets 
of many critical biological processes. Monitoring of cell migration and 
invasion is critical in biomedical research, in order to know the pathways 
regulating migration and invasion, and to develop agents that control these 
processes. Some reports require credible assays for monitoring migration, 
and invasion and several are available, including the “scratch assay” and 
the “transwell assay. 
Similarly, the xCELLigence CIM assay might be used to investigate 
possible therapeutics and study the fundamental biology of invasive and 
migratory processes. Nevertheless, in contrast to classic transwell assays, 
this CIM assay may follow migration and invasion in real-time at minute or 
second intervals automatically with no need for exogenous labels. This 
technique has been shown to be extremely positive when working with 
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primary cells. It has been recommended that the CIM assay eliminates the 
variability and provide flexibility, accuracy, fast, high quality results for less 
time and clear data presentation. The migratory cells requirement attaches 
to the microelectrode to be identified, thus the CIM assay is not suitable 
with non-adherent cells or cells grown in over each other as LNCaP cells. 
Though, coating the membrane with ECM proteins or using certain 
chemokine to increase cell attachments might overcome this (Iqbal et al., 
2013). Real time cell proliferation, migration and invasion experiments 
were performed using the ‘xCELLigence’ system (ACEA, Biosciences, San 
Diego, CA, USA), which comprise of the Real Time Cell Analyzer Dual 
Purpose (RTCA-DP) instrument was placed in a humidified incubator 
maintained at 5 % CO2 and at 37°C, E-plate 16 for proliferation while CIM 
plates (Cell migration & invasion) (Roche Diagnostics GmbH). As cells 
attached to the bottom of the well and grow over, the RTCA software 
(Roche) monitors and reports as change in Cell Index (Rove et al.2012). 
CI is a measure of cell number, cell attachment, and cell increasing.  
2.6.1  MTS PROLIFERATION ASSAY 
Cell proliferation was determined with CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (MTS) kit. PC3 and LNCaP cells were trypsinized 
and cultured on 96-well plates overnight in a humidified incubator at 37˚C 
in 5% CO2 environment. The media was aspirated and replaced with 
100μL of serum-free media HAMS-F12 and RPMI-1640 medium containing 
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1% FCS respectively and treated with different concentrations of QRFP      
1 nM, 10 nM and 100 nM for 24 and 48 hours. Media supplemented with 
10% FCS was used as a positive control. Following QRFP treatment, 20 µl 
MTS reagent was added to plate containing 100 µl of culture medium in 
each well. The absorbance at 490 nm was recorded using an ELISA plate 
reader (EL800, Bio-Tek Instruments, Inc, Winooski, VT, USA). The 
percentage of the absorbance was calculated against untreated cells.   
2.6.2   xCELLigence PROLIFERATION ASSAY 
For proliferation assay 100 μl of media was added to each well of the           
E-plate 16 and scanned to check all connections are ok. Background 
measurement was taken before plating the cells. PC3 and DU145 cells 
were split as described above and counted on hematocytometer. 
Aroun100 μl of cell suspension (6x103) cells were seeded in each well. 
Plate was left for 30 mints at room temp under the hood for the cells to 
settle down before being put on the SP/DP system. After 24 hours’ 
incubation, cells were treated with QRFP 0 nM=basal, 1 nM, 10 nM, 100 
nM and 10 % FCS as positive control (5 μl). Plate was put on the plate 
reader, until the end of experiment, which was in total 24 and 48 hours. 
2.6.3   xCELLigence INVASION ASSAY 
 For invasion assays, most the stuffs including; Eppendorf tubes, CIM plate 
assembly tool, matrigel and tips, were placed in the fridge, 24 hours before 
the experiments and all experiments were carried on ice. Complete media 
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was changed with serum free media at least 4 hours before starting the 
experiment. CIM plate was scanned to inspect connections were 
satisfactory. Matrigel was diluted at 1/15 using cold serum free media. 50 
μl of matrigel was added to create a 3D biomatrix film in each well prior to 
cell seeding of the upper chamber of the CIM plate and the excess 30 μl 
coat of matrigel was removed and plate was left for 4 hours in the hood. 
160 μl pre-warmed media with QRFP (0 nM, 1 nM, 10 nM and 100 nM) 
also EGF 50 ng/ml as positive control were added to the lower chamber of 
the plate. Both the upper and bottom chambers were carefully placed 
together. Additional 30 ul of serum free media was added to the top 
chamber. Plate was loaded on RTCA, connections were checked and left 
to equilibrate inside the chamber. Background measurement was taken 
after 1-3 hours.  Plates were taken out and 100 ul of PC3 and DU145 cells 
were added to upper chamber and left in the hood for 30 mints to settle 
down the cells. Plate was loaded on the RTCA for 8 hours. 
2.6.4   xCELLigence MIGRATION ASSAY 
For migration assays, the same method was followed without Matrigel 
steps. 
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2.7   APOPTOSIS ASSAY 
Many critical methods of apoptosis markers include chromatin 
condensation which uses YO-PRO-1 dye stain to distinguish between 
normal and apoptotic cells from a cell population. Propidium iodide and 
Hoechst 33342 are often used together for flow cytometric or fluorescence 
imaging analysis of the stages of apoptosis and live cells.                           
Other apoptosis appears in the cell nucleus, such inter-nucleosomal DNA 
fragmentation and finally chromatin condensation. Several of the assays 
used to detect apoptosis investigate the characteristic DNA fragmentation 
that occurs through apoptosis. DNA fragmentation ELISA assay was used 
as a biochemical hallmark of late stage apoptosis to illuminate apoptosis 
in both the extrinsic and intrinsic apoptotic pathways (Hooker et al., 2012).  
2.7.1   Vybrant® APOPTOSIS ASSAY  
PC3 and LNCaP cells were harvested and plated in 24-well plates and 
incubated 24 hours for the apoptosis assy. Cells were replaced and 
incubated in serum-free media for at least 4 hours prior to commencement 
of cell treatments with 0nM= (basal), 1 nM, 10 nM and 100 nM QRFP, with 
Hydrogen peroxide (1:200 000) used as positive control and 100 nM leptin 
as negative control. After the individual time period had elapsed cells all 
cells were labelled by Hoechst 33342 ® stain (Invitrogen, Eugene, OR, 
USA) for 30 minutes before to the adding of the nucleic acid stain YO-
PRO® (Life Technologies, Carlsbad, CA, USA). Two independent time-
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points were used for the apoptosis assay: 24 and 48 hours.  YO-PRO® is 
an iodine-based stain that only labels cells that are identifying apoptotic 
cells and does not label living cells wile Hoechst for live cells, thus allowing 
detection of cells undergoing apoptosis using (fluorescent microscopy).   
YO-PRO® allows assessment of apoptosis without interfering with cell 
viability. Cells were labelled for an additional 30 minutes with YOPRO® 
and were washed twice later with PBS warmed solution. Plates were 
imaged using the GE healthcare IN Cell Analyzer 1000. Number of 
apoptotic cells was analysed using the formula below:  
YO-PRO® - labelled (apoptotic) cells× 100 = % rate of apoptosis  
Hoechst® - labelled (total) cells 
 
2.7.2   DNA RAGMENTATION ELISA 
This kit detects BrdU-labelled fragments released from degraded cells in a 
sandwich ELISA format. Apoptosis levels were measured 
using Photometric Enzyme-Linked ImmunoSorbent Assay (ELISA) for 
detection of 5-bromo-2′-deoxy-uridine (BrdU) labelled DNA fragmentation 
in cell lysates. About of 10,000 of PC3, DU145 and LNCaP cells were 
cultured in 96 well plates for 24 hours independently. 10 µM of BrdU 
reagent was added to label the cells overnight following this cells were 
incubated with QRFP (1, 10 and 100 nM) for 24 and 48 hours. 
Camptothecin, DNase and H2O2 (2 µM) were used as positive control.  
100 µl of anti-DNA coating solution was added to each 96 well plate and 
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left to incubate at 37 ºC for 1 hour. The plate was then washed three times 
with wash solution. The final wash solution was then left in situ prior to 
irradiation in a microwave oven for 5 minute to allow denaturing of the 
immunocomplex BrdU-labeled DNA-fragments. 100 µl of Anti-BrdU 
antibody peroxidase conjugate (Anti-BrdU-POD) was then added and 
incubated for 90 minutes which interacts with the BrdU-labeled DNA to 
form an immunocomplex. After washing the plate 100 µl of substrate 
solution was added and incubated in the dark for 20 minutes before adding 
20 µl of stop solution and incubating for an additional 5 minutes and then 
measured the plate at 450 nm. The results were calculated as values 
comparative to basal and analyzed by Graphpad software for statistical 
significance. 
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Table 2.3 The Human Phospho-Kinase Array coordinates. 
List of phosphokinase and phosphorylation site used in assay  
 
Akt 1/2/3 (S473) 
 
Akt 1/2/3 (T308) Fgr (Y412) 
AMPK alpha1 (T183) AMPK alpha2 (T172 Fyn (Y420) 
beta-Catenin Chk-2 (T68) GSK-3 alpha/beta 
(S21/S9) 
c-Jun (S63) CREB (S133) Hck (Y411) 
EGF R (Y1086) eNOS (S1177) HSP27 (S78/S82) 
ERK1/2 (T202/Y204, 
T185/Y187) 
FAK (Y397) HSP60 
JNK 1/2/3 (T183/Y185, 
T221/Y223) 
Lck (Y394) Lyn (Y397) 
MSK1/2 (S376/S360) p27 (T198) p38 alpha (T180/Y182) 
p53 (S15) p53 (S392) p70S6 Kinase (T421/S424) 
PDGF R beta (Y751) PLC gamma-1 (Y783) PRAS40 (T246) 
Pyk2 (Y402) RSK1/2/3 (S380) Src (Y419) 
STAT2 (Y689) STAT3 (S727) STAT3 (Y705) 
STAT5a (Y699) STAT5a/b (Y699) STAT5b (Y699) 
STAT6 (Y641) WNK-1 (T60) TOR (S2448) 
Yes (Y426) GSK-3 alpha/beta 
(S21/S9) 
PLC gamma-1 (Y783) 
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2.8  SERUM COLLECTION  
Human blood samples (serum) were collected following ethical approval 
from 3 patient groups: healthy controls, benign prostatic hypertrophy (BPH) 
and prostate adenocarcinoma (PCa). Samples were stored at -80 oC and 
were thawed slowly on ice. Circulating levels of human QRFP were 
determined by Enzyme-Linked Immunosorbent Assay (ELISA) using the 
QRFP-26 (Human) - EK-048-76 EIA Kit (Phoenix Pharmaceuticals, Inc 
USA) and employed as per manufacturer’s protocol. The assay employs a 
competitively enzyme immunoassay technique. 
Five Serial dilutions were prepared giving concentrations ranging from    
100 ng/ml- 0.01 ng/ml. Air was used as blank. 50 µl of undiluted samples 
were added to each well of standards, positive control, 25 µl primary 
antibody and 25 µl biotinylated peptide. All samples were measured in 
duplicate and incubated for 2 hours at room temperature.  The plate was 
washed 4 times with 350 µl/well of 1×assay buffer. 100 µl/well of SA-HRP 
solution were added and incubated for 1 hour at room temperature. 
Following plate second washing 100 µl/well of TMB substrate solution was 
added and incubated at room temperature for 1 hour. Terminate reaction 
with 100 µl/well of stop solution (2N HCI) was then added directly and 
mixed thoroughly using a plate rocker. Absorbance O.D. was then 
measured by using a micro-plate reader (Tecan Group Ltd. Männedorf, 
Switzerland) at 450 nm and analyse results.  
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 2.9   STATISTICAL ANALYSIS 
All results presented are expressed as the mean ± S.D. A student’s t-test 
was used to difference between two groups. Comparisons between more 
than two groups were analysed by ANOVA (non-parametric) analysis 
followed by post hoc Tukey’s multiple comparison test. Values were 
considered to be statistical significance set at either *, p < 0.05, **, p < 0.01 
or ***, p < 0.001. All statistical analyses were performed using Graph Pad 
software (La Jolla, CA, USA). 
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CHAPTER 3  
 
THE EXPRESSION OF QRFP AND ITS 
RECEPTOR (GPR103) IN PROSTATE 
CANCER CELL LINES AND TISSUE 
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3   INTRODUCTION 
The QRFP is a member of RFamide family of neuropeptides, characterized 
by their common protein C-terminus consisting of an arginine (R) and an 
amidated phenylalanine (Crawford). QRFP exerts its functional effects 
through activation of Gprotein coupled receptor GPR103.  The human 
QRFP gene was discovered using a search of the DNA sequence 
information. To date only one type of GPR103 has been identified in human 
(GPR103), and two types of receptors GPR103a and b has been identified 
in rodents.  Initial studies using protein quantification and quantitative PCR 
analysis showed QRFP and its receptor (GPR103) were abundantly 
expressed in the brain include hypothalamus, cortex and spinal cord. 
QRFP is strongly conserved hypothalamic neuropeptide that has been 
characterized in various species. In 2013 a group of researchers 
demonstrated that GPR103 is also expressed in human prostate cancer 
tissues and its expression significantly increases with progression of 
cancer. However, the studies to date have demonstrated conclusively the 
effect of QRFP on prostate cells. 
Appetite is commonly influenced in advanced cancer patients leading to 
anorexia and consequently insufficient food intake (Dwarkasing et al., 
2014). The pathogenesis of anorexia is multifactorial and is associated to 
disorders in any of these complex interaction including physiologic, 
gastrointestinal, neuronal system and endocrine mechanisms as well as 
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nutritional factors (Adams et al., 2009). Furthermore, cytokines, hormones, 
and chemicals derived from the tumour are found in the circulation and 
might prompt a various set of neurochemical events causing an imbalance 
between food intake and energy expenditure in cancer anorexia (Ihnatko 
et al., 2013). Anorexia in cancer patients is thought to be caused by the 
inefficiency of food intake regulating systems in the hypothalamus to react 
adequately to negative energy homeostasis during cancer development 
(Dwarkasing et al., 2015). Under normal conditions food intake and energy 
consumption are controlled by complicated, redundant, and distributed  
neural systems involving thousands of genes and reflecting the essential 
biological significance of sufficient nutrient supply and energy homeostasis 
(Lenard and Berthoud, 2008). The hypothalamus controls a number of 
body functions, including feeding behaviour by different mechanisms, 
where interconnecting nuclei, particularly the arcuate nucleus (ARC), 
through interaction of peripheral hormonal and metabolic signals control all 
processes relating to regular energy homeostasis (Sedlackova et al., 
2012). The hypothalamus is the major regulator of feeding behaviour and 
receives information from peripheral hormones for instance peptide YY, 
glucagon like peptide-1, ghrelin and adipose signals including leptin and 
insulin and integrates input from several brain regions (Primeaux et al., 
2013). Neuronal pathways through these nuclei are organised into a 
complicated neural network in which specific orexigenic  and anorexigenic 
peptides circuits affect feeding and energy expenditure (Lenard and 
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Berthoud, 2008).  Thus, it is assumed that several neuropeptides play a 
significant role in the regulator of appetite and hormonal secretion might 
be involved in cancer-associated anorexia (Oswiecimska et al., 2005). 
There are many peptides implicated in the regulation of energy 
homeostasis, some of which are secreted centrally and others peripherally 
in the gastrointestinal tract (GI), while some secreted at both locations 
(Orbetzova, 2012). Disturbances of neuropeptide and neurotransmitter 
secretion impact the hormonal secretion such as neuropeptide Y (NPY), 
leptin, ghrelin and Insulin in cancer-associated anorexia (Jatoi et al., 2001).  
Leptin has been observed to play a main role in body mass regulation by 
acting in the central nervous system (CNS) to both increase energy 
expenditure and reduces food intake. Leptin crosses the blood-brain 
barrier (BBB) in a process that is highly organized and its receptors exist 
both centrally, in the hypothalamus, and peripherally, in several of organs 
including skeletal muscle, liver, pancreatic islets, kidney, bone marrow and 
lung (Kastin and Pan, 2000). Neurons holding anorexigenic neuropeptides 
are triggered by the adipocyte hormone leptin and stimulate reduced food 
intake and weight loss (Wisse et al., 2001). Low leptin concentrations in 
the brain increase the activity of the orexigenic signals for instance 
neuropeptide Y that stimulate feeding and negative energy expenditure, 
and reduction the activity of the anorexigenic signals that leads anorexia 
(Inui, 2001). In patients with advanced cancer, the serum leptin levels 
might be significantly lower as a result of decreased body fat weight 
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(Perboni and Inui, 2006). Serum leptin level appear to increase in the 
presence of anorexia-inducing cytokines, like interleukin-1β (IL-1β), and IL-
6 and tumor necrosis factor α (TNFα) (Engineer and Garcia, 2012). 
Neuropeptide Y (NPY), a neurotransmitter, is the most predominant 
peptides of the hypothalamus that stimulates food intake and is implicated 
in the regulation of sympathetic activity, body mass, and energy balance., 
but also produces various other effects on behaviour and other functions 
(Inui, 1999) & (Sanchez-de-la-Torre et al., 2011). NPY consists of an 
interrelated orexigenic network which includes orexin, galanin, agouti-
related protein (AgRP), opioid peptides and melanin-concentrating 
hormone (MCH). Most of these peptides are up-regulated in ob/ob mice 
that deficiency functional leptin, and their expressions are increased in 
fasting (Chigr et al., 2014). A number of studies suggest that changes of 
the NPY regulation play a role in the pathogenesis of anorexia associated 
cancer. This neuropeptide has been involved in the appetite-motivate 
effects of megestrol acetate, one of the drugs used to cure cancer 
associated anorexia. The other supposition is that it stimulates 
Neuropeptide Y synthesis, transfer and release in the hypothalamus 
(Perboni and Inui, 2006). Many RFamide-related peptides have been 
found in vertebrates and invertebrates and affect a range of physiological 
system including food intake, analgesia, locomotor activity, hormone 
regulation and blood pressure (Primeaux et al., 2013). Polyglutamylated 
RFamide peptide (QRFP) is a potent agonist of the G protein-coupled 
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receptor, GPR103 which is expressed in various tissues, but mainly in the 
hypothalamus (Jossart et al., 2014). It is hypothesized that QRFP exert 
actions in different brain areas in the hypothalamus and beyond the 
hypothalamus (Bruzzone et al., 2007). Some brain regions related to 
feeding behaviour were considered QRFP binding locations and several 
also expressed GPR103 (Primeaux et al., 2013). Besides increasing food 
intake, QRFP increases fat mass, body weight and adipogenesis and 
reduces thermogenesis (Jossart et al., 2014). The only description of 
circulating, QRFP is in anorexia women where levels are higher (Galusca 
et al., 2012). However, circulating levels of QRFP in human prostate 
cancer have not been described. 
 
3.1  HYPOTHESIS 
Human expression and circulating QRFP levels are potentially associated 
with prostate cancer and can possibly be used as a novel biomarker in 
prostate cancer. 
3.2  AIMS 
 The aim of this chapter is to investigate if QRFP & GPR103 are 
expressed in have the expression in human prostate cancer tissue 
and prostate cancer cell lines PC3, DU145 and LNCaP cells.  
  To determine human serum QRFP levels in prostate cancer.  
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3.3   RESULTS 
 
3.3.1 EXPRESSION OF QRFP AND GPR103 mRNA IN PROSTATE 
CANCER CELL LINES AND HUMAN PROSTATE TISSUE 
RT-PCR was used to detect, the expression of QRFP peptide & GPR103 
receptor mRNA in human benign and malignant prostate cancer tissue and 
in human prostate cancer cell lines (PC3, DU145 and LNCaP cells). The 
cells were cultured according to the methods previously described; Total 
cellular RNA was extracted from cells using 200 µl of a cell lysis buffer 
mixed with 10 µl/ml β-Mercaptoethanol (BME) per well. Each well was 
scraped using a 1 ml pipette tip to ensure adequate lysis of the cells. The 
following cell lysates and buffer was removed and placed in an Eppendorf 
tube on dry ice immediately for rapid freezing. For prostate cells RNA 
purification was performed using the GenElute™Mammalian Total RNA 
Miniprep kit according to the protocol. For human tissue RNA was purified 
employing a TRIZOL® RNA isolation as described in protocol (Deshpande 
et al. 2008). RNA was extracted and converted into cDNA. The cDNA was 
amplified by RT PCR using the primers for QRFP & GPR103 described in 
table 1. Both GPR103 and QRFP gene expression was observed in PC3 
cells, LNCaP cells and in human prostate tissue (Figure 3.1). 
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Figure 3.1 RT-PCR analysis for QRFP & GPR103 gene expression in 
prostate cancer. The mRNA for both QRFP (136 bp) and GPR103 (140 
bp) were detected in human prostate tissue also in PCa cell lines PC3 and 
LNCaP. Bands were excised and purified using QIAquik gel extraction kit 
(Qiagen) and sequenced to confirm their identity. A no sample negative 
control was done using water as an alternative to cDNA and RT to 
emphasize absence of genomic contamination. 
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3.3.2 QRFP AND GPR103 PROTEIN EXPRESSION IN HUMAN 
PROSTATE TISSUE AND CELL LINES   
Protein was extracted from BPH tissue, LNCaP, PC3 and DU145 cells in 
order to demonstrate the presence of QRFP and GPR103 protein. Protein 
levels were identified using western blot using the relevant antibodies Anti-
QRFP & GPR103 with secondary anti-goat. Please see (table 2-2) for the 
relevant antibody concentrations. 
 
 
 
 
Figure 3.2 Detection protein expression of QRFP & GPR103 in PCa. 
Western blot analysis revealed protein expression for QRFP (14 kDa) and 
GPR103 (49 KDa) in the three prostate cancer cell lines (PC3, DU145 and 
LNCaP), and I was also able to detect expression of GPR103 and QRFP 
in human prostate tissue. 
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3.3.3   DETERMINING QUANTITATIVE EXPRESSION OF QRFP & 
GPR103 IN HUMAN PROTATE CANCER 
In order to evaluate if there was any variance between the expression of 
QRFP & GPR103 mRNA and protein between benign and malignant 
prostate tissue. Five human prostate tissue samples were used for each 
group of benign and malignant. QRFP & GPR103 mRNA levels in human 
prostate tissue were determined by a real-time PCR assay. GAPDH was 
used as an internal reference gene for each sample. The data showed 
expression of QRFP & GPR103 were statistically significantly higher in 
prostate cancer samples compared to the samples from benign prostate 
hyperplasia (BPH) according to a t-test for QRFP ***P<0.001 and GPR103 
***P<0.001 (Figure 3.3/3.4). The explanations for this are possibly several 
and will be discussed later. As used mRNA for determine any difference 
between QRFP and GPR103 protein expression in benign and malignant 
three samples from each group benign and malignant were applied. The 
resultant western blot is presented below (Figure 3.5/ 3.6/ 3.7).  
Quantification of the PCR and western blot were achieved. The resultant 
graphs and blot are shown consistent data. The expression levels of both 
QRFP and GPR103 are significantly higher in the malignant prostate 
tissues compared to the benign hyperplastic prostate tissues (BPH). 
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Figure 3.3   Bar chart representing quantification QRFP mRNA expression 
in benign prostatic hyperplasia and tumour resection, (***P<0.001, for n = 
5 per group, mean ± S.D). 
 
 
 
 
 
 
 
Figure 3.4 Bar chart representing quantification GPR103 mRNA 
expression in benign prostatic hyperplasia and tumour resection, 
(***P<0.001, for n = 5 per group, mean ± S.D). 
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Figure 3.5 Quantification of the western blot showing protein expression 
levels of QRFP (14 KDa) and GPR103 (49 kDa) in human benign and 
malignant tissue. B-actin was used as a loading control.   
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Figure 3.6   Bar chart representing QRFP protein quantification expression 
in benign and malignant prostate tissue, (**P<0.01 for n = 5 per group, 
mean ± S.D). 
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Figure 3.7 Bar chart representing GPR103 protein quantification 
expression in benign and malignant prostate tissue, (*P<0.05 for n = 5 per 
group, mean ± S.D). 
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3.3.4   CIRCULATING QRFP LEVELS IN PROSTATE CANCER 
Serum levels of QRFP were measured in a total of 44 men with the age 
range of 40 – 91.3 years. QRFP serum concentrations were significantly 
lower in BPH and cancer patients *p < 0.05 and **P<0.01 respectively 
compare to controls. It was noted the BPH group appeared to have a 
higher mean level of QRFP as compared to the prostate cancer group (*p 
< 0.05) Figure 3.8. The intra- assay coefficients of variation for these 
samples varied between were control 3.1%, benign 3.7% and cancer 
3.76%. 
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Figure 3.8 Graphical representation of QRFP serum levels in controls 
and patients. QRFP serum levels (ng/ml) were significantly decreased 
both in hyperplasia and cancer groups *p < 0.05 and **P<0.01 when 
compared to the control group and also significantly decreased in cancer 
compared to hyperplasia group *p < 0.05. 
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3.4   DISCUSSION 
The fundamental starting point of this project was to determine whether the 
neuropeptide, QRFP and its receptor GPR103 mRNA and protein 
expressed in human prostate cancer tissue and cell lines. This assist to 
hypothesis that QRFP may potentially, plays a role in prostate cancer 
development. Given that QRFP regulates food intake and obesity and 
obese people have more aggressive from of prostate cancer. This study 
might possibly provide evidence backing theory QRFP has a mechanism 
in the link between obesity and prostate cancer. 
Results from this study demonstrate that increased mRNA and protein 
expression of GPR103 and its ligand QRFP in the human prostate tissue 
and in prostate cancer cell lines PC3, LNCaP and DU145 cells. The 
purpose of the electrophoresis of the PCR products is simply to 
demonstrate that QRFP and GPR103 mRNA are present in prostate 
cancer cells. The data detected from western blot further confirmed protein 
expression of QRFP and GPR103 in human prostate cancer tissue 
samples and cell lines (PC3, LNCaP and DU145) cells.  The gene level of 
QRFP and GPR103 mRNA expression were also examined comparing 
between benign and malignant human prostate tissue. Interestingly, the 
increase expression level of QRFP & GPR103 were significantly higher in 
malignant prostate samples compared to benign prostate hyperplasia 
(BPH). Western blot further confirmed the protein expression levels of 
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QRFP/GPR103 which was similar to qRT-PCR analysis. QRFP protein 
expression was also significantly higher in malignant tissue compared with 
benign tissue. However, the increased expression of QRFP and GPR103 
in malignant prostate tissue was based on sample size of n=5. In this 
studies I did not take into account factors such as weight, age, stage and 
grade of disease and type of drug treatment. Further studies are required 
with large sample size to confirm whether there is a difference in gene 
expression of QRFP and GPR103 between benign and malignant prostate 
tissue with closely matched patients’ situation in terms of treatment 
received and stage/grade of PCa. 
This study supports the hypothesis that increase expression of 
QRFP/GPR103 in prostate malignant tissue may play an important role in 
prostate cancer development. It could as well be considered that increased 
QRFP/GPR103 expression in malignant prostate tissue correlates to a 
pathological condition and provides cancer cells ability to support its high 
metabolic rate. The two main drugs commonly used by pharmacological 
therapy, glucocorticoids and megestrol acetate, however both have limited 
efficiency. A better grasp of the underlying mechanisms of this disease will 
assistance in the development of new therapies for patients with cancer-
induced anorexia. This study sought to explain a relationship between 
circulating QRFP and prostate cancer. Thus far, no study has been 
demonstrated that QRFP has a role in prostate cancer and it the effect 
 
  
113 
 
seemed to be mediated by exogenously applied QRFP.                                 
The data described here allow us to demonstrate the role of QRFP in 
pathological feeding behaviour and other role functions in cancer patient 
specific which associated with anorexia. It was logical thus to examine the 
levels of circulating serum QRFP to detect if indeed patients with prostate 
cancer have different levels of QRFP than their non-affected counterparts. 
To my knowledge, this is the first study to evaluate circulating serum QRFP 
levels in human cancer patients which showed that there was a significant 
difference in serum QRFP levels with BPH and cancer groups within the 
control group (healthy men) provided by the assay kit I used.   In the small 
group of patients in this study, (n = 44) it can be realized that QRFP level 
in the mean with hyperplasia was significant lower compared with health 
group. Cancer group appeared significant lower compared with the benign 
group. These differences in circulating levels support the previously 
discussed data of differences in mRNA and protein levels in patients with 
BPH and PCa, at the prostate level, implicating a role of QRFP in prostate 
cancer. Moreover, cancer groups appeared to have the lowest circulating 
serum QRFP level. A number of studies published report QRFP as a 
neuropeptide with orexigenic action, therefore playing a significant role in 
energy homeostasis and regulation of food intake. The actual expression 
and signalling characteristics and physiological actives of QRFP and its 
receptor GPR103 are remain unrevealed (Davies et al., 2015). In these 
situations, the possibly negative energy balance previously described in 
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anorexia issues would be partially responsible for the QRFP profile as well 
to undernutrition affect. Moreover, this finding support the opinion that 
variations in endogenous QRFP can be a part of a wide adaptive response 
include other regulators of feeding behaviour. Low circulating QRFP level 
might be associated with anorexia and other some symptoms noted in 
cancer patient. It is possible that a tumor may produce factors that inhibit 
NPY transport, or release through neuronal targets downstream of NPY. 
In anorectic cancer patients, neuropeptide Y concentration were found to 
be lesser than controls, which linked with the level of anorexia (Takahashi 
et al., 2010, Aoyagi et al., 2015). Number of studies have published that 
NPY immunostaining were higher in PCa than that in benign epithelium. 
Their studies also suggested that NPY can directly regulate PCa cell 
development through Y1-R, NPY and the related receptors are 
overexpressed in PCa and might play a pertinent role in PCa development 
at both androgen dependent and independent stages. In addition, more 
aggressive the prostate cancer has lower NPY circulating levels (Liu et al., 
2007).  
I noted that QRFP mRNA tissue expression higher in the PCa than in BPH 
which showed QRFP enhanced PCa migration and invasion while human 
serum level QRFP were circulated lower in PCa than in benign. There is a 
critical requirement to differentiate those patients with advanced prostate 
cancer from those with non-advanced ones. These interesting findings 
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may lead to QRFP as a prognostic biomarker. In an analysis of Gleason 
grade the trend proposes that there can be a link between QRFP levels 
and Gleason score. The sample size in the study however were small and 
were not able to match for BMI, age, type of drug treatment many of our 
subjects were on. In conclusion the present study suggests that circulating 
level of QRFP are decreased among cancer patients with advanced 
disease. This exploratory investigation recommends additional studies are 
required of QRFP in patients with cancer associated anorexia with full 
detailed assessment including recent oral intake and age and wild range 
of subjects covered in the study. 
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CHAPTER 4  
 
FUNCTIONAL EFFECTS OF QRFP ON 
PROSTATE CANCER CELL LINES 
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4  HYPOTHESIS 
There has been significant progress in the comprehension of signalling and 
mechanical mechanisms regulating cell death, growth, adhesion, migration 
and invasion in prostate cancer. Prostate cancer mortality is caused by the 
migration of cancer cells from their site of origin within the prostate gland 
to multiple distant organs in the body. Increased cell invasion shapes a 
primary cellular property of the metastatic phenotype, and this in 
transformation comes from enhanced cell migration and/or increased 
protease activity. (Voll et al., 2014). Understanding these mechanisms is 
assisting us to obtain a best assessment of the diseased state. 
Accumulating evidence from different areas of immunology, physiology 
and psychology has confirmed that the endocrine systems and immune-
nervous are functionally connected with each other. This interconnected is 
thought to be very significant and has been proposed to play a key role in 
various different diseases, such as cancers (MacKinnon, 2000). 
Neuropeptides act as effective mitogens for several cancer types, such as 
small cell lung cancer and prostate cancer (Patrikidou et al., 2012). 
Neuropeptides play an important role in functional regulation in the 
microenvironment of the tissues in physiological condition. The normal 
prostate organ contains many neuropeptides such as neuropeptide Y 
gastrin-releasing peptide (GRP) and substance P secreted by either the 
neuroendocrine cells or autonomic and sensory nerve terminals. The 
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functions of neuropeptides produced by the neuroendocrine cells might be 
to regulate prostate cancer development (Nagakawa et al., 2001). 
Certainly, many peptides have been shown to impact prostate cancer cells 
such as bombesin which enhances the migration and invasion of prostate 
cancer cells (Sumitomo et al., 2000). QRFP is a neuropeptide involved in 
energy homeostasis. To my knowledge, this is the first study demonstrating 
a very high expression of QRFP in malignancy compared to BPH in human 
prostate. QRFP may have a potential functional effect on prostate cancer 
cells and these can be demonstrated using in vitro models. 
 
4.1  AIMS 
 To determine if QRFP has proliferative effects on PC3, DU145 and 
LNCaP cell lines.  
 To identify if QRFP induce the cellular migration or invasion of 
prostate cancer cell lines PC3 and DU145 cells.   
 To determine if QRFP has an apoptotic effect on PC3, DU145 and 
LNCaP cell lines. 
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4.2  RESULTS 
4.2.1 REGULATION OF QRFP ON PROSTATE CANCER CELL 
PROLIFERATION 
MTS calorimetric assay was applied to measure cell viability of the prostate 
cancer cell lines PC3 & LNCaP cells following stimulation with various 
concentration of QRFP (1, 10 and 100 nM). Around 6000 cells were plated 
in 96 well plates experiments were performed in quadruplets. Data are 
demonstrated as the mean ± S.D and are represented relative to basal. 
QRFP appears to clearly inhibit the proliferation of both human prostate 
cancer cells lines PC3 and LNCaP cells after 24 hours’ incubation (Figures 
4.1/4.3). There was no significant effect of QRFP in cell viability in 48 hours 
treated cells compared to basal (Figures 4.2/4.4).  
The data obtained show that there was no functional proliferative outcome 
of QRFP on prostate cancer cell lines (PC3 & LNCaP). However, further 
experiments are needed to determine the role of QRFP on prostate cancer 
cell proliferation. 
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4.2.2  CELL PROLIFERATION ASSAY USING xCELLigence SYSTEM 
Cell proliferation experiments were performed using different 
concentrations of determine the effect of QRFP different concentrations (1, 
10 and 100 nM) on prostate cancer cell lines in 24 hours, using the 
xCELLigence system. EGF (50 ng/ml) was used as appositive control. 
There were no significant changes the doubling times in both prostate 
cancer cells PC3 and DU145 cells with all doses of QRFP (Figures 
4.5/4.7). However, there appeared to a slight increase in doubling time in 
both cell lines at a concentration of 1 nM. Cell proliferation for 24 hours 
showed similar trend as with MTS assay that is no effect of QRFP cell 
proliferation. In contrast, 48 hours showed increased doubling times 
significant effect being at the highest dose of QRFP used (100 nM) *P<0.05 
on PC3 cells and DU145 cells, nevertheless were not statistically 
significant changes on QRFP doses (1 and 10 nM) dependent manner 
compared to basal, the results are presented in (Figures 4.6/4.8). 
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Figure 4.1 MTS assay demonstrating the effects of QRFP on PC3 cell 
proliferation at 24 hours using concentration dependent (1, 10 and 100 
nM), respectively 10% FCS was used as positive control. Data are 
expressed as rate to basal viability mean ± S.D, (n = 5) *P<0.05. 
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Figure 4.2 MTS assay demonstrating the effects of QRFP on PC3 cell 
proliferation at 48 hours using concentration dependent (1, 10 and 100 
nM), respectively 10% FCS was used as positive control. Data are 
expressed as rate to basal viability mean ± S.D, (n = 5) *P<0.05. 
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Figure 4.3 MTS assay demonstrating the effects of QRFP on LNCaP cell 
proliferation at 24 hours using concentration dependent (1, 10 and 100 
nM), respectively 10% FCS was used as positive control. Data are 
expressed as rate to basal viability mean ± S.D. (n = 5) *P<0.05. 
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Figure 4.4 MTS assay demonstrating the effects of QRFP on LNCaP cell 
proliferation at 48 hours using concentration dependent (1, 10 and 100 
nM), respectively 10% FCS was used as positive control. Data are 
expressed as rate to basal viability mean ± S.D, (n = 5) *P<0.05. 
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Figure 4.5 The effect of QRFP on PC3 cell proliferation using 
xCELLigence system. Representative graph the doubling time in hour of 
QRFP concentration dependent (1, 10 and 100 nM) compared to basal 
cells for 24 hours as described in materials and methods. EGF50 ng/ml 
representative as positive control. Results were calculated by the 
xCELLigence RTCA software mean ± S.D, (n = 5) *P<0.05. 
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Figure 4.6 The effect of QRFP on PC3 cell proliferation using 
xCELLigence system. Representative graph the doubling time in hour of 
QRFP concentration dependent (1, 10 and 100 nM) compared to basal 
cells for 48 hours as described in materials and methods. EGF50 ng/ml 
representative as positive control. Results were calculated by the 
xCELLigence RTCA software mean ± S.D, (n = 5) *P<0.05, **P<0.01. 
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Figure 4.7 The effect of QRFP on DU145 cell proliferation using 
xCELLigence system. Representative graph the doubling time in hour of 
QRFP concentration dependent (1, 10 and 100 nM) compared to basal 
cells for 24 hours as described in materials and methods. EGF50 ng/ml 
representative as positive control. Results were calculated by the 
xCELLigence RTCA software mean ± S.D, (n = 4) *P<0.05. 
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Figure 4.8 The effect of QRFP on DU145 cell proliferation using 
xCELLigence system. Representative graph the doubling time in hour of 
QRFP concentration dependent (1, 10 and 100 nM) compared to basal 
cells for 48 hours as described in materials and methods. EGF50 ng/ml 
representative as positive control. Results were calculated by the 
xCELLigence RTCA software mean ± S.D, (n = 4) *P<0.05, **P<0.01. 
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4.2.3  EFFECTS OF QRFP INCUBATION ON PC3 AND DU145 CELL 
MIGRATION AND INVASION 
xCELLigence system also applied to determine cell migration and 
invasion assay. 
4.2.3.1 CELL MIGRATIO ASSAY 
The effect of QRFP treatment on PC3 cell after 8 hours showed there was 
a significant concentration dependent increase in cell migration (10 nM) 
*P<0.05 and (100 nM) **P<0.01 (Figure 4.9).  In DU145 cells there was a 
less significant increase in cell migration with different QRFP concentration 
after 8 hours’ treatment compared with PC3 cells. The only statistically 
significant change in cell migration was QRFP (100 nM) **P<0.01 
compared to basal as showed in (Figure 4.10).  EGF 50ng/ml was used as 
a positive control as well lead to a statistically significant increase in cell 
migration **P<0.01. 
4.2.3.2 CELL INVASION ASSAY 
To determine whether QRFP contributes to prostate cancer cell line 
invasion, using the xCELLigence system. Cells were stimulated with either 
QRFP concentration dependent as described in protocol experiments, 
respectively. EGF 50 ng/ml used as positive control. Data are 
demonstrated as mean ± SD of four or five wells processed in parallel. A 
representative experiment is shown in (Figure 4.11) at the 8 hours QRFP 
increase invasion of PC3 cell were statistically significant (100 nM) 
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**P<0.01 and (10 nM) *P<0.05. However, no statistically changes were 
noted with 1 nM QRFP as compared to basal. QRFP shown less effect on 
DU145 cells invasion compared to PC3 cells which was statistically 
changes at dose (100 nM) **P<0.0. In contrast no statistically effect on 
doses (10 nM) and (1 nM) as compared to basal in (Figure 4.12). 
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Figure 4.9 The effect of QRFP on PC3 cell migration using 
xCELLigence system. Representative graph rate of QRFP concentration 
dependent (1, 10 and 100 nM) compared to basal cells for 8 hours as 
described in materials and methods. EGF50 ng/ml representative as 
positive control. Results were calculated by the xCELLigence RTCA 
software mean ± S.D, (n = 5) *P<0.05, **P<0.01. 
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Figure 4.10 The effect of QRFP on DU145 cell migration using 
xCELLigence system. Representative graph rate of QRFP concentration 
dependent (1, 10 and 100 nM) compared to basal cells for 8 hours as 
described in materials and methods. EGF50 ng/ml representative as 
positive control. Results were calculated by the xCELLigence RTCA 
software mean ± S.D, (n = 5) **P<0.01. 
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Figure 4.11 The effect of QRFP on PC3 cell invasion using 
xCELLigence system. Representative graph rate of QRFP concentration 
dependent (1, 10 and 100 nM) compared to basal cells for 8 hours as 
described in materials and methods. EGF50 ng/ml representative as 
positive control. Results were calculated by the xCELLigence RTCA 
software mean ± S.D, (n = 5) *P<0.05, **P<0.01. 
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Figure 4.12 The effect of QRFP on DU145 cell invasion using 
xCELLigence system. Representative graph rate of QRFP concentration 
dependent (1, 10 and 100 nM) compared to basal cells for 8 hours as 
described in materials and methods. EGF50 ng/ml representative as 
positive control. Results were calculated by the xCELLigence RTCA 
software mean ± S.D, (n = 5) *P<0.05, **P<0.01. 
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4.2.4   EFFECTS OF QRFP ON APOPTOSIS ASSAYS 
The apoptosis assay was carried out using YO-PRO-1 staining as per the 
protocol described earlier for 2 time points 24 and 48 hours. Results are 
demonstrated as mean ± S.D and were performed in triplicate. QRFP 
resulted induced apoptosis after 24 hours’ incubation in PC3 cell at lowest 
QRFP concentration (1nM) *P<0.05, and no statically change have shown 
at 10 and 100 nM (Figure 4.13). Though, QRFP after 48 hours showed a 
significantly increase apoptosis at dose (100nM) *P<0.05 compared to 
basal (Figure 4.14). QRFP appeared to be significantly increase apoptosis 
in LNCaP cells at (1 nM) *P<0.05 after 24 hours’ treatment relative to basal 
as shown in (Figure 4.15). However, QRFP showed in a significant 
increase in apoptosis after 48 hours’ time point in LNCaP cell compared to 
basal cells, *P<0.05 at (10 and 100 nM). Extra experiments need achieved 
to confirm these results (Figure 4.16). Camptothecin 2 mM was used as a 
positive control and showed a significant increase in apoptosis of PC3 cells 
and LNCaP cells, **P<0.01 after 24 hours. 
DNA fragmentation assay was carried out as per the protocol described 
earlier for 2 time points 24 and 48 hoursr. Results are demonstrated as 
mean ± S.D. DNase a known drug to induce apoptosis in several cellular 
models was used as a positive control to confirm that the assay was 
successful and showed a significant increase in apoptosis of PC3 cells 
**P<0.01, at 24 hr and 48 hr. (Figure 4.17) presented QRFP induced 
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concentration dependent increase in apoptosis of PC3 cells and 
statistically significant *P<0.05 on dose (1 nM) compared to control basal 
cells at 24 hours. While no statically changes in doses (10 nM) and (100 
nM). For 48 hours QRFP incubation on PC3 cells was statically significant 
on high dose (100 nM) *P<0.05, and no significant effect on doses (1nM) 
and (100 nM) compared to basal cells as showed in (Figure 4.18).  DU145 
cell at 24 hours which presented apoptosis in the lower QRFP dose (1nM) 
*P<0.05 were no significantly change in doses (10 nM) and (100 nM) 
compared to basal (Figure 4.19). However, QRFP treatment 48 hours 
showed significant effect on doses (10 nM) and (100 nM) *P<0.05 relative 
to basal cells (Figure 4.20). This experiment preformed also on androgen-
sensitive LNCaP cells were significant increase apoptosis on doses (1 nM) 
and (1 0nM) *P<0.05 and no significant change on high dose (100 nM) at 
24 hours (Figure 4.21).  In LNCaP cells at 48 hours also QRFP showed 
statically significant increase apoptosis on doses (10 nM) and (100 nM) 
*P<0.05 were no statically change on dose 1 nM (Figure 4.21). DNase was 
used as a positive control showed a significant increase in apoptosis of 
LNCaP cells **P<0.01 at 24 hours, however no statically change at 48 
hours. Camptothecin (2 mM) induced a significant increase in apoptosis 
**P<0.01. 
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Figure 4.13 Yo pro-1 and propidium iodide used to measurement of 
PC3 cell apoptosis. Statistical analysis of the rate of apoptosis under 
different QRFP concentrations (1, 10 and 100 nM) for 24 hours, 
respectively Camptothecin was used as positive control. Data are 
expressed as rate to basal (n = 4) *P<0.05 and **P<0.01. 
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Figure 4.14 Yo pro-1 and propidium iodide used to measurement of 
PC3 cell apoptosis. Statistical analysis of the rate of apoptosis under 
different QRFP concentrations (1, 10 and 100 nM) for 48 hours. Data are 
expressed as rate to basal (n = 4) *P<0.05. 
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Figure 4.15 Yo pro-1 and propidium iodide used to measurement of 
LNCaP cell apoptosis. Statistical analysis of the rate of apoptosis under 
different QRFP concentrations (1, 10 and 100 nM) for 24 hours, 
respectively Camptothecin was used as positive control. Data are 
expressed as rate to basal (n = 4) *P<0.05 and **P<0.01. 
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Figure 4.16 Yo pro-1 and propidium iodide used to measurement of 
LNCaP cell apoptosis. Statistical analysis of the rate of apoptosis under 
different QRFP concentrations (1, 10 and 100 nM) for 48 hours. Data are 
expressed as rate to basal (n = 4) *P<0.05. 
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Figure 4.17 Assessment of apoptosis by TUNEL assay on PC3 cells. 
Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 24 hours, respectively Camptothecin 
was used as positive control. Data are expressed as rate to basal (n = 4) 
*P<0.05 and **P<0.01. 
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Figure 4.18 Assessment of apoptosis by TUNEL assay on PC3 cells. 
Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 48 hours. Data are expressed as 
rate to basal (n = 4) *P<0.05. 
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Figure 4.19 Assessment of apoptosis by TUNEL assay on DU145 
cells. Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 24 hours, respectively Camptothecin 
was used as positive control. Data are expressed as rate to basal (n = 4) 
*P<0.05 and **P<0.01. 
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Figure 4.20 Assessment of apoptosis by TUNEL assay on DU145 
cells. Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 48 hours. Data are expressed as 
rate to basal (n = 4) *P<0.05. 
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Figure 4.21 Assessment of apoptosis by TUNEL assay on LNCaP 
cells. Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 24 hours, respectively DNase was 
used as positive control. Data are expressed as rate to basal (n = 4) 
*P<0.05, **P<0.01. 
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Figure 4.22 Assessment of apoptosis by TUNEL assay on LNCaP 
cells. Statistical analysis of the rate of apoptosis under different QRFP 
concentrations (1, 10 and 100 nM) for 48 hours. Data are expressed as 
rate to basal (n = 4) *P<0.05. 
 
 
  
136 
 
QRFP 
concentration 
Cell line/ (Hour) 
(nM) PC3  DU145  LNCaP 
24 48 24 48 24 48 
Camptothecin     ++                ++     +++ 
1 +                / +           / +           / 
10 +/-              + /            + +          + 
100  /                + /            + +/-        + 
 
Table 4.1: Table illustrates the overall effects of QRFP on cellular 
apoptosis in PC3, DU145 and LNCaP cells. Level of significance of 
increase/decrease of apoptosis: / = no change, +/-- = change no 
significant, + = (p < 0.05), ++ = (p < 0.01) and +++ = (p < 0.001). 
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4.3   DISCUSSION 
Reregulation of cellular apoptosis, proliferation, migration, invasion and 
adhesion are key process involved in cancer development. In fact, many 
peptides have been shown to impact and modulate prostate cancer cells 
via regulating cell apoptosis, proliferation, migration, invasion and 
adhesion. For instance, neuropeptide neurotensin (NT) and bombesin, 
have been shown to impact on prostate cancer development in 
experimental models. Neuropeptide Y has also been also shown 
proliferative or anti-proliferative effects in different cell systems (Lee et al., 
2001b).  My study present clear evidence that human neuropeptide QRFP 
plays roles in stimulating key steps in regulation of vital pathogenesis 
functions in prostate cancer cells. This study included (three) different 
prostate cancer cell lines to investigate the proliferative effect of QRFP: 
androgen-independent PC3 cells, DU145 cell cells and androgen-
dependent LNCaP cells. Meanwhile, both xCELLigence system and an 
MTS assay were performed to enhance analytical accuracy. Real time 
xCELLigence system allows account of the cell lines response to metal 
toxicity more accurately as compared to typically used end-point assays. 
The data observed from this system indicated QRFP has no proliferation 
effect in both androgen-independent PC3 cells and DU145 cells at all-time 
point 24 and 48 hours. However, longer treatment of QRFP after 48 hours 
appear to show anti-proliferation effects in both PC3 cells and DU145 cells. 
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The similar results from MTS assay were observed no proliferation 
changes at 24 hours’ post treatment. Though, there was slight trend 
decrease proliferation cells at highest QRFP dose in PC3 cells and LNCaP 
cells after 48 hours’ treatment, nevertheless these were not statically 
significant. Besides, as demonstrated in (figure 4.2/4.4), QRFP appears to 
induced apoptosis at a high dose, leading to concept that 100nM might be 
the effective dose on prostate cancer cells. 
As shown that QRFP does not regulate proliferation. An additional 
functional assays were carried out to demonstrate the effect of QRFP on 
prostate cancer cell lines. Tumour cell migration and invasion are 
prerequisite for developing to metastasis. In order to monitor the migration, 
and invasion after QRFP treatment in prostate cancer cell lines the real 
time cell analysis (RTCA) was also used. Notably there is a limitation of 
this system that it is unable to count the cells grow on top of each other like 
LNCaP cells. Also, the disadvantages that prostate cancer cells grow in 
clusters/aggregates instead of in a monolayer and weak cell surface 
adhesion will also be a common problem, to investigate cell migration and 
invasion. Differential effects of tissue culture coating substrates on prostate 
cancer cell adherence, morphology and behaviour (Liberio et al., 2014). 
Therefore, LNCaP cells has been omitted for determined If QRFP has 
metastasis effect on prostate cancer cells. Interestingly, it has been found 
that QRFP induced migration on two prostate cancer cell lines PC3 cells 
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and DU145 cells after 8 hours (Figure 4.9/4.10). In the PC3 cells there 
seems to be a dose-dependent significant increase in cell migration with 
the highest rate of cell migration being at the highest doses of QRFP used 
(10 nM &100 nM). The same observation obtained from DU145 cell 
increase migration, however just in highest QRFP concentration (100 nM). 
The acquirement of tumor cell invasiveness is an essential aspect of tumor 
development and a key factor of morbidity and mortality in prostate cancer 
patient. xCELLigence system applied to monitoring invasion cells using the 
same protocol in invasion assay above. This system provide Matrigel as 
extracellular matrix component coated on upper surface of the 
microporous membranes to enhance invasion cells. Interestingly PC3 cells 
after 8 hour appears significant increase invasion through matrigle at the 
two doses of QRFP used 10 nM and 100 nM. Corresponding to the cell 
migration assay the rate of cell invasion appeared to increase in a dose 
dependent manner, with the highest rate of invasion being shown in the 
highest dose of QRFP (100 nM). Also QRFP induced invasion in Du145 
cells at high dose (100 nM) individual at 8 hours (Figure 4.11/4.12). In the 
same set of experiments, EGF 50 ng/ml, used as positive controls. 
These two different functions assay migration and invasion presented 
consistence finding. Treatment of prostate cancer cell lines with different 
concentration of QRFP or exposure times presented change in migration 
and invasion level.  QRFP show stronger effect in PC3 than in DU145 cells. 
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It might due to that PC3 cells have characteristic more metastatic potential 
than DU145 cells which have a moderate metastatic potential, however 
both cell lines could reflect the characteristic of the most advanced types 
of prostate cancer. This reveals consistently with the previous studies 
suggesting that the neuropeptides secreted by neuroendocrine cells play 
a key role in the progression as well as the spreading of the cancer 
(Alonzeau et al., 2013). Though the mechanisms of the effect of QRFP on 
cancer migration and invasion remains investigated.                                                 
The surprising findings and interesting research demonstrated that the pro-
apoptotic effect of neuropeptide QRFP on prostate cancer cell lines. 
Besides, only few reports about neuropeptides and receptors that can 
inhibit development and/or stimulate apoptosis of prostate cancer cells 
(Alexandre et al., 2014). Only one study showed neuropeptides orexins 
has apoptotic role in colon cancer, and this finding enhance a new 
dimension to the biological function of these neuropeptides which may 
have significant implications of suppression cancers (Rouet-Benzineb et 
al., 2004). Thus, this is first study presented clearly that neuropeptide can 
regulate the apoptosis potential of prostate cancer cells.  Fluorescent dyes 
YO-PRO® 1 and PI has shown that 24 hours’ treatment of PC3 cells with 
low dose QRFP (1 nM) produced a significant decrease in cell viability and 
induced in apoptosis (Figure 4.13). In addition, 48 hours’ treatment PC3 
cells with QRFP showed induced apoptosis statically change on relatively 
higher dose (100 nM) and (10 nM) but this was no statically significant 
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(Figure 4.14).  Consistently LNCaP cells after 24 hours showed induced 
apoptosis and inhibited growth of cells at dose QRFP (1 nM) but no effect 
with other doses (Figure 4.15). Although, 48 hours’ treatment of QRFP at 
dose (10 nM) and (100 nM) showed an increased level of apoptosis in 
LNCaP cells (Figure 4.16). The effect of QRFP on apoptosis in both cell 
lines were found to be dose and time dependent. The similar results were 
obtained from PC3 cells as well has shown in LNCaP cells, nonetheless 
LNCaP cells appearance slightly more increase apoptosis and yet this cell 
line is described as being high sensitive to apoptosis than PC3 cells. 
TUNEL assay for detection the later stage of apoptosis cells via DNA 
fragmentation which is another hall mark of apoptosis was used for further 
determination and confirm of the possible role of QRFP in modulating cell 
apoptosis. Consistent with previous results, I found that extensive DNA 
fragmentation was only observed after 24 hours in PC-3 cells and DU145 
cells, exposed to QRFP (1nM), produced a significant increase in 
apoptosis compared to basal cells control (Figure 4.17).  It is appearance 
that after 48 hours’ treatments DU145 cells more sensitive to increase 
apoptosis on doses (10 and 100 nM) compared to PC3 cells were only 
significantly increase on dose 100 nM (Figure 4.18). Consistence to AI PC3 
and DU145 cells found LNCaP cells presented slightly more increase 
apoptosis at two time points 24 and 48 hours with doses dependent (Figure 
4.21/4.22). Eventually in the two apoptosis assays the effect of QRFP on 
prostate cancer cell lines apparent induced in apoptosis at 24 hours was 
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statistically significant on dose (1 nM). Whereas at 48 hours’ time point or 
(10 nM) and (100 nM) dose of QRFP was there an actual increase in the 
rate of apoptosis in either cell line. Camptothecin a known as anti-cancer 
drug to induce apoptosis in many cellular models was used as a positive 
control which sensitive to detect by the both assays used. Camptothecin 
induced a significant increase in apoptosis in the three cell lines (**P<0.01). 
These data shown that QRFP inhibit cell-proliferation in the three prostate 
cell lines PC-3 and DU145 cells (androgen resistant) and LNCaP cells 
(androgen-dependent), indicating that QRFP induced death cells in 
prostate cancer cell lines is not dependent on androgen receptor 
expression of the cells. 
In conclusion the finding from functional assays to assess the QRFP role 
on prostate cancer cells were identical. These findings that the QRFP 
regulates prostate cancer cell lines migration, invasion and apoptosis are 
novel and surprising, given the prominent role that QRFP have been shown 
to have in regulating prostate cancer cells development. This leads to 
hypothesis that QRFP has duality functional effect in prostate cancer cells 
depend on dose dependent and time point. However, as far I know no 
studies presented the ambivalence of neuropeptide regulation functions in 
cancers, therefore, depth studies required to demonstrate and confirm the 
controversial finding. 
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CHAPTER 5  
 
THE MECHANISM OF QRFP ON SIGNAL 
TRANSDUCTION PATHWAYS IN 
PROSTATE CANCER 
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5   INTRODUCTION 
The molecular information of prostate carcinogenesis has not been fully 
outlined, nevertheless it is clear that for normal prostate gland cells develop 
into malignant prostate cancer cells, it requires many transformation steps 
(Isaacs, 1997). Accumulating evidence suggests that changes of genetic 
alterations resulting in tumor suppressor genes and oncogenes expression 
are responsible for the growth and progression of prostate cancer (Shand 
and Gelmann, 2006). Alterations in cancer genes (such as in prostate 
cancer) likely result in a large number of molecular events occurring in an 
erroneous fashion. A main goal for researchers is to understand the 
potentially altered genes that play important roles in cancer progress 
(Sarkar et al., 2010). One of the important events is protein 
phosphorylation, which when changed, can result in system wide disorder 
and deregulation of the signal transduction pathway (Radivojac et al., 
2008). Protein tyrosine phosphorylation and de-phosphorylation are 
greatly conserved signalling mechanism for regulating proteins, has been 
discovered in all eukaryotes studied. Protein phosphorylation controls 
various physiological and pathological processes in the human body such 
as, metabolism, cell cycle, differentiation, cell survival, mitogenesis and 
gene transcription. The kinase family is one of the major target families in 
the human genome. Every kinase and phosphatase targets various 
substrates. Abnormalities in these kinase pathways have been implicated 
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in the development of several malignancies, including pancreatic, lung, 
breast and prostate cancer. Many lines of evidence propose a role for 
protein kinase in prostate cancer such as p53, EGFR, β-Catenin AMPK, 
AKT and MAP kinase signal transduction pathways (Markert et al., 2011), 
(Zadra et al., 2014) & (Edlind and Hsieh, 2014). Erroneous function of 
tumour suppressors, including PTEN, TP53, ras and RB, CDKN have been 
linked to the development of prostate cancer (Mulholland et al., 2006).  
Several of the defining features of cancer, such as apoptosis, proliferation, 
migration, invasion and metastasis result from disorder of regulatory 
signalling pathways. Certainly, since their implication in carcinogenesis, 
kinases remain critical targets for many of the oncological drugs (Harsha 
and Pandey, 2010) & (Cheng et al., 2011). The use of microarrays for gene 
expression analysis has led to an increase in the number of reports 
regarding this subject. These findings have described a variety of changes 
in gene expression associated with many diseases, such as prostate 
cancer (Massoner et al., 2013).  In several cases, different kinases were 
implicated in multiple steps involved in the synthesis of a single protein. 
The study on protein phosphorylation is significant due to the important 
role of kinases and phosphatases in cellular processes. As several of these 
cancer cells originated from human tumours, they can lead to functional 
proteomic studies depending on the experimental design. Examining the 
proteomes for proteins that hold patterns similar to the optimal 
phosphorylation action of a protein kinase will aid the identification of 
 
  
146 
 
possible physiological substrates of the kinase. The current protein 
profiling of cultured cells using antibody arrays is allowing in-depth 
examination of therapeutic targets in cancer researches (Gembitsky et al., 
2004). Also using of antibody arrays for high quantity phosphoproteomic 
profiling of cultured cells is helpful research to assess aberrantly activated 
signaling transduction networks including MAPK kinase pathways (Harsha 
and Pandey, 2010). Proteomic protein phosphorylation at the cellular level 
is required to know the intracellular signaling upon external and internal 
prompts. To demonstrate signalling pathway essential for the oncogenic 
function of QRFP, Phospho-Kinase Array were employed in PC3 cells. 
 
5.1   HYPOTHESIS 
Intracellular signalling pathways mediated by QRFP 
The process of signal transduction through receptor tyrosine kinases is 
initiated by an extracellular stimulus that activates its designated receptor, 
thereby initiates downstream signalling mechanisms. This can be 
established by a sequential phosphorylation of a three-tier kinase cascade, 
which conveys the signal to the nucleus, where a cellular response can be 
transcription mounted. The effects of many treatments such as chemical 
modifiers, growth factors, and androgens on PCa cells, have been termed 
up to now. However, the network and function of the MAP kinase pathways 
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in PCa are still unclear (Koul et al., 2013). Utilisation of techniques that 
incorporate signalling kinases, including the MAP kinases pathway, ERK, 
p38, JNK and AKT/PKB kinases has increased our understanding of the 
control of cellular event by growth factors (proliferation, differentiation and 
development) and also stresses (apoptosis). Western blotting analysis was 
significant used in research specific in cancer area to identify the protein 
expression (Liu et al., 2014).  
 
5.2   AIMS 
 To demonstrate if QRFP has a role in the protein kinase pathways 
in prostate cancer cell lines. 
 To demonstrate if QRFP activates specific MAPKs pathways ERK, 
JNK and p38 in PC3 and DU145 cell lines.  
 To demonstrate if QRFP regulate phosphor-AKT in PC3 and DU145 
cell lines. 
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5.3  RESULTS 
5.3.1 THE EFFECT OF QRFP ON PHOSPHORLATION 43 SIGNALLING 
MOLUCULES IN PC3 CELLS 
Human Phospho-Kinase Array was performed to identify the possible 
signalling pathway kinases that may be involved in QRFP dose dependent 
induced activation of PC3 cells. At the same time this allowed for the 
detection of the relative phosphorylated levels of 46 proteins, as well as 
MAP Kinases, Src family and JAK/STAT pathways amongst others. 
Experiments were carried out with different doses of QRFP (1, 10, 100 nM) 
for 60 minutes in PC3 cells. The samples were collected and analysed as 
given in the protocol (Materials and methods). Out of the 46 proteins, 
QRFP affected phosphorylation of 19 proteins.  
Interestingly, all QRFP concentrations demonstrated an increase in the 
phosphorylation in the MAPK proteins, p38 (T180/Y182) and JNK 
(T183/Y185, T221, and Y223). Additionally, QRFP also increased the 
phosphorylation of Akt 1/2/3 (S473), STAT2 (Y689), STAT5a/b (Y699), 
GSK-3a/ß (S21/S9), AMPKa1 (T183), AMPKa2 (T174), EGF R (Y1086), 
HSP27 (S78/S82), Lyn (Y397), Chk-2 (T68), Fyn (Y420), Yes (Y426), Lck 
(Y394) and Hck (Y411). In contrast, the three QRFP concentrations 
showed decreased ERK1/2 (T202/Y204, T185/Y187) and mTOR (S2448) 
in (Figure 5.1/5.2). 
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Figure 5.1 The effects of QRFP on phosphorylated signaling proteins 
in PC3 cells. Representative Immunoblots showing multiplex detection of 
phosphorylated proteins in PC3 cells treated by dose dependent QRFP (1, 
10 and100 nM) at time points 60 minutes of incubation. 
 
 
 
 
 
 
 
 
  
150 
 
PC3 cells 60 minutes
E
R
K
1/
2
JN
K
 1
/2
/3
A
kt
 1
/2
/3
p3
8a
A
M
P
K
a1
G
S
K
-3
a/
ß
S
TA
T2
A
M
P
K
a2
TO
R
S
TA
T5
a/
b
0
5000
10000
15000
20000
BASAL
Q1 nM
Q10 nM
Q10 nM
M
e
a
n
 P
ix
e
l 
D
e
n
s
it
y
 
 
 
E
G
F 
R
H
S
P
27 S
rc
Lc
k
Fy
n
Y
es
H
cK
C
hk
-2
Ly
n
0
5000
10000
15000
PC3 cells 60 minutes
BASAL
Q1 nM
Q10 nM
Q100 nM
M
e
a
n
 P
ix
e
l 
D
e
n
s
it
y
 
Figure 5.2 The effects of QRFP on phosphorylated signaling proteins 
in PC3 cells. Graphic representation of the most significant fold changes 
in protein phosphorylation levels in PC3 cells compared to untreated cells 
(basal). Data analysis was performed using a one-way ANOVA.  
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Human Phospho-Kinase Array was performed to identify the possible 
signalling pathway kinases that can be involved in QRFP at two different 
time points, namely 5 and 25 minutes. Experiments were carried out using 
PC3 cells and stimulated by QRFP (100 nM). The samples were collected 
and analysed as given in the protocol (Materials and methods).  
Interestingly, at 5 minutes QRFP 100 nM treatments showed an increased 
phosphorylation of the MAPK proteins ERK1/2 (T202/Y204, T185/Y187) 
were showed slight increase in JNK (T183/Y185, T221, and Y223) and Akt 
1/2/3 (S473) also increased the phosphorylation EGF R(Y1086). However, 
some interesting proteins showed decrease phosphorylation p38α 
(T180/Y182), AMPKα1 (T183), AMPK α2 (T172), mTOR (S2448), Chk-2 
(T68) GSK-3a/ß (S21/S9) Figure 5.3. 
At 25 minutes of treatment of PC3 cells by QRFP 100 nM, there was a 
significant increase in the phosphorylation of the MAPK proteins p38α 
(T180/Y182), JNK (T183/Y185, T221, and Y223) and Akt 1/2/3 (S473), 
compared to 5 minutes’ activation and baseline. In addition to this, the 
increase in phosphorylation was also present in AMPK α2 (T172), STAT2 
(Y689), STAT6 (Y641), STAT5a/b (Y699), Chk-2 (T68) and GSK-3a/ß 
(S21/S9).  In contrast, some interesting proteins exhibited a decrease in 
phosphorylation, namely ERK1/2 (T202/Y204, T185/Y187), AMPKα1 
(T183), EGFR (Y1086) and mTOR (S2448) Figure 5.3. 
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Figure 5.3 The effects of QRFP on phosphorylated signaling proteins 
in PC3 cells. Representative graphic showing multiplex detection of the 
most significant fold changes in protein phosphorylation level in PC3 cells 
treated by 100 nM QRFP for two time points (5 and 25 minutes) of 
incubation compared to untreated cells (basal). Data analysis was 
performed using a one-way ANOVA.  
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5.3.2 THE EFFECT OF QRFP ON MAPK EXPRESSION IN PC3 and 
DU145 CELLS  
To examine the signalling pathways likely to be involved in QRFP, the 
expression of phosphorylated forms of ERK1/2, p38 kinase, JNK and AKT 
were analysed by western blotting. PC3 and DU145 cells were treated with 
QRFP (100 nM) for time duration between 0, 5, 15, 30 and 60 minutes to 
perform time dependent effects of QRFP on MAPK and AKT 
phosphorylation. Following stimulation of PC3 cells and DU145 cells with 
QRFP resulted in a significant activation of ERK 1/2 **P<0.01 and 
***P<0.001 respectively at 5 minutes’ treatment concentration of 100 nM 
QRFP, (figure 5.4/5.5).  A significant increase in p38 phosphorylation was 
observed at differing times in the two cell lines. In PC3 cells the greatest 
activation was at 30 minutes (**P<0.01) and decreased significantly at 15 
and 60 minutes *p < 0.05 (Figure 5. 6). 
In DU145 cells, activation of p38 increased significantly at about 5 minutes 
(p < 0.05). At 15 minutes, p38 levels appeared to drop back down to near 
basal levels before increasing again at 30 minutes (p < 0.05), with 
maximum activation occurring at around 60 minutes (P<0.01) compared to 
basal (figure 5.7). In PC3 cells, JNK phosphorylation occurred around 30-
60 minutes following stimulation with QRFP p < 0.05, (figure 5.8). However, 
in DU145 cells JNK activation was at its peak around 5 minutes (P<0.01) 
and appeared to reduce towards basal levels between15-30 minutes, 
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before increasing again after 60 minutes p < 0.05, (figure 5.9). 
Phosphorylation of AKT also appeared to increase significantly in PC3 cells 
at about 15 minutes’ post-stimulation and the level remained significantly 
higher even at 60 minutes P<0.01, (figure 5.10). Activation of AKT in 
DU145 cells occurred at around 30 minutes (p < 0.05) and increased 
significantly at about 60 minutes P<0.01, (Figure 5.11).    
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Figure 5.4 The effect of QRFP on (ERK 1/2) MAPK expression in PC3 
cells.  
Western blot analysis showing changes in ERK1/2 protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in ERK 1/2activation in PC3 
cells. Data represents the mean ± S.D from three independent 
experiments; **P<0.01 compared to basal expression. 
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Figure 5.5 The effect of QRFP on (ERK 1/2) MAPK expression in 
DU145 cells 
Western blot analysis showing changes in ERK1/2 protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
 The graph showing quantification of changes in ERK 1/2 activation in 
DU145 cells. Data represent mean ± S.D from three independent 
experiments; ***P<0.001 compared to basal expression. 
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Figure 5.6 The effect of QRFP on (p38) MAPK expression in PC3 cells 
Western blot analysis showing changes in p38 protein phosphorylation and 
corresponding total protein expression following treatment with 100 nM 
QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
 The graph showing quantification of changes in p38 activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 and **P<0.01 compared to basal expression. 
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Figure 5.7 The effect of QRFP on (p38) MAPK expression in DU145 
cells. 
Western blot analysis showing changes in p38 protein phosphorylation and 
corresponding total protein expression following treatment with 100 nM 
QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in p38 activation in DU145 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 and **P<0.01 compared to basal expression. 
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Figure 5.8 The effect of QRFP on (JNK1/2) MAPK expression in PC3 
cells. 
Western blot analysis showing changes in JNK1/2 protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
 The graph showing quantification of changes in JNK1/2 activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 compared to basal expression. 
 
 
 
  
160 
 
Basal 5' 15' 30' 60'
0.0
0.5
1.0
1.5
2.0
DU145 cells
*
**
Time(minutes)
S
A
P
K
/J
N
K
p
ro
te
in
 e
x
p
re
s
s
io
n
(r
e
la
ti
v
e
 t
o
 b
a
s
a
l)
 
Figure 5.9 The effect of QRFP on (JNK1/2) MAPK expression in DU145 
cells. 
Western blot analysis showing changes in JNK1/2 protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in JNK1/2 activation in 
DU145 cells. Data represent mean ± S.D from three independent 
experiments; *p < 0.05 and **P<0.01 compared to basal expression. 
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Figure 5.10 The effect of QRFP on (AKT) MAPK expression in PC3 
cells 
Western blot analysis showing changes in AKT protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in AKT activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; 
**P<0.01 compared to basal expression. 
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Figure 5.11 The effect of QRFP on (AKT) MAPK expression in DU145 
cells 
Western blot analysis showing changes in AKT protein phosphorylation 
and corresponding total protein expression following treatment with 100 
nM QRFP at varying time points (0 = Basal, 5, 15, 30 and 60 minutes) of 
incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in AKT activation in DU145 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 and **P<0.01 compared to basal expression. 
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5.4   DISCUSSION 
It has been shown that in functional assays, exposure of prostate cancer 
cells to QRFP increased cell migration, invasion and apoptosis in a 
dependent dose-time manner. Human Phospho-Kinase showed a variation 
in the effect of the three QRFP doses. The three QRFP doses 1, 10 and 
100 nM demonstrated an increase in phosphorylation of the Src kinases 
member including Lck, fyn, yes, HcK, and lyn as well EGF R for the initial 
panel of phosphoprotein. Increased activation of Src co-operates with a 
wide range of proteins such as receptor tyrosine kinases, GPCR, 
epidermal growth factor receptor (EGF-R) and others regulation of a 
central pathways, include Ras/Raf/ /ERK, PI3K/PTEN/AKT, focal adhesion 
kinase (FAK)  and STATs  (Tatarov and Edwards, 2007) & (Li et al., 2010b). 
Several studies have indicated that an increased expression of the Src  
family and EGFR play a significant role in cell invasion, metastases and 
prostate cancer progression (Varkaris et al., 2014).                                                                       
In contrast, QRFP decreased ERK1/2 and mTOR activation. Both are 
associated with prostate cancer proliferation and in line with our findings 
QRFP inhibits prostate cell proliferation. Activation of Akt 1/2/3, STAT2, 
STAT5a/b, GSK-3a/ß and HSP27 share many common functions including 
cell proliferation, migration, invasion and enhancement of prostate 
progression. Meanwhile, p38, AMPKa1, AMPKa2, and Chk-2 inhibit cell 
proliferation and induction of cell apoptosis. Cancer development is 
 
  
164 
 
associated with increased phosphorylation of Akt and inhibition of 
apoptosis pathways. The changes in Akt activity leads to the modulation of 
prostate cancer cell proliferation, survival and tumour growth (Li et al., 
2007). The transcription factor STAT5a/b represents a possible therapeutic 
target for progressive prostate cancer. Recently it has been shown that 
STAT5a/b activation enhances proliferation but is also involved in the 
induction of metastatic prostate cancer cells, by the promotion of migration 
and invasion in PC3 and DU145 cells (Gu et al., 2010).  HSP27 has been 
shown to increase cell migration and invasion upon increase MMP-2 
expression and is associated with prostate cancer progression (Shiota et 
al., 2013) & (Voll et al., 2014). It has been shown that selenium can inhibit 
the growth of colon cancer cells by activation of AMPK·1 and suppression 
of mTOR signalling via Akt-dependent or independent pathways. In 
addition, other studies have indicated that AMPK·1 is required for the 
inhibition of mTOR and cell cancer proliferation (Lee et al., 2010b).  The 
overexpression of IGF-binding protein-3 (IGFBP-3) activated the down 
regulation of AMPK, and AMPKα1/2 siRNA induced inhibition of the mTOR 
pathway and apoptosis in prostate cancer cells (Du et al., 2015). In the 
present study QRFP activated AMPK, leading to inhibition of the mTOR 
pathway and suppression of cell proliferation in prostate cancer cell lines. 
GSK-3 has been shown to be very unique in different signalling pathways, 
a process which is complex and controversial. Inhibition of GSK-3 activity 
is expected to be tumour promoting in many cancers. It can inhibit tumours 
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by supressing the Wnt/beta-catenin pathway (Gao et al., 2015). Chk2 is 
regulated by upstream ATM pathways, which are frequently activated 
simultaneously in cells exposed to various genotoxic stresses, such as 
cytotoxic chemotherapy agents (Smith et al., 2010). Generally, data 
suggests that alterations in CHEK2 can contribute to prostate cancer risk 
and that the DNA-damage–signalling pathway could play a significant role 
in prostate cancer progression (Dong et al., 2003). Time dependence of 
QRFP effects in PC3 cells results phosphorylation proteins in different 
manner. Nearby, 5 minutes QRFP100 nM showed increase 
phosphorylation of the MAPK proteins ERK1/2 for short time while 
negligible increase activation of JNK and Akt 1/2/3 also increased the 
phosphorylation EGF. The over-expression of EGF R proteins have been 
observed in both androgen insensitive PC3 and DU145 cells. 
Phosphorylation EGFR mediated activation many intracellular signaling 
cascades including of MAPK kinase MEK/ERK, phosphoinositide 3-kinase 
(PI3K)–Akt pathways (Gan et al., 2010). Activated ERK and Akt translocate 
to the nucleus, leads in downstream effects prostate cancer, including cell 
proliferation, cell apoptosis, angiogenesis, migration and invasion (Huang 
and Chang, 2011). However, some interesting proteins showed decrease 
phosphorylation of p38α, AMPKα1, AMPK α2, mTOR, Chk-2 and GSK-
3a/ß.  
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QRFP appears also has a role by increasing phosphorylation of proteins 
at 25 minutes including of MAPK pathway JNK, p38α and AKT, however 
ERK showed a decrease. Moreover, the increased phosphorylation 
appeared in (AMPK α2, STAT2, STAT6, STAT5a/b, Chk-2 and GSK-3a/ß). 
Phosphorylation p38α has been reported as stimulatory effect on induction 
pro-apoptosis and inhibit EGF R also negatively regulate with cancer cell 
progression (Swat et al., 2011a). mTOR observed significant decrease in 
phosphorylation from dose and time dependency. So far the effects of 
QRFP on these signalling events in prostate cancer cells remain unclear. 
Examine the QRFP effect in PC3 cells by using human phosphor array 
appears spotted various proteins pathways functions. QRFP has been 
found to exhibit an increase in phosphorylation of a range of proteins 
including MAPK through a number of cellular signalling pathways. In PC3 
cells, I studied QRFP induced signalling pathways, and the role of cell its 
GPCR (GPR103). MAPK regulates different cellular processes in PCa; a 
crucial player in cancer pathways seems to be the ERK pathway.               
The increased expression level of this signal pathway was revealed in 
human prostate cancer compared with normal prostate tissues (Johnson 
et al., 2008) & (Chen et al., 2013b).                                                                                                
The data I present demonstrate significant increase in ERK1/2 
phosphorylation after 5 mins using the highest concentration of 100 nM 
QRFP in PC3 and DU145 cells which was determined with the cell 
migration and invasion studies.  ERK1/2 has been shown to be activated 
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by several pathways depending on the distinct ligand, cell surface receptor, 
and cell type (Robertson et al., 2010). ERK1/2 is activated by a complex 
cascade comprising of Ras/Raf/MEK/ERK which regulate gene 
expression; moreover, this pathway also regulates the activity of several 
genes implicated in apoptosis (Lu and Xu, 2006). High expression levels 
of the Ras/Raf/MEK/ERK pathway might be promoted by autocrine and 
paracrine acting growth factors and has been related with progressive PCa 
(Johnson et al., 2008). Ras signaling is involved in cancer cell invasion and 
metastasis. Also it has been shown that the activation of EGFR-ERK1/2 
pathway promoted the migration and invasion of prostate cancer cells (Li 
et al., 2015). However, it has been observed that Ras/Raf/MEK/ERK is 
expressed at low levels in hormonal- independent prostate cancer lines. 
Therefore, while it is reasonable to consider that activation of 
Ras/Raf/MEK/ERK cascade could contribute to prostate cancer 
development and it could not be that simple as some of these well-known 
prostate cancer cells such as PC3 and DU145 cells have low expression 
level of this cascade (Swat et al., 2011b).  It has been shown that activating 
ERK by agents such as Resveratro and Bryostatin in DU145 cells and 
Phenylethyl isothiocyanate in PC3 cells induced apoptosis; additionally, 
vitamin D has inhibitory effects on cell proliferation by decreasing activated 
ERK (Ghosh et al., 2005).  Also, a previous study proposed that activation 
of ERK1/2 signalling contributes to apoptosis via the suppression of the 
survival signalling AkT in cervical cancer cell (Zhuang and Schnellmann, 
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2006). This pathway, has been found to be implicated in different of 
pathways depending on the individual ligand, cell surface receptor and kind 
of cells (Robertson et al., 2010). The observation that ERK activation 
responded to QRFP at a short time point, whilst a longer time point led to 
a reduction in ERK, may be due to the fact that ERK pathway has a low 
expression level in androgen independent such PC3 and DU145 cells and 
poor outcome. Otherwise, as previously discussed, this may be a case of 
demonstrating ERK1/2 activation early related to through use of the correct 
dose of 100 nM QRFP or time-point which related to migration and invasion 
functions. Most published the effect of activation ERK pathway in prostate 
cancer is involved in cell proliferation, cell survival and poorly differentiated 
metastatic, however recently has been shown  activation ERK  promotes 
cell migration and invasion in prostate cancer cells (Rodríguez-Berriguete, 
2012) & (Ding et al., 2015). In contrast, some studies have shown activate 
ERK dependent apoptosis in the three prostate cancer cell lines (Ghosh et 
al., 2005).This was the first study identified the effect of QRFP on ERK 
pathway in mediating prostate cancer cell.  
Unlike ERK1/2, P38 is weakly activated by mitogens but strongly activated 
in cells in response to stress events include inflammation, UV radiation, 
osmotic shock and heat.  Activation of p38 in PCa could be a result of up 
regulated upstream kinases (MKK3/6) and down regulated MAPK 
phosphatases. Recently, it has been suggested MKK4 may contribute to 
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activation of p38 MAPK in some conditions (Koul et al., 2013) & (Frank and 
Miranti, 2013). Phosphorylation p38 has been demonstrated in PCa cell 
lines when exposure by toxic agents, and their activation is implicated in 
apoptosis (Chang et al., 2008). p38 MAPK is involved in apoptosis 
induction by acts to have some roles such as in activating caspases 
(Maroni et al., 2004). In other studies, TGF-β1 has shown associated with 
enhanced activation of caspases-8, -9 and -3 in PC3 and DU145 cells and 
induced apoptosis particularly through activation p38 pathway (Al-Azayzih 
et al., 2012). Exposure of PC3 cells to arsenic trioxide induced apoptosis 
through activation of the p38 pathway (Su et al., 2013). Many evidences 
shown that p53 and PTEN have negative expression in prostate cancer 
androgen-independent PC3 and DDU145 cells by activation p38 pathway 
when exposure to some chemicals Berberine and Decitabine (Festuccia et 
al., 2008).  Also TNFα, activates p38 induces apoptosis in LNCaP cells but 
not in PC3 cells (Frank and Miranti, 2013). Many different groups have 
been reported to active the p38 by IL-6, EGF, FGF-1/2, TNF-α, 
keratinocyte-derived growth factor (KGF), vitamin-D, and Neu 
differentiation factor (NDF) are implicated to prostate cancer (Koul et al., 
2013). Hence, p38 activation may contribute to suppression of prostate 
cancer progress (Shimada et al., 2006). Otherwise, it has been 
demonstrated that the activation of MMP-2 in prostate cancer cell invasion 
mediated through the p38 MAPK pathway (Koul et al., 2013). Chen et a 
reported that stimulation of the G protein-coupled receptor, P2Y, induced 
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PCa cell invasion regulated by the activation of p38 pathway (Chen et al., 
2004). Due to dual functions of p38 activation in genotoxic stress the exact 
effects in prostate cancer still in doubt. The novel data shown significant 
increased activation p38-phosphorlation in prostate cancer androgen-
independent by QRFP dose 100 nM. The literature reviews indeed propose 
a significant role for activation p38 in prostate cancer cells however the 
precise role has not been completely elucidated. The data presented here 
is in line with the literatures and assists only to provide support. Preferably 
the further investigations required Caspases-3 and MMp-2 expression 
would help demonstrate and confirm the true significance of this results. 
It has been suggested that similar to p38, JNK known as activated protein 
kinase (SAPK) induction apoptosis in response to several kinds of stress 
pathway (Wada and Penninger, 2004). JNK has mediated by upstream 
MKK7 kinase also associated with p38 activated upstream MKK4 (Sui et 
al., 2014).  JNK could activate a range of transcription factors including, c-
Jun, c-fos, Elk-1, c-My, ATF-2 and p53. Also, JNK phosphorylation can 
activate mitochondria protein Bcl-xL and Bcl-2 (Rodriguez-Berriguete et 
al., 2012).  JNK MAPK is activated in response to certain growth factors or 
stresses such as chemotherapeutic agents, ultraviolet (UV) radiation 
commonly leads to cell death by activation of the mitochondrial apoptotic 
pathway in, prostate cancer cells (Gururajan et al., 2005). Phosphorylation 
of the JNK pathway induces apoptosis by activation of c-Jun, ATF-2, AP-1 
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and Fas/Fssl mediate the activation of caspeases (Sui et al., 2014).  An 
apoptotic role mediated of JNK signalling has also been presented in 
apoptosis induced by many chemotherapeutic agents, including 
doxorubicin, vinblastine, cisplatinum and etoposide (Kuntzen et al., 2005). 
Shivendra V. et al, reported that Guggulsterone could induced apoptosis 
in PCa cell lines through activation JNK pathway (Xiao et al., 2011).          
The objective of this study was to demonstrate whether QRFP has a role 
effect through activation JNK1/2 pathway on two prostate cancer cell lines 
PC3 and DU145 cells. However, QRFP mediated activation of JNK 
pathway in prostate cancer cells and whether this induces apoptosis, or 
progression has not been studied. This is first study showed that QRFP 
has increased activation of JNK MAPK in PC3 cells at 30-60 minutes, also 
has shown increased significantly JNK activity at time point 5-60 minutes 
in DU145 cells than in PC3 cells, but more increase activation in PC3 
cells. This study shows that the death cell prostate cancer cell lines caused 
by is associated to activation of JNK pathways. The correlation between 
QRFP and JNK/SAPK activation mediated apoptosis induction is not a cell 
line specific effect and also not affected by p53 status. The result appears 
to suggest it induced apoptosis, however, it has not provide any insight into 
the signalling pathways involving this process.  
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AKT signaling pathway activated by several growth factors, cytokines and 
oncogenes (Shukla et al., 2007). They have shown that activation of the 
PI3K-Akt phosphorylation through some of mechanisms could contribute 
to induced tumor invasiveness and cancer development. Several reviews 
highlight the possible role for the PI3K/AKT pathway in PCa progression. 
Additional finding from current study is that pharmacological inhibition of 
the Akt pathway significantly affects EGFR induced PCa cell migration 
(Gan et al., 2010). Due to the high expression of Akt phosphorylation 
signals in response to external stimuli and is activated in many human 
cancer, I hypothesized that treated QRFP on prostate cancer cell lines 
mediated Akt pathway might be has a role in prostate cancer cells. In this 
study, has shown strong effect of QRFP by increase activation of Akt 
signalling in human prostate cell lines. PC3 cells indicated increase 
activation of AKT more than DU145 cell. It possible that PC3 cells has 
higher-expression phosphorylation of AKT (Guo et al., 2010). The 
PI3K/Akt/mTOR signaling pathway has been shown to regulate many 
cellular proses including cell survival, proliferation, metabolism, migration, 
and angiogenesis. It is well recognised that the activation of the p38 and 
JNK and pathways has been associated with events leading to apoptosis. 
Furthermore, the ERK and P13/AKT signal pathway plays critical role in 
regulation cancer cells survival and proliferation. It is interesting that QRFP 
seems to activation both kinases involved in survival pathways and 
apoptosis pathways; however, I am planning to perform downstream 
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signalling mediators and genes involved in both cell survival and apoptosis 
process to confirm the actual role of QRFP in prostate cells. It noteworthy 
to mention for example leptin that have been previously demonstrated to 
promote various cancer growths does activate AKT, p38 and JNK 
phosphorylation (Hoda et al., 2012b). To confirm some results from 
western blot, we evaluate inhibit MAPK pathway and p-Akt expressions. 
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CHAPTER 6  
 
  THE ROLE OF QRFP ON AGR-2, MMPs, 
CASPASE-3 AND AMPK IN PCa 
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6   INTRODUCTION 
ANTERIOR GRADIENT PROTEIN-2 HOMOLOG (AGR-2) 
Human AGR2, is a secreted protein that is exclusively expressed in several 
organs such as stomach, lung, colon, and prostate (Hu et al., 2012). 
Besides, AGR2 is implicated in an array of biological processes in different 
cancer models such as regulation of p53, cell proliferation, migration, 
invasion, metastasis, cellular transformation, and cell adhesion (Wang et 
al., 2008). Recently, researchers have focused to find specific roles of 
AGR2 in cancers since it is involved in tumor development, metastasis and 
drug resistance (Salmans et al., 2013). They have detected elevated 
AGR2 levels in multiple human carcinomas including lung, colon, ovarian, 
breast and prostate cancers compared to the normal tissues. In prostate 
cancer cells, AGR2 is one of many such genes recognized as 
overexpressed (Dumartin et al., 2011). Additionally, AGR2 is elevated in 
PCa cells compared to non-malignant prostatic epithelial cells at the 
transcriptional and protein levels. The signal level for AGR2 in the PCa cell 
is ~50-fold higher than that in normal counterpart luminal epithelial cells 
(Maresh et al., 2010).  AGR-2 is stated to be an androgen inducible and 
just over-expressed through early stages of carcinogenesis in prostate 
cancer (Chanda et al., 2014). Contrariwise, modern studies have observed 
lower level of AGR-2 expression in high-grade tumors (al, 2013) &  
(Chanda et al., 2014). 
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MATRIX METALLOPROTEINASES (MMPs) 
A family of endopeptidases identified, as MMPs are a possible objective 
for cancer therapy. The Matrix metalloproteinases (MMP) family contains 
zinc and calcium -dependent proteinases that response to remodelling and 
degrades basement membrane and extracellular matrix components such 
as elastin, proteoglycans, glycoproteins, and denatured collagen  (Gong et 
al., 2014). Thus, MMPs influence several significant processes, such as 
cell differentiation, proliferation, migration, apoptosis, and cell–cell 
interactions. Wherever degradation of the basement membrane and 
extracellular matrix is the first stage in invasion and metastases (Bonnans 
et al., 2014). The proteinases 72 kDa MMP-2 and 92 kDa MMP-9 have 
been identified as markers for cancer invasion and metastases in a variety 
of different cancers include colon, breast and specifically associated with 
prostate cancer (Roomi et al., 2009).  Moreover, the expression of MMP-2 
and MMP-9 in benign and malignant prostate is detected in tissue and 
serum samples (Zhang et al., 2004). Activated MMP-2 can activate other 
MMPs such as MMP-9 through enzymatic cleavage. It has been shown 
increase in expression of MMP-2 extensively reported in prostate cancer 
and correlated with larger tumor size, higher Gleason score (Oguic et al., 
2014). Recent publications indicated that MMP-2 expression has been 
found in metastatic cancer, however has not expressed in micro-
metastasis and surrounding stromal cells of low grade disease, strongly 
proposing that increased MMP-2 expression is related with prostate cancer 
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development and metastasis (Trudel et al., 2003). frequently used Prostate 
cancer cell lines LNCaP, DU-145, and PC-3 have been determined as low, 
moderate, and high metastatic possible in Matrigel invasion assays, 
respectively. Thus, this study aimed to identification of the role QRFP and 
molecular markers that can predict PCa readiness and progression 
through activation MMP2 pathway. 
CASPASES (cystein-dependent aspartate-specific protease 
expression)  
It is unclear whether caspases are fundamental for apoptosis or other 
proteases may control their functions. activation of caspases cascades in 
PCa plays a crucial role in the execution-phase of cell apoptosis (Wong, 
2011). Cytochrome –C release from the mitochondria functions as a critical 
stage in the activation of downstream caspase-3, an apoptosis executioner 
(Ow et al., 2008). Also that is fundamental for the nuclear changes related 
with apoptosis, counting chromatin condensation. Caspase-3 is commonly 
expressed in human tissue include prostate and human prostate cell lines 
(Jager and Zwacka, 2010). Overexpression or loss of expression of 
caspase-3 has been stated in malignancies and many of human cell lines. 
Caspease-3 mediated cleavage of P21 has been revealed to transform 
prostate cancer cells from the arrest to apoptosis. This leads to 
acceleration of chemotherapy induced apoptotic process in the PCa cells 
(Eastham) & (Persad et al., 2004). In several examples caspase-3 
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generates a constituent kinase activities responsible for transduction of the 
apoptotic pathway. Investigation of these kinases especially their 
deregulation, will allow us finding new targets for gene therapy in PCa. In 
this study, to demonstrated the effect of QRFP on the activation of 
caspase-3 by immunoblot in PCa cell lines PC3 and DU145 cell. 
ADENOSIN 5′-MONOPHOSPHATE-ACTIVATED PROTEIN KINASE 
(AMPK) 
The main role of activation AMPK is to restore cellular energy balance 
through controlling ATP process by enhancing processes that increase 
ATP meantime inhibiting consuming ATP processes (Woodard and 
Platanias, 2010) & (Hardie, 2011). In active proliferating cells, it has been 
stated that activation of AMPK lead cell cycle prevents via up-regulation of 
the p53-p21 alliance (Motoshima et al., 2006). Since PC3 cells do not 
contain wild-type p53 alleles, the induction of p21 by AICAR observed in 
the present study was probably p53-independent (Motoshima et al., 
2006b) & (Aimola et al., 2012). Collectively, these findings suggest that 
AMPK activation can inhibit the growth of prostate cancer cells by at least 
three distinct mechanisms (Towler and Hardie, 2007). Conversely, other 
reports indicate that AMPK might play tumour-promoting roles in the 
prostate and AMPK activation is higher in PCa than in normal prostate 
tissue. Certainly, it has been suggested that AMPK can really contribute to 
resistance to anti-cancer therapy in some situations (Viollet et al., 2010) & 
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(Jurmeister et al., 2014). AMPK activation is produced after 
phosphorylation at threonine 172 in the AMPK structure via upstream 
kinases. Furthermore, AMPK phosphorylation at Thr172 is detectable in 
some of PCa cell lines, including the androgen-independent DU-145 and 
PC-3 cells and the androgen-sensitive LNCaP cells (Park et al., 2009). 
Some of molecules and signalling pathways have been described to be 
control by AMPK through direct phosphorylation like AMPK substrate and 
as well as indirectly by gene expression regulation. Signalling pathway of 
the apoptotic Fas death receptor is reduced in DU-145 cells, in spite of high 
cell-surface expression of wt Fas, and due to the enhanced AMPK activity. 
Other pharmacological regulator of AMPK such as AICAR is shown to 
suppress the proliferation and viability of a PCa cells, including the 
androgen-dependent LNCaP cell and androgen-insensitive (PC3, DU145 
and C4-2) cells (Zhou et al., 2009) & (Zadra et al., 2014). In view of the 
paradoxical findings on the role of AMPK in cancers, I seek to improve our 
grasp of AMPK signalling pathway in PCa cells by characterizing the 
transcriptional production of AMPK activation. Also to emphasis on the 
effect of QRFP through AMPK activation on prostate cancer cell lines (PC3 
& DU145) and discuss the possibility that AMPK might be a therapeutic 
target for PCa. 
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MAPK PATHWAY FUNCTION STUDIED BY INHIBITION  
Biochemical reagents such as inhibitors of components of the MAPK 
pathway are overwhelmingly a viable alternative or an integral tool in 
understanding the functional requisite in a given pathway. Such inhibitors 
have enabled researchers to distinguish between the major MAP kinase 
cascades and to recognize the function of various MAP kinases in cellular 
activation by extracellular stimuli (Burkhard and Shapiro, 2010). Several 
studies suggested that some neuropeptides which regulate energy 
homeostasis, can as well either directly or indirectly be implicated in the 
progress of benign prostatic hyperplasia and prostate malignancy 
(Malendowicz et al., 2011). In this concern, special attention is being 
founded on obesity and prostate cancer incidence and accumulating data 
suggest the higher risk of aggressive cancer development in obese 
patients. 
6.1   HYPOTHESIS 
It is important to comprehend the mode of regulation of different cellular 
processes by signalling modules, which is one of the essential functions of 
signal transduction study. Therefore, it is significant to understand the 
downstream effects of various signaling pathways and the cellular 
reactions that they regulate. Understanding cell signalling in cancer can 
provide possible targets for anticancer drugs to enhance apoptosis and/or 
inhibit tumour progression (Tang et al., 2014). The common way to 
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determine the involvement of signaling pathway in the researched cellular 
regulate is through blocking its activity followed by measuring effects of this 
inhibited on the cellular study (2011). Thus, this study targeted to 
identification of the role QRFP and molecular markers that can predict PCa 
readiness and progression through activation various downstream 
signaling pathways. 
 
6.2  AIMS 
 To demonstrate the effect that QRFP has on anterior gradient 2 
(AGR2) expression in PCa cell lines. 
 To demonstrate the effects of QRFP on matrix metalloproteinases 
(MMP) in PCa cell lines. 
 To demonstrate if QRFP activates Caspase-3 in PCa cell lines. 
 To demonstrate if QRFP activates AMPK in PCa cell lines. 
 To demonstrate if QRFP has a role by knockdown it’s receptor 
GPR103 PCa. 
 To demonstrate the effect that QRFP has on MAPK, PI3K/AKT and 
AMPK inhibitors in PCa cell lines. 
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6.3    RESULTS 
 
6.3.1   METHODS FOR ASSESSING THE EFFECTS OF QRFP ON 
AGR2 EXPRESSION 
PC3 and DU145 cell lines were cultured as described above until confluent 
in 6 well plates. Cells were incubated in serum starvation media for 
overnight prior to treatments. AGR2 protein evaluates were varying doses 
0=(basal),10 nM and 100 nM QRFP supplemented to the media and the 
cells were incubated for 24 hours and the resultant protein lysates were 
quantified as before and then analysed using western blot as described 
above using the AGR2 primary antibody and GAPDH 1:1000.  In order to 
evaluate the pathways by which QRFP eventually applies its effects on 
AGR2 activation and to demonstrate if QRFP induced migration and 
invasion in prostate cancer cells by activated AGR2 protein expression at 
18 KDa. Result showed QRFP induced significant activation of AGR2 on 
PC3 cells on both doses 10 and 100 nM *p < 0.05 and **P<0.01 
respectively at 24 hours compared to basal levels (Figure 6.1).  
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Figure 6.1The effect of QRFP on AGR-2 protein expression in PC3 
cells.  
Representative western blot analysis showing changes in AGR-2 protein 
activity and corresponding GAPDH protein expression following treatment 
with 10 and 100 nM QRFP for 24 hours of incubation; lanes correspond 
to bar chart. 
 The graph showing quantification of changes in AGR-2 activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 and **P<0.01 compared to basal expression. 
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6.3.2  THE EFFECT OF QRFP ON MMP-2 PROTEIN EXPRESSION IN 
PC3 and DU145 CELLS 
PC3 and DU145 prostate cancer cell lines were cultured as described 
above until confluent in 6 well plates.  Cells were incubated in serum 
starvation media for overnight prior to treatments. Exposer PC3 and 
DU145 cells at time dependent (2, 4, 6, 8 and 12 hours) with 100 nM QRFP 
which corresponded to the greatest dose migration and invasion functional 
effect. The resultant protein lysates were quantified and then analysed 
using western blot as described above using the MMP-2 primary antibody 
and GAPDH at 1:1000 dilution in order to evaluate the pathways by which 
QRFP eventually applies its effects on MMPS activation and to 
demonstrate if QRFP induced migration and invasion in prostate cancer 
cells by activated MMP-2 protein expression at 65 KDa Result showed 
QRFP induced activation MMP-2 on PC3 cells which reached significant 
activation *p < 0.05 at time dependent 2 hr and the level remained 
significantly higher even at 8 hr later turned back to basal levels (Figure 
6.2). An increase in activation of MMP-2 showed on time pointe in DU145 
cells higher than in PC3 cells, the maximum increase significant activations 
were seen at 2, 8, and 12 hours **P<0.01 and slightly drop to significant 
activation at 4 and 8 hours *p < 0.05 all data compared to cell basal (Figure 
6.3). 
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Figure 6.2 The effect of QRFP on MMP-2 protein expression in PC3 
cells 
Representative western blot analysis showing changes in MMP-2 protein 
activity and corresponding GAPDH protein expression following treatment 
with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 10 and 12 
hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in MMP-2   activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 compared to basal expression. 
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Figure 6.3 The effect of QRFP on MMP-2 protein expression in DU145 
cells 
Representative western blot analysis showing changes in MMP-2 protein 
activity and corresponding GAPDH protein expression following treatment 
with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 10 and 12 
hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in MMP-2   activation in 
DU145 cells. Data represent mean ± S.D from three independent 
experiments; *p < 0.05 and **P<0.01 compared to basal expression. 
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6.3.3   THE EFFECT OF QRFP ON TOTAL CASPASE-3 ACTIVITY IN 
PC3 and DU145 CELLS 
PC3 and DU145 prostate cancer cell lines were cultured as described 
above until confluent in 6 well plates.  Cells were incubated in serum 
starvation media for overnight prior to treatments. Incubation PC3 and 
DU145 cells for time dependent (1, 2, 4,6,10 and 12 hours) with 100 nM 
QRFP which corresponded to the greatest apoptosis functional effect. The 
resultant protein lysates were quantified and then analysed using western 
blot as described above using the Caspase -3 primary antibody and 
GAPDH at 1:1000 dilution to determine whether QRFP promoted 
apoptosis of prostate cell lines by measured protein expression of 
Caspase-3. A significant activation of Caspase-3 in PC3 cells were 
indicated at time point 1, 2, 6 and 12 hours *p < 0.05 and appeared to come 
towards basal levels at time 4 hours and 10 hours (Figure 6.4). Similar 
activation shown in DU145 cells were statically significant activation at time 
pointe 1, 4, 6 and 12 hours *p < 0.05 and rapid decreased to basal levels 
at time point 2 hours and 10 hours (Figure 6.5). 
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Figure 6.4 The effect of QRFP on total Caspase-3 protein expression 
in PC3 cells 
Representative western blot analysis showing changes in Caspase-3 
protein activity and corresponding GAPDH protein expression following 
treatment with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 
10 and 12 hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in Caspase-3   activation in 
PC3 cells. Data represent mean ± S.D from three independent 
experiments; *p < 0.05 compared to basal expression. 
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Figure 6.5 The effect of QRFP on total Caspase-3 protein expression 
in DU145 cells 
Representative western blot analysis showing changes in Caspase-3 
protein activity and corresponding GAPDH protein expression following 
treatment with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 
10 and 12 hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in Caspase-3   activation in 
DU145 cells. Data represent mean ± S.D from three independent 
experiments; *p < 0.05 compared to basal expression. 
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6.3.4   THE EFFECT OF QRFP ON AMPK ACTIVITY IN PC3 and DU145 
CELLS 
PC3 and DU145 prostate cancer cell lines were cultured as described 
above until confluent in 6 well plates.  Cells were incubated in serum 
starvation media for overnight prior to treatments. Stimulate PC3 and 
DU145 cells for time dependent (2, 4, 6, 8 and 12 hours) with 100 nM 
QRFP which corresponded to the greatest apoptosis functional effect. The 
resultant protein lysates were quantified and then analysed using western 
blot as described above using the AMPK primary antibody and GAPDH at 
1:1000 dilution to demonstrated the effect of QRFP mediated the AMPK 
expression on prostate cancer cell lies QRFP induced strong activation of 
all at time points AMPK activity in PC3 cells reached significant activation 
at 2 hr *p < 0.05, high significant at 4 hr and 8 hr **P<0.01 and highest 
increase activation at 6-12 hours ***P<0.001 (Figure 6.6). DU145 cells 
presented also QRFP increase significant effect on AMPK activity at time 
pointe 2, 8 and 12 hours **P<0.01 and significant effect at 4 and 6 hours 
*p < 0.05 all data related to basal cells (Figure 6.7). 
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Figure 6.6 The effect of QRFP on AMPK protein expression in PC3 
cells 
Representative western blot analysis showing changes in AMPK protein 
activity and corresponding GAPDH protein expression following treatment 
with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 10 and 12 
hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in AMPK activation in PC3 
cells. Data represent mean ± S.D from three independent experiments; *p 
< 0.05 and **P<0.01 compared to basal expression. 
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Figure 6.7 The effect of QRFP on AMPK protein expression in DU145 
cells 
Representative western blot analysis showing changes in AMPK protein 
activity and corresponding GAPDH protein expression following treatment 
with 100 nM QRFP at varying time points (0 = Basal, 1, 2, 4, 6, 10 and 12 
hours) of incubation; lanes correspond to bar chart. 
The graph showing quantification of changes in AMPK   activation in 
DU145 cells. Data represent mean ± S.D from three independent 
experiments; *p < 0.05 and **P<0.01 compared to basal expression. 
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6.3.5   GPR103 GENES SILENCING INHIBITTS p-AKT PATHWAY IN 
PC3 cells  
To investigate the potential role of GPR103 in QRFP induced AKT 
signaling, siRNA specific for the silence GPR103 receptor was employed 
in according to manufacturer's instructions in method chapter. The mRNA 
level of GPR103 significantly decreased in PC3 following siRNA 
transfection at increasing concentration of siRNA. Figure 6.8. A, has shown 
silence the expression of GPR103 mRNA decreased significantly with 
increasing doses of siRNA *P<0.05, **P<0.01 and ***P<0.001 respectively. 
I observed and dose dependent reduction in   GRP103 expression and 
maximum reduction was observed at 10nM siRNA concentration. Future 
studies were conducted using this 10nM siRNA concentration for AKT 
phosphorylation experiments.  
The maximum inhibition of GPR103 was achieved at siRNA (10 µM) 
concentration. AKT phosphorylation studies were conducted in cells 
transfected with GPR103 siRNA. The QRFP induced p-AKT protein 
expression was significantly decreased in cells transfected with GPR103 
siRNA compared to control in PC3 cells as showed in (Figure 6.8. B). 
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Figure 6.8. siRNA mediated knockdown of GPR103 receptor PC3 
cells. Bar chart representing the effects of siRNA mediated knockdown of 
genes targeted using real-time PCR. By using siRNA concentration from 
3, 6 and10 nM range and complexed with 2 µg/ml Lipofectamine™ 2000 
and transfected for 24 hours. The following day mRNA expression for 
GPR103 expression were measured using real-time PCR to quantify 
GPR103 expression. Data showed dose dependent significantly 
decreased in GRP103 expression and maximum reduction was observed 
at 10nM siRNA concentration. Data are presented as mean ± S.D, the 
experiment was performed in 4 wells *P<0.05, **P<0.01 and ***P < 0.001 
as compared with control (basal) cells. 
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Figure 6.9 Effect of GPR103 receptor knockdown on QRFP induced 
AKT phosphorylation in PC3 cells. 
 By used 10 nM siRNA complexed with 2 µg/ml Lipofectamine™ 2000 and 
transfected for 24 hr. The following day cell culture media was changed 
and cells were allowed to settle for 3 hours prior to stimulation with or 
without QRFP.  Representative western blot and graph presented PC3 
cells transfected with GRP103 siRNA QRFP induced AKT phosphorylation 
was completely abolished compared to non-transfected cells. Data 
represent mean ± S.D from three independent experiments; ***P<0.001 
compared to basal expression. 
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6.3.6    THE EFFECT OF QRFP WITH MAPK, PI3K/AKT AND AMPK 
IINHIBITORS IN PC3 AND DU145 CELLS.    
To further determine whether mitogen-activator protein kinase (MAPK), 
AKT, and AMPK signaling pathways are involved in QRFP mediated 
prostate cells immigration. Approximately 70% confluent PC3 and DU145 
cells were seeded in CIM-Plate and incubated with designated signaling 
inhibitors for 1 h prior to subsequent treated with QRFP peptide (100 nM) 
alone or combined p38 (SB202190; 10 µM), PI3K inhibitor (LY294002; 10 
mM), AMPK inhibitor (compound C;) and MAPK inhibitor (U0126; 10 mM) 
for 8 hours. Following stimulation xCELLigence system applied to 
determine cell migration.  
As showed in Figure 6.10/6.11 incubation PC3 and DU145 cells with AMPK 
and P38 inhibitors combined with the peptide significantly increased the 
migration rate compare to the cell incubated with the peptide alone 
*P<0.05, **P<0.01 respectively. In contrast, the effect of QRFP with PI3K 
inhibitor in PC3 and DU145 cells showed significantly reduced cell 
migration compared to basal cells or basal related with QRFP **P<0.01. 
PC3 and DU145 cells were treated with a selective MEK/ERK1/2 inhibitor 
U0126 combined with the peptide or alone shows no QRFP change effects 
on this pathway.  
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Figure 6.10 The effects of QRFP and combination inhibitors on 
migration signalling pathways in PC3 cell.  Representative graph rate 
of QRFP 100 nM, p38, AMPK P13K and U0126 inhibitors were incubated 
for 8 hours compared to QRFP alone and to basal cells. Data were 
evaluated using the xCELLigence RTCA software mean ± SD, (n = 5) #P < 
0.05, *P<0.05 and **P<0.01. 
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Figure 6.11 The effects of QRFP and combination inhibitors on 
migration signalling pathways in DU145 cell.  Representative graph 
rate of QRFP 100 nM, p38, AMPK, P13K and U0126 inhibitors were 
incubated for 8 hours compared to QRFP alone and to basal cells. Data 
were evaluated using the xCELLigence RTCA software mean ± SD, (n = 5) 
#P < 0.05 and *P<0.05. 
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6.4   DISCUSSION  
Anterior gradient 2 (AGR2) appears high-expressed in prostate cancer and 
involved to promote cell migration, invasion, cellular transformation and 
drug resistance (Hu et al., 2012). Also controls the cell adhesion rates of 
detached cells, which may correlate with the ability of metastatic cells 
(Hrstka et al., 2010). The interesting data obtained from western blot 
presented QRFP induces increase in anterior gradient (AGR2) expression 
in PC3 cells compared to DU145 cells on dose dependency. However, this 
referred to the low expression of AGR2 whereas overexpressed in PC3 
cells. Again QRFP at 100 nM seems to show strong effect on prostate 
cancer cells. Interestingly Bu, et al. reported that while high-expressed 
AGR2 in prostate cancer cells increased migration and invasion and 
apparently metastatic spread, however, AGR2 supressed cell growing and 
proliferation (Maresh et al., 2010) . This finding might explain our previous 
data which QRFP induce prostate cancer cell migration and invasion and 
suppression cell proliferation. It has been confirmed that AGR-2 
expression was strong associated with cyclin D1 and negative association 
with P53 and p21 in prostate cell lines. Also it has been revealed that 
downregulation of AGR2 was related to cellular senescence, by active p16, 
p21, p27 and suppression PI3K/Akt/ ERK in prostate cancer cells (Hu et 
al., 2012). 
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 The mechanism of expression AGR2 could be involved in molecular 
crosstalk among ER and other pro-oncogenic signalling pathways 
including insulin-like growth factor receptor (IGFR), epiderma-l growth 
factor receptor (EGFR), ERK, and PI3K /AKT pathway (Hrstka et al., 2013). 
However, this leads to a potential role of QRFP in the manipulation of 
AGR2 activation and consequently a role for AGR2 in prostate cancer 
progression.  
Several reports have showed that increased expression levels of MMP-2 
in the serum or tissue samples of prostate tumor patients are associated 
with late stage. As well indicated the expression of MMPs associate with 
migration, invasive and metastatic possible of prostate cancer cell lines 
(Xiao et al., 2012). Expression of MMP-2 is linked to prostate cancer 
advance, whereas the Inhibition of MMP-2 expression suppresses the 
prostate cancer metastatic. To understanding the mechanisms by which 
QRFP effect activation of MMP-2 mediate activation MAPK is sought after 
for the possible therapeutic applications of cancer migration and invasion. 
Further examined has been early performed of the upregulate MAPK 
signaling pathways of MMP-2 associated with cellular migration and 
invasion. It is acknowledged that the MAPK pathway regulates cancer cell 
metastasis. Several recent suggestions have been connected with the 
activation of ERK1/2 signaling pathway and MMPs (Shuvojit Moulik, 2014).  
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 Association of MMPs in EGFR transactivation by GPCRs has been 
described formerly (Amorino et al., 2007). For the first time to our 
knowledge that QRFP is found to effect activation MMP-2 expression on 
prostate cancer cell lines, QRFP is found to affect activation MMP-2 
expression in prostate cancer cell lines, which potential supports the role 
of QRFP on cell migration and invasion. The expression and the activities 
of MMP-2 upon exposure to 100 nM QRFP at time dependent showed 
increase in activation in PC3 cells than DU145 cells. In order to fully clarify 
the mechanisms implicated in QRFP induced PC3 and DU145 cell 
migration and invasion. Attributed to the overexpression of MMP 2 
observed in a progression metastasis bone which related to PC3 cells. 
MMP-2 expression has been shown regulate by many transcriptional 
factors g AP-1/2, ETS, Sp-1, and NF-κB (Gong et al., 2014). MAPK 
signalling pathways (ERK, p38 JNK) and AKT have been indicated to 
upregulate MMPs expression (Yang et al., 2013). Though, the previous 
studies indicated the association between activation of EGFR and 
downstream signal pathway Raf/MEK/ ERK1/2 signalling pathway and 
MMP expression (Chen et al., 2015). Moreover, there is a potential direct 
association between MMP2 and ERK1/2 activity which could involve with 
cFos and STAT3 (Shuvojit Moulik, 2014). Enhance MMP-2 expression by 
p38 MAPK pathway mediated TGF-β- has been involved in migration and 
invasion in prostate cancer cell lies (Huang et al., 2005).  Chen et al, 
presented shikonin (Chinese medicine) could supressed metastasis PC3 
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and DU145 cells through inhibited MMP-2 expression mediated inactive 
AKT/mTOR and activation ROS/ERK1/2/ and p38/JNK pathway (Chen et 
al., 2014b).  This data clearly demonstrated that QRFP involved in increase 
activation of MAPK signalling pathways and AKT signlaing and activities 
downregulates MMP-2 expression in PC3 cells and DU145 cells. QRFP 
may has potential roles in developing prostate cancer metastasis on dose 
and time dependent manner. It is of interest, therefore, to define whether 
apoptosis is induced by the QRFP through the MAPK and AKT signaling 
pathway mediate downregulate caspase-3 and induce apoptosis in 
prostate cancer cell lines. The data obtained from immunoblot showed the 
first time unprecedented that QRFP increase the activation of caspase-3 
in both of prostate androgen insensitive in time dependent manner. 
Therefore, the unusual observed from the results is unstable of increase 
activation in all time points started treatment from 1 hr pending 12 hrs 
which has been shown in PC3 cells and DU145 cells.                                        
Activation and or inactivation of some protein kinases such as 
Ras/Raf/MEK and the stress-activated kinase JNK and an essential for the 
cysteine protease caspase pathway have also been stated (Drew et al., 
2002). The MAPK p38 activity could regulate downstream caspases 
cascade and is significant for the activation of Caspase-3 in prostate 
cancer cell lines. It has been shown that Gyromagnetic fields (GMFs) 
inhibit cell growth and induce cell death mediated by activation of the p38 
MAPK pathway mediate Caspases (Lei et al., 2015). PC3 cells treated with 
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a growth factor TGFβ1, has shown suppress cell proliferation and induction 
cell apoptosis through activation MAPK p38/ JNK/SAPK pathway which 
turn to enhance activation Caspease-3 (Al-Azayzih et al., 2012). Moreover, 
aurothiomalate (ATM) causes activation of ERK/ p38 and JNK MAPK 
phosphorylation mediate activation Caspase-3 and induced apoptosis in 
PC3U cells (Trani et al., 2009). It is complex to explain the variable of 
Caspease-3 activation in both cell lines investigated might be as explained 
early QRFP has dual function in the same time in prostate cancer cells. 
Otherwise these finding indicate that potential additional kinase is involved 
in this pathway and that this molecule might be particularly activated by the 
QRFP. This result demonstrated that QRFP has potential role effect to 
induce apoptosis in prostate cancer cells.                                                                               
In further to confirming apoptosis induction, the present study clearly 
demonstrated that QRFP increase activation of AMPK expression in PC3 
cell and DU145 cells. Our data shows higher expression level of AMPK 
activity in PC3 cell at all-time point treatment peaking at 6 hours. However, 
the effects of QRFP on activation AMPK was less in DU145 cells just at 
two-time point significance activation 2 hr and 4 hr later on the activation 
decreased to level basal cells. Recent studies have demonstrated that 
Increased expression AMPK levels in androgen dependent cells LNCaP 
and androgen independent cells DU145 while PC3 cell higher expression 
(Choudhury et al., 2014) & (Grossi et al., 2015). Pharmacologically 
activation of AMPK has been shown to suppression cell proliferation and 
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viability of many prostate cancer cell lines (Jurmeister et al., 2014). Besides 
the roles in controlling metabolism and energy balance, AMPK is found for 
its association to a wide range of cellular survival pathways, such as the 
phosphatidylinositol 3-kinase (PI3-K) pathway. AMPK activation can inhibit 
the activation of the protein target of mTOR, a key downstream component 
of the PI3-K pathway. Thus, AMPK’s site in both the metabolic pathway in 
addition to its position upstream of the mTOR signaling pathway make it a 
possible therapeutic target for the treatment of PCa (Shackelford and 
Shaw, 2009) & (Kim and He, 2013). Many mechanisms can be involved in 
activation of AMPK results pleiotropic effects in the suppression of prostate 
cancer and tumor development, such inhibition of PI3k/Akt/mTOR 
pathway, cell cycle progression and up-regulation of p53 and p21 axis 
leading to induction apoptosis (Zadra et al., 2014). Furthermore, the AMPK 
pathway associated with a number of tumor suppressor genes, including 
upstream activator LKB1 and direct activates p53 and TCS2 (Kim et al., 
2014). However, Induction of apoptosis is a challenge, since it could 
enhance the effects of classical anticancer agents. The data are in line with 
literature observations highlighting the role of AMPK activated by QRFP 
induced suppression proliferation cells and induced apoptosis in prostate 
cancer cell lines depend on dose and time manner.                                              
To prove whether the QRFP mediated effects were through GPR103 
receptor. The receptor was knockdown with GPR103 siRNA. The findings 
from study showed that QRFP induced AKT activation was abolished when 
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GPR103 receptor was knockdown in PC3 cells. These findings suggest 
that QRFP effects were mediated through GPR103 receptor in PC3 cells. 
Mechanistic analysis of QRFP mediated migration studies revealed that 
multiple signalling pathways are involved in QRFP induced migration of 
prostate cells. Pharmacological reagents that inhibit MAPK pathways were 
used to determine whether MAPK signaling is involved in the cells 
immigration.  Previous studies showed that PCa cell migration and invasion 
are mediated through the p38 MAPK pathway; this leads to the activation 
of heat shock protein 27 that involved in regulates of MMP-2 activation and 
cell invasion. Other studies suggested that the overexpression of p38 
MAPK can induce the high sensitivity to apoptosis induction leading to cell 
death, p38 is not an essential for cellular apoptosis. Furthermore, it has 
been shown that inhibition of p38 MAP kinase pathway caused inhibition 
of the DNA synthesis, survival, and proliferation of PC3 cells. p38 MAPK 
has been found plays a dual role as a regulator of cell death, and it can 
mediated cell proliferate or cell death depending on a cell type specific 
manner also in type of stimulus (Koul et al., 2013). Stimulates AMPK 
activation can influence many effectors proteins implicated in many 
regulatory processes which control or contribute to the pathogenesis of 
PCa (Choudhury et al., 2014). The role of AMPK PCa pathogenesis 
remains in debate. Studies have presented that AMPK is expressed in 
human PCa cell and inhibition of its activity, using the inhibitor compound 
C, has suppression effects on cell growth (Frigo et al., 2011). Conversely, 
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some medicines which are used in the cure of diabetes and other metabolic 
diseases, such as metformin, have been shown to decrease cancer risk 
and to supress PCa cell proliferation and cell growth in animal models 
mediate AMPK activation (Zadra et al., 2013). At present, though, it is 
unclear how AMPK regulates in PCa cell migration and invasion. Given 
together in this study the effect of QRFP mediate inhibit p38 and AMPK 
pathway observed increased significantly cell migration in both cell lines 
PC3 and Du145.  In contrary, the results from this study exhibited that 
inhibition of PI3K-pathway reduced significantly the effect of QRFP 
migration in PC3 and DU145 cells. While, inhibited the MAPK/ ERK with 
U0126 showed no change effect of QRFP migration on this pathway in 
both cell lines PC3 and Du145. The MAPK ERK and PI3K-Akt signal 
pathway have been revealed to control the progression pathway leading to 
metastasis of PCa in addition to the development and progress of many 
other tumors. This means, over-expression of AKT/PI3K is highly related 
with the development metastasis of PCa. Many other studies have also 
presented that targeting PI3K-Akt signaling pathway with antisense, siRNA 
or small molecule inhibitors outcomes in the down-regulation of migration 
and invasion and tumorigenesis in cancer cells. It have been presented 
that the activation of MMP-2 and the invasiveness to be not mediated via 
ERK, signaling pathway in human melanoma cells (Denkert et al., 2002). 
In addition, Inhibition of the MAPK ERk and PI3K/Akt signaling pathway 
can inhibit cancer cell proliferation, migration and invasion, and metastasis 
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(Hennessy et al., 2005) & (Chen et al., 2011). Taken together, our data 
suggest that QRFP promotes migration and invasion of prostate cells 
which consistence with result obtained from functional assay and also with 
litters reviews.  
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CHAPTER 7 
 
THE REGULATION OF QRFP & GPR103 
EXPRESSION BY ADIPOKINES IN 
PROSTATE CANCER 
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7   INTRODUCTION 
 
 A variety of hormones, adipokines and bioactive peptides regulate the 
growth prostate gland. Obesity results in an abnormal release of these 
hormones , which can form part of the motive that stimulates prostate 
carcinogenesis (Mistry et al., 2007). World widely, the WHO estimates 
presented that by 2015 more than 2.3 billion people are overweight and 
around 700 million people are obese (Suzuki et al., 2010). The relationship 
between prostate cancer and obesity is complicated. Many reviews 
suggested that the obesity is linked with increased risk of prostate cancer. 
However, various molecular mechanisms have been suggested to clarify 
these explanations (Lughezzani, 2012). However, the details of these 
mechanisms remain uncertain. Thus it is important to continue to 
investigate the pathways that are associated with obesity and prostate 
cancer (Alshaker et al., 2015). As elucidated in the introduction chapter 
white adipose tissue is core site of energy storage in human, while, brown 
adipose tissue mostly utilizes energy and produces heat. Adipocytes 
produces and secretes bioactive molecules which are termed as 
adipokines. The adipose tissue energy metabolism and the immune 
system is well determined by two main adipokines which has opposite in 
function namely leptin and adiponectin. In latest years, researchers have 
extensively focused particularly on both adipokines for their ability to 
regulate cancer cell phenotype directly. Many properties of adipokines 
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might have impact on progression of prostate carcinogenesis (Al-Hamodi 
et al., 2014) & (Burton et al., 2010). Both circulating leptin levels and 
adipose tissue leptin mRNA increases in obesity. Clinical studies showed 
that leptin levels in blood are correlated with prostate cancer progression 
(Ribeiro et al., 2006) & (Mitsuyama et al., 2015). Leptin has been shown to 
stimulate intracellular signalling pathways correlated with cell proliferation, 
migration, invasion and inhibition of apoptosis mainly in androgen 
independent PCa cell lines (PC3 and DU145). Conversely, leptin has not 
been found as a growth promoter of androgen dependent LNCaP cells 
(Hoda et al., 2012b).  Leptin receptor mRNAs for both long and short forms 
were determined in the androgen-independent PC3 and DU145 human 
prostate cancer cell lines. In vitro studies showed that exogenous leptin 
administration induced the growth of these two cell lines. However no 
mitogenic response to the ligand was observed in the androgen dependent 
LNCaP prostate cancer cell line (Baillargeon and Rose, 2006). Adiponectin 
receptors mRNA has been found to be expressed in both beneigh and 
malignant human prostate tissues and also in PCa cell lines androgen-
independent PC3 and androgen-dependent LNCaP. Adiponectin levels are 
inversely correlated with the risk of prostate cancer. Lower adiponectin 
concentrations are independently correlated with high-aggressive prostate 
cancer (Mistry et al., 2006). Recently, a new member of adipokine family 
was discovered named chemerin, a chemoattractant protein. In adipose 
tissue expression of chemerin and its receptor, (CMKLR1, or ChemR23) 
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are significantly higher in obese adipose tissue. Chemerin and CMKLR1 
are involved in regulation of adipogenesis (Sell et al., 2009).                      
Many of neuropeptides have distinguished expression patterns in the 
hypothalamus and main effect on the central regulation of energy balance. 
QRFP is a potent agonist of GPR103, involved in enhanced food intake, 
increased body weight and fat mass, adipogenesis and decreases 
thermogenesis. QRFP mRNA level has been found expressed in 
peripheral tissues specific in white adipose tissue in mouse model. 
However, the expression of QRFP in adipose tissue is reduced in diet-
induced obesity (Jossart et al., 2014). While, the role of GPR103 in 
regulating peripheral metabolic pathways is unclear (Mulumba et al., 
2010). In rats, QRFP management changes macronutrient selection and 
particularly increases the intake of a calorically heavy high fat diet 
(Primeaux et al., 2013).  Several studies found that effects of QRFP on 
food intake are mediated by the hypothalamic neuropeptides and adiposity 
signal, including leptin (Primeaux et al., 2013). Bernard Beck et al, 2009, 
resulted the role of leptin in the ventromedial hypothalamus by presenting 
an influence on the orexigenic drive, as proposed by the reverse 
relationship between plasma leptin and QRFP in this part. Plasma leptin 
concentration increased in animals chronically injected with QRFP 43. 
Moreover, expression of QRFP is up regulated with leptin deficiency in 
obese animal models (Beck and Richy, 2009). This leads that QRFP could 
has a function downstream of leptin in the regulation of feeding behavior. 
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The study  suggested that the QRFP could be good target for the 
pharmacological treatment of diet-produced obesity (Beck and Richy, 
2009).  
7.1   HYPOTHESIS 
In this chapter, I have investigated whether QRFP & GPR103 expression 
is regulated by adipokines leptin, adiponectin and chemerin.  
7.2  AIM 
 To demonstrate the role of adipokines in regulation of mRNA 
QRFP and GPR103 expression in prostate cancer cell lines. 
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7.3   RESULTS 
7.3.1   REGULATION OF QRFP & GPR103 EXPRESSION BY 
ADIPOKINES AND HORMONES IN PROSTATE CANCER  
Cytokines produced by adipocytes are associated with prostate cancer 
progression. Real time PCR was used to investigate the effect of the 
adipokines on QRFP and GPR103 expression in prostate cancer cell lines. 
PC3 cells were treated by Leptin (100 nM), adiponectin (10 nM), and 
Chemerin (1 nM) for 24 hours then assessed by real time PCR assay. The 
RNA was converted into cDNA and primers for the following genes (QRFP 
and GPR103) were used as previously described. The using primers for 
GAPDH as an internal control are showed below. The data obtained 
showed that both QRFP and GPR103 mRNA were significantly increased 
with Leptin stimulation**P<0.01 compared to basal. However other drugs 
used in the current study did not show any statistical significant changes in 
the expression of QRFP and GPR103 mRNA expression (Figure 7.1/7.2). 
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Figure 7.1 Effects of adipokines on GPR103 expression in PC3 
prostate cell lines. PC3 cells were incubated for 24 hours with different 
drugs. GPR103 levels following stimulation with adipokines are shown. 
Data shown are mean ± S.D. Leptin significantly increases GPR103 
production at 24 hours. The experiment was performed in triplicate wells 
**P<0.01 as compared with basal. 
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Figure 7.2 Effects of adipokines on mRNA QRFP expression in 
prostate cell lines.  PC3 cells were incubated for 24 hours with different 
drugs. QRFP levels following stimulation with adipokines are shown. Data 
shown are mean ± S.D. Leptin significantly increases mRNA QRFP 
production at 24 hours. The experiment was performed in triplicate wells 
**P<0.01 as compared with basal. 
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7.3.2   THE EFFECT OF LEPTIN ON REGULATION OF QRFP & GPR103 
mRNA EXPRESSION IN PROSTATE CANCER 
In order to examine what is the optimal dose of leptin that induces 
significantly increase in QRFP and GPR103 expression. PC3 cells were 
stimulated with concentration of leptin ranging from 1 to 100 nM. Total RNA 
was extracted from PC3 cells after treatment with leptin 1, 10, 50 and 100 
nM for 24 hours as previously described. RT-PCR demonstrate mRNA 
QRFP and GPR103 expression a significant up-regulation from 50 nM 
Leptin *p < 0.05 and peaks at a treatment dose-dependent effect of 100 
nM **P<0.01 (Figure 7.3/7.4).  Similarly, to examine what is the optimal time 
required for leptin to significantly increase in QRFP and GPR103 
expression. PC3 cells were treated with 100 nM of leptin time dependently 
from 4-24 hours. RNA was extracted from PC3 cells after treatment with 
100 nM leptin for 4, 8, 12 and 24 hours as previously described. mRNA 
QRFP and GPR103 expression demonstrate a significant increase of from 
12 and 24 hours *p < 0.05 and**P<0.01 respectively (Figure 7.5/7.6).         
To assess the relative changes of Leptin time dependency effect on mRNA 
QRFP and GPR103 in DU145 cells. RNA was extracted from DU145 cells 
after treatment with leptin 100 nM for 4, 8, 12 and 24 hours as previously 
described. QRFP and GPR103 gene expression showed a significant 
increase from 4 and 8 hours *p < 0.05 and**P<0.01 respectively. The levels 
then begin to return to basal at 12 hours and significant decreased at 24 
hours (Figure 7.7/7.8). 
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Figure 7.3 Effects of Leptin (100 nM) stimulation for 24 hours on GPR103 
genes expression in PC3 cells was evaluated by using RT-PCR. mRNA 
expression levels were normalized against GAPDH mRNA expression. 
Data are expressed as mean ± S.D, from three independent experiments 
*p < 0.05 and **P<0.01. 
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Figure 7.4 Effects of Leptin (100 nM) stimulation for 24 hours on QRFP 
genes expression in PC3 cells was evaluated by using RT-PCR. mRNA 
expression levels were normalized against GAPDH mRNA expression. 
Data are expressed as mean ± S.D., from three independent experiments 
*p < 0.05 and **P<0.01. 
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Figure 7.5 Effects of Leptin on GPR103 expression in prostate cell 
lines.  PC3 cells were incubated for time dependence 4,8,12 and 24 hours 
and evaluated by using RT-PCR. Leptin significantly increases GPR103 
gene expression at 24 hours. Data shown are mean ± S.D, the experiment 
was performed in triplicate wells *P<0.05 and **P<0.01, as compared with 
basal. 
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Figure 7.6 Effects of Leptin on QRFP expression in prostate cell lines. 
PC3 cells were incubated for time dependence 4,8,12 and 24 hours and 
evaluated using RT-PCR. Leptin significantly increases QRFP gene 
expression at 12 hr and 24 hr. Data shown are mean ± S.D, the experiment 
was performed in triplicate wells *P<0.05 and **P<0.01, as compared with 
basal. 
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Figure 7.7. Effects of Leptin on GPR103 expression in prostate cell 
lines. DU145 cells were incubated for time dependence 4,8,12 and 24 
hours and evaluated by using RT-PCR. Leptin significantly increases 
GPR103 gene expression at 4 and 8 hours. Data shown are mean ± S.D, 
the experiment was performed in triplicate wells *P<0.05 and **P<0.01, as 
compared with basal. 
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Figure 7.8. Effects of Leptin on QRFP expression in prostate cell 
lines. DU145 cells were incubated for time dependence 4,8,12 and 24 
hours and evaluated by using RT-PCR. Leptin significantly increases 
QRFP gene expression at 12 and 24 hours. Data shown are mean ± S.D, 
the experiment was performed in triplicate wells *P<0.05 and **P<0.01, as 
compared with basal.  
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7.3.3 LEPTIN REGULATES QRFP & GPR103 GENE EXPRESSION IN 
PROSTATE CANCER CELLS VIA MAPK AND PI3 KINASE PATHWAY  
It is well documented in the literature that leptin induces its functional 
effects via activation of MAPK and PI3 kinase signalling pathways. In this 
current study we employed real time PCR to demonstrate the relative 
change in QRFP and GPR103 gene expression in the presence and 
absence of MAPK and PI3 kinase inhibitors. 
PC3 cells were treated by a combination with or without Leptin (100 nM), 
MAPK inhibitor (U0126; 10 mM) or PI3K inhibitor (LY294002; 10 mM) for 
24 hours. Following stimulation RNA was extracted and converted into 
cDNA. The primers for the following genes (QRFP and GPR103) were 
used as previously described. The primers for GAPDH as an internal 
control are showed below. The data obtained showed that both QRFP and 
GPR103 mRNA were significantly increased with Leptin 
stimulation**P<0.0. 
However, the effects were inhibited in the presence of PI3K and U0126 
inhibitor which showed significant reduction in QRFP and GPR 103 mRNA 
expression*P<0.05 compared to basal cells stimulated with leptin. *P<0.05 
and **P<0.01 on PC3 cells compared to Leptin stimulate levels (Figure 
7.9/7.10). 
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Figure 7.9 Effects of Leptin and MAPK inhibitors on mRNA GPR103 
expression in prostate cell lines. PC3 cells were incubated for 24 hours 
with different Leptin, P13K and U0126 and evaluated using real-time PCR. 
Data shown are mean ± S.D. The experiment was performed in triplicate 
wells. *P<0.05 and **P<0.01, as compared with basal while #P<0.05 and 
##P<0.01 compared to Leptin. 
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Figure 7.10 Effects of Leptin and inhibitors on mRNA QRFP 
expression in prostate cell lines. PC3 cells were incubated for 24 hours 
with different Leptin, P13K and U0126 and evaluated using real-time PCR. 
Data shown are mean ± S.D. The experiment was performed in triplicate 
wells. *P<0.05 and **P<0.01 as compared with basal. while #P<0.05 and 
##P<0.01 compared to Leptin. 
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7.4   DISCUSSION 
It is essential to understand the associations between obesity and prostate 
cancer and effects of adipokines on QRFP and GPR103 expression in 
prostate cancer. In the present study, different adipokines have been used 
to investigate their effects on mRNA QRFP and GPR103 in prostate cancer 
cell lines in vitro. The results obtained from these experiments 
demonstrated for the first time mRNA levels of QRFP and GPR103 are 
significantly increased with adipokine Leptin. Conversely adiponectin and 
chemerin stimulation showed no significant effect on QRFP and GPR103 
gene expression in PC3 cells. Particular consideration is expecting for the 
potential role of the leptin with QRFP and GPR103 gene expression, 
because of its association with the development of prostate cancer. 
Moreover, my study demonstrated the optimal dose of leptin required to 
induce significant increase in QRFP and GPR103 mRNA expression in 
PC3 cells. Time dependent studies demonstrated that effects of leptin on 
QRFP and GPR103 gene expression in PC3 cells is time dependent. To 
confirm my results other androgen insensitive cells (DU145) were 
employed. Inversely, DU145 cells showed different leptin time dependent 
response compared to PC3 cells. In conclusion, leptin appears to have a 
time and dose dependent effects on QRFP and GPR103 mRNA 
expression in different prostate cancer cell lines. Evidence from literature 
supports that leptin as a growth factor induces prostate cancer cell 
 
  
221 
 
migration and invasion (Frankenberry et al., 2004). My previous findings in 
this thesis showed that QRFP induces prostate cancer cell migration and 
invasion in prostate cancer cell lines. Given leptin regulates QRFP 
expression, it is reasonable to preclude that leptin effects might be 
mediated via involvement of QRFP and QRFP may be downstream target 
for leptin. This finding could support the hypostasis that increase effects of 
leptin on QRFP and GPR103 may have association on progression of 
prostate cancer. Leptin receptors are expressed in androgen independent 
PC3 and DU145 cells. Leptin binds receptor the long Ob-Rb and activities 
various pathway including JAK/STAT that activate MAPK and PI3K/AKT 
pathway leads to induction cellular growth, migration and invasion in 
prostate cancer. Whereas the short form leptin receptor Ob-Rb mainly 
activate only MAPK ERK1/2 pathway but not STAT (Miyazaki et al., 2008) 
&  (Dutta et al., 2012).  Inhibition of these pathways with specific chemical 
inhibitors not only prevents the phosphorylation of respective key signal-
transduction elements, but also directly blocks the endometrial cancer cell 
proliferation. Also, prevention of leptin-induced activation of the JAK/STAT 
pathway by specific chemical inhibition in turn significantly reduces the 
activation of ERK and AKT pathways (Sharma et al., 2006). 
In an attempt to examine the signalling pathways involved in leptin-
mediated induction of QRFP and GPR103 expression in prostate cancer 
cells. I examined the influence of PI3 Kinase, ERK, AMPK and p38 MAPK 
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kinase pathway inhibitors on leptin induced QRFP and GPR103. Findings 
from this study demonstrated that PI3K and U126 MAPK inhibitor 
decreases leptin induced QRFP and GPR103 mRNA expression in PC3 
cells, suggesting that leptin induced QRFP and GPR103 expression via 
involvement of PI3 kinase and ERK MAPK kinase pathway.  
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CHAPTER 8 
 
GENERAL DISCUSION 
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GENERAL DISCUSSION 
 
The biology and physiological role of peptide QRFP and receptor systems 
are described. I demonstrate their presence in tumors, with a focus on 
prostate cancers. This study has explored a potential novel role for the 
neuropeptide QRFP in prostate carcinogenesis.  Employing most common 
PCa cell lines in addition to benign and malignant human prostate tissue I 
managed to demonstrate the expression of QRFP &GPR103 its receptor. 
It should be noted that, these studies have limitations as to the interactions 
do not necessarily translate to the circulating in-vivo environment 
conditions such as absence of blood flow and many factors involve may 
affect the final outcomes most of these failures are not necessarily 
published. For this study prostate cancer cell lines PC3, Du145 and LNCaP 
cell lines were used as surrogates for CaP rather than in-vitro cultures of 
human prostatic cells. These cell lines are well characterised cellular 
models most widely used in studies involving prostate cancer research. 
Three of the most commonly used cell lines of PCa were derived from 
metastatic lesions:  PC3 from bone, DU145 from brain and LNCaP from a 
lymph node. These cell lines were representing different spectrums of 
prostate cancer with aggressive form, moderate metastatic potential and 
low metastatic potential, also hormone refractory was demonstrating both 
androgen insensitive and androgen sensitive disease respectively. One of 
the significant biological variances between the three cell lines is the 
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androgen receptor (AR) express. LNCaP cells with expression of luminal 
differentiation markers androgen receptor (AR) and prostate-specific 
antigen (PSA) while the PC3 and DU145 cells presents negative AR or 
PSA mRNA/protein. Since these cell lines are immortalised cell cultures 
established from metastases, they therefore useful in studying the 
biochemical changes in advanced disease cells and in evaluating their 
response to chemotherapeutic agents. However, they have significantly 
different characteristics. 
In the present study, I reported the presence and function of QRFP and its 
receptor GPR130 in human prostate tissue and in human prostate cell 
lines. In mammals, the mRNAs encoding the QRFP and its receptor 
GPR103, are mainly expressed in the brain, especially in the 
hypothalamus, and in different peripheral organs such as adipose tissue, 
testes. Consistent with this report, PCR and immunoassay data reveal that 
GPR103 and its ligand QFRP is highly expressed in human prostate 
compared to three prostate cancer cell lines: LNCaP, DU145 and PC3. 
Moreover, both gene and protein expression studies data showed that 
QRFP and its receptor are highly expressed in malignant prostate tissue 
compared to benign tissue both at mRNA and protein level. Interestingly, 
QFRP is highly expressed in cancerous cells and because this 
neuropeptide is an α-amidated and that the expression of peptidyl-glycine 
alpha-amidating monooxygenase (PAM), the enzyme responsible for the 
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amidation of neuropeptides is overexpressed in high Gleason’s score has 
been reported by other studies (Alonzeau et al., 2013).  
The same study also reported that QFRP and GPR103 are present in the 
same carcinomatous formations, indicating that this peptide may act on 
cancer cells via an autocrine/paracrine mechanism. Furthermore, QFRP 
and GPR103 are particularly existing in cancerous structures labelled with 
EM66, a fragment of SgII that has been earlier recognised as an indicator 
of neuroendocrine differentiation (Anouar et al., 1998). Supported by 
modern investigations identifying important roles of peptides in the control 
of cancer cell proliferation and apoptosis, migration and invasiveness. The 
present study was to investigate the effect of QFRP on the prostate cancer 
cells. It was hypothesized that the increase in prostate cancer growth by 
this peptide might originate not only from mitogenic potential but also from 
its ability to inhibit cancerous cell proliferate. The impact of QRFP on 
prostate cancer cells metastasis and inhibit growth was studied by 
measuring proliferation rate, migration and invasion and apoptosis 
potential in prostate cancer cells. My findings showed that in prostate 
cancer cell lines PC3, DU145 and LNCaP, QRFP suppress proliferation 
and induce apoptosis on doses and time dependency. Also enhanced 
migration and invasion in the AI cells PC3 and DU145 were found. Most of 
the PCa deaths are result of the development of an androgen-resistant 
phenotype of PCa either via some co-activators or by mitogen activated 
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cell signaling activities that lead to the overexpression of anti-apoptotic 
genes and survival of the cancer cells. This leads to conduct the further 
experiments by using androgen insensitive cell lines, furthermore the other 
reason for halt carrying out the LNCaP cells due to manner of growing 
these cells over each other on plate. 
This study provides the first description of the signaling profile of QRFP 
actions in the PCa cell lines. Furthermore, the possible involvement of 
MAPK and PI3K signaling pathways in QFRP-induced effects in these cell 
lines was also investigated. In an attempt to explore how QRFP and its 
receptor regulate signal transduction in prostate cells, I studied the effect 
of QRFP on MAPK and AKT signaling pathways. QRFP upon binding to its 
receptor in PC3 and DU145 leads to the activation of several signaling 
molecules including the mitogen-activated protein kinases (ERK/MAPK), 
p38 MAPK, JNK MAPK and phosphoinositide 3-kinase (PI3K)/Akt 
pathways. Those pathways are critically involved in either prostate cancer 
cell survival, migration, invasion and/or cell death pathways, depending on 
the cell type and cell stimulus. Therefore, the potential involvement of 
MAPK and AKT signal-transduction pathways in mediating the effects of 
QRFP in prostate cell lines was studied by measuring the phosphorylation 
of their downstream components, AKT and ERK1/2, respectively. Inhibition 
of this pathway in the presence of QRFP neuropeptide on PC3 and DU145 
was able to abolish the mitogenic and anti-apoptotic effects.  Consistent 
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with the cell migration and invasion results, incubation of cancer cell lines 
(PC3 and Du145) with QRFP enhanced MMP2 activation. Evidence from 
previous studies shows that matrix metalloproteinase-2 (MMP2) is 
important in the pathogenesis of prostate cancer. Over expression of 
MMP2 has been associated with neoplasm, prostate, breast, cervical, 
cutaneous, ovarian and gastric cancer (Jezierska and Motyl, 2009) & 
(Gong et al., 2014). Further investigation is achieved to confirm QRFP 
induced migration and invasion by activation of AGR-2 in PCa cells.     
AGR-2 has been shown a biomarker elevated in metastatic PCa related 
with the neuroendocrine phenotype (Kani et al., 2013).  
This study also approved QRFP has potential apoptosis effect by activation 
down regulates caspase 3 and AMPK pathways in PC3 and DU145 cells. 
The direct involvement of GPR103 was evident, since silencing the 
receptor using siRNA against GPR103 resulted in significant reduction in 
QRFP induced AKT activation in PC3 cells. Not surprisingly, the QRFP 
effects were not completely abolished by knockdown of GPR103 receptor. 
This was possibly due to either not achieving complete knockdown of 
GPR103 receptor in PC3 cells by siRNA or possibly due to activation of an 
orphan GPCR. For example, it has been suggested that QRFP may have 
alternative receptor through which may elicit its functional roles in rodents 
(GPR103A and GPR103B), however to-date only one subtype of GPR103 
receptor has been identified in human. 
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I attempted to determine the specific QRFP effect on PCa cells by inhibiting 
MAPK and PI3k pathway. Cryptotanshinone has been shown to prompted 
caspase-independent cell apoptosis by activation of JNK and p38 and 
inhibition of ERK1/2 pathways in Rh30 and DU145 cells. This finding is 
strongly supported by other studies Inhibition of p38 or silencing p38 
abolish cryptotanshinone-induced apoptosis. Additionally, expression of 
substantially active MKK1 enhanced ability of cryptotanshinone inhibition 
of ERK1/2 expression and induction apoptosis (Chen et al., 2013a).  It has 
shown that activated Akt in DU145 cells and up-regulated glycolysis, 
AICAR-mediated AMPK expression inhibited proliferation without evidence 
of increased cell death. Supporting a tumor-suppressing role, silencing 
AMPK activation or a dominant negative AMPK altered enhanced 
proliferation, migration PCa cell lines (Choudhury et al., 2014).  
These reviews are in line with my outcomes from this study that inhibiting 
p38 and AMPK increased the QRFP migration effect, however inhibiting 
PI3k pathway suppress migration cells and also showed no migration 
respond by inhibit ERK pathway in PC3 and DU145 cells. Based on the 
data obtained from my study QRFP is involved in activation of different 
MAPK, AKT and downregulate Caspase-3, AMPK, MMP-9 and AGR-2 
pathways, it appears that QRFP activated ERK pathway for short time is 
not respond to proliferation might be maintenance survival cells. Activation 
of upstream MAPK JNK and downstream Caspease-3 pathway could be 
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linked to the suppression proliferation and induction amount of cell death 
dependent on time and dose dependence. While activation AMPK pathway 
might be possibly to reduce the migration cells. The potent QRFP effect on 
enhance cell migration and invasion strongly related mediated activation 
PI3k/AKT, MMP-9 and AGR-2 pathway. 
According to the letters reviews the relation between obesity and PCa 
remain in debate. Overall, controversy exists over whether obesity 
enhance the risk of PCa, however, studies strongly indicate that obese 
individuals is an important risk factor for PCa mortality (Freedland and 
Aronson, 2004). In this study I highlighted firstly on the information that 
directly link obesity to prostate cancer. I also briefly explain some of the 
risk factors linked to obesity and their association with PCa. My study 
supported that by demonstrated for the first time mRNA levels of QRFP 
and GPR103 are significantly increased in response to adipokine Leptin in 
PC3 cells. This finding might support the hypostasis that increase effects 
of leptin which are higher in obesity on QRFP and GPR103 this might be 
one of the causes for increased incidence of aggressive prostate cancers 
in obese individuals. Previous study from Somasundar et al, reported that 
leptin the obesity gene stimulates human prostate cancer cell lines in vitro 
(Somasundar et al., 2003). It has been reported that leptin promotes 
cancer cells proliferation and metastasis potential through activation of 
MAPK and AKT dependent signal transduction pathways these pathways 
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are important for cancer cell proliferation oncogenic transformation and 
tumour progression, and these pathways involve protein kinases at many 
levels (Hoda et al., 2012a). Furthermore, MAPK inhibitor PI3K and U126 
decreases leptin induced QRFP and GPR103 mRNA expression in PC3 
cells, suggesting that leptin induced QRFP and GPR103 expression 
involve PI3 kinase and ERK MAPK kinase pathway. Given that 
metabolically active neuropeptides are differentially expressed in tissues 
and in the circulation of normal and cancer patients. For example, 
circulatory levels of orexin were lower in cancerous patients compared to 
controls. I sought to investigate the circulatory levels of QRFP using 
commercially available ELISA kit. The present study suggests that 
circulating level of QRFP are decreased among cancer patients with 
benign and advanced disease. This investigation recommends additional 
studies are required of QRFP in patients with cancer associated anorexia 
with full detailed assessment including recent oral intake and age and wild 
range of subjects covered in the study. 
In conclusion, induction of apoptosis is a most important challenge, since 
it could progress the effects of model anticancer agents. The data are in 
line with literature observations highlighting the role of AMPK and AKT 
pathway activated by QRFP induced suppression proliferation cells and 
induced migration and invasion and apoptosis in prostate cancer cell lines 
depend on dose and time manner. 
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 In the future, the main challenges for successful clinical therapy 
application will be better understanding, within specific peptide and 
receptor are over-expressed and at which stage of carcinogenesis and 
cancer development. Thus, a better knowledge of the QRFP signaling 
pathways deregulated in PCa might lead to better preventive and 
therapeutic strategies for this disease. 
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